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On a global scale, Europe bears 25% of all estimated cancer cases worldwide, while account-
ing for only 9% of the world’s population.1 Simultaneously, cancer is the second leading 
cause of death after cardiovascular diseases in Europe, accounting for 26% of all deaths in 
2016.2
Between 1995 and 2018, the incidence of cancer increased by approximately 50%, while 
mortality due to cancer increased with 20% during the same time span.2 Consequently, the 
number of patients with cancer increased through the last decades. Identified reasons for this 
development are advances in cancer research covering screening, diagnostics, and medical 
treatment.2–4
As research efforts to reduce the burden of cancer continue, worldwide healthcare spending 
increases rapidly.5 In Europe, health expenditure on cancer care were estimated at 103 billion 
EUR, of which 31% (i.e. 32 billion EUR) could be attributed to cancer drugs alone.6 In 
fact, cancer medicines have been found to be particularly highly priced, both in absolute and 
relative (i.e. compared to other therapeutic areas) terms.7 In addition, expenditure on cancer 
drugs increased at a higher rate than the incidence of cancer and overall health expenditure 
during the last two decades.7
Although healthcare spending on cancers increase, healthcare resources remain limited. 
Hence, funding novel treatments requires additional budget or funding will be at the expense 
of other treatments. This can lead to displacement effects (i.e. when novel treatments with 
less favourable cost-effectiveness are funded at the expense of treatments with a more favour-
able cost-effectiveness profile), and decision makers need to be aware of such opportunity 
costs.8 The following dilemma may arise: novel treatments are needed to improve population 
health and well-being but reimbursing all of them will inevitably result in exceeding the 
financial capacity of a healthcare system. Therefore, novel treatments will no longer be af-
fordable. And indeed, the 2020 drug monitoring report of the Dutch Healthcare Authority 
(Nederlandse Zorgautoriteit, NZa) concluded that in the Netherlands, the affordability 
of novel and expensive treatments is already at risk.9 This holds true for most countries 
worldwide.10–13
To ensure the affordability of health care, reimbursement decision makers may use various 
approaches and many countries have adopted (elements of ) value-based pricing for this 
purpose.7 With such an approach, prices at which novel treatments are reimbursed are 
determined based on the value that patients and health systems perceive for the particular 
treatment.7 A formal Health Technology Assessment (HTA) can aid in determining this 
value in a transparent and reliable way.
This dissertation explores the utilisation of HTA in the field of haemato-oncology with the 
aim of identifying and addressing challenges in assessing both costs and cost-effectiveness of 
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novel treatments in haemato-oncology. This chapter will briefly outline important concepts 
related to HTA, define the research objectives and describe the outline of this dissertation.
HEALTH TECHNOLOgy ASSESSMENT
The main aim of HTA is to inform decision-making in healthcare (e.g. on the reimbursement 
of a treatment) by incorporating a multidisciplinary approach and evaluating economic, 
organisational, social and ethical aspects of a health technology.14 As such, HTA actively 
interprets medical evidence and puts it into context with the pertinent healthcare system.15 
Since its beginnings in the 1980s, HTA has often been (re-)defined.16 A recent report of 
the European Network for Health Technology Assessment (EUnetHTA) defines nine domains 
of HTA which are interrelated and highlight the multidisciplinary aspect of HTA.17 These 
domains are (1) health problem and current use of technology, (2) description and technical char-
acteristics of technology, (3) safety, (4) clinical effectiveness, (5) costs and economic evaluation, (6) 
ethical analysis, (7) organisational aspects, (8) patient and social aspects, and (9) legal aspects.
This dissertation covers several of these aspects, while its main focus lies on identifying and 
addressing challenges in the domain of costs and economic evaluation. Since all of the defined 
domains are interrelated, other domains of interest in this dissertation are safety, clinical 
effectiveness, as well as patient and social aspects.
Economic evaluation
Economic evaluations assess both allocation and efficiency of resources to improve health 
outcomes or health care in general. Several methods of conducting economic evaluations ex-
ist including cost-benefit analysis, cost-effectiveness analysis (CEA), and cost-utility analysis 
(CUA). While the latter two aim at informing decision-makers on how to best allocate exist-
ing budget to maximise (health) outcomes, only CUAs incorporate health-related quality of 
life (HRQoL) in their outcome measures and are therefore preferred in most jurisdictions.18 
Since CUAs are an integral part of this dissertation, some important conceptual aspects will 
be outlined hereafter.
Cost-utility analysis
CUAs can critically appraise both incremental costs and effects of one treatment when com-
pared to one or several other treatments.19 In this way, decisions can be made on the basis 
of evidence rather than on “what was done before”, “educated guesses”, or ”gut feelings”.19
Several analytical perspectives are available to conduct CUAs. In the field of cancer, either 
a healthcare payer or a societal perspective is commonly adopted.20 The chosen perspective 
depends to a large extent on the type of decision-maker intended to be informed and on 
recommendations issued by pharmacoeconomic guidelines of the respective jurisdiction.19
11
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As the name already suggests, a healthcare perspective typically covers all effects and costs 
within the healthcare sector that are related to the prevention, diagnostics, pre-treatment, 
treatment, hospital stays, and follow-up care or rehabilitation of the technologies under 
investigation. However, since health economics is deeply rooted in welfare economics, a 
perspective that also covers the impact of the novel treatment on the welfare of the entire 
society is often recommended.19,21–23 Such a societal perspective ideally covers both effects 
and costs not only within the healthcare sector, but includes patient and family aspects as 
well.21,19,24 Regarding effects, a societal perspective may go beyond the patients’ health and 
HRQoL to include for instance care-related quality of life of caregivers, when appropri-
ate.25 Regarding costs, a societal perspective typically also covers costs for patients and their 
families. Examples are for instance costs from out-of-pocket expenses, informal care, or loss 
of productivity due to illness.19
Since most pharmacoeconomic guidelines prefer a lifetime horizon on costs, so-called 
“future costs” should be considered as well.19,26 These can be divided into related or unrelated 
medical costs and non-medical consumption costs. The former includes costs for follow-up 
visits or treating diseases that are related or unrelated to the disease for which the interven-
tion is assessed. The latter are defined as costs of consumption (e.g. food and living) minus 
production (e.g. work during life years gained). However, since most pharmacoeconomic 
guidelines do not explicitly mention the inclusion of future non-medical consumption costs, 
the impact of these costs on the results of economic evaluation studies remains understud-
ied.26,27
Generally, CUAs can either be conducted alongside clinical trial studies (also referred to 
as “piggyback studies”28) or as decision-analytic models. In the latter case, evidence from a 
variety of different sources can be integrated into the analysis.29 However, this requires an 
extensive synthesis of all necessary model input parameters on both effects and costs. While 
methodological aspects of most steps for conducting CUAs are well documented, synthesis-
ing evidence on both effects and costs probably remains one of the most challenging aspects. 
Therefore, the step of synthesising evidence for HTA in general and CUAs in particular will 
be introduced in more detail below.
SyNTHESISINg EvIDENCE FOR HEALTH 
TECHNOLOgy ASSESSMENT
Research questions in the costs and cost-effectiveness domain of HTA can be answered in 
two ways. First, existing evidence, including published economic evidence or existing eco-
nomic evaluations submitted for reimbursement decisions, can be searched and reviewed 




Synthesising evidence from published economic evaluations
Critically appraising already available evidence can be useful for several reasons. It reveals 
what is already known, points to what is still unknown, and can reveal knowledge gaps 
about economic aspects of a given topic.30 Searching for economic evidence in a systematic 
and standardised way ensures that no relevant information is missing or left out due to 
methodological biases. To aid in systematically synthesising published economic evaluations, 
the Centre for Reviews and Dissemination (CRD) published a guidance in 2009.31 This guid-
ance suggests searching the NHS Economic Evaluation Database (NHS EED) and the Health 
Economic Evaluations Database (HEED) to identify economic evaluation for systematic 
literature reviews (SLRs). Also the Cochrane Handbook for Systematic Reviews of Interventions 
recommends the use of the NHS EED database to search for economic evidence.32 However, 
the HEED is no longer accessible since 2014, and the NHS EED is no longer updated since 
2015. Consequently, researchers and policy makers need to rely on biomedical databases, to 
find relevant information. Since these databases primarily index biomedical literature, index-
ing economic literature is not in their focus. This makes the detection of health economic 
evidence a challenging task.
While guidance exist on conducting SLRs, this guidance is fragmented, not always specifi-
cally aimed at finding economic evaluations, or not detailed.30 Without a comprehensive and 
uniform guidance, it cannot be ensured that reviews of economic evaluations are conducted 
in a reliable and systematic way.
Synthesising evidence on effects
To fulfil the criteria of evidence-based medicine, observations from randomised controlled 
trials (RCTs) regarding benefits and harms of (novel) treatments are seen as best available 
research evidence.33,34 Typically, RCTs are conducted after a series of clinical studies with 
different goals and objectives. Classically, these studies are referred to as clinical trials and 
have been divided into phases I through IV.35 Due to the relatively larger patient population 
and an extended follow-up time when compared to phase I-II studies, RCTs are often self-
evidently presented as the “golden standard” of establishing safety and efficacy.36 Therefore, 
RCTs are often used to inform both the safety and clinical effectiveness domains of HTA. 
However, the use of phase II clinical data for HTA has increased lately. This is mainly due 
to efforts to improve a timely access for patients to novel treatments, especially in cancer 
care. After all, clinical trials in oncology last on average 40% longer when compared to other 
therapeutic areas.37
To what extent data from phase II clinical studies can be used to conduct CUAs, especially 
when novel and expensive treatments may have potential curative effects, has initiated a 




Synthesising evidence on costs
Generally, costs are calculated by multiplying quantity and price. In health care, quantity 
often refers to resource use. For instance, the number of tablets a patient ought to receive 
during treatment or the number of days a patient spends at the hospital during a treatment. 
To derive costs, this quantity is multiplied with the price for one tablet of the treatment or 
the price for one day at a hospital. Depending on the chosen health-economic perspective, 
many other types of resource use such as travel time to the hospital or hours of informal care 
may be of interest.
Challenges in synthesising evidence on costs may arise for both measuring resource 
quantity and valuing it with a respective unit costs or price. To gather evidence on resource 
use, RCTs might be an obvious source of information as they already closely follow patients 
during the study time. Items related to a healthcare perspective such the number of hospital 
days or type and amount of medication administered are often already recorded and should 
therefore be readily available. However, since clinical trials have a limited follow-up period 
and employ rather strict in- and exclusion criteria, the collected evidence might not be easily 
transferrable to the entire patient population. In addition, trial data are rarely made publicly 
available to a degree that would allow its use for further analyses.39
Alternatively, information on resource use could be synthesised from costing studies, pa-
tient questionnaires, or electronic patient dossier.19,40–42 However, on the one hand, costing 
studies from a preferred bottom-up, micro-costing approach are very time consuming and 
often not feasible. On the other hand, self-reported utilisation of resource showed to be of 
variable accuracy and underreporting seems to be a frequent issue with this methodology.43
Good quality electronic patient records per contra, could be used not only to prompt 
better care, improve coordination of care, or monitor the health of populations.44 They could 
also be used to conduct research,44 including the evidence synthesis on costs. This is because 
(parts of ) these records are often used to inform financial claims from the hospital to the 
health insurers. Hospitals are therefore well-advised to maintain a detailed administration of 
all patient related activities to be able to claim costs for those activities.
Such a database would lend itself for gathering information on healthcare resource use.
THE COST-UTILITy OF NOvEL TREATMENTS IN 
HAEMATO-ONCOLOgy
As stated earlier, prices for cancer drugs in general are high and increasing throughout the 
last decades. And since the treatment of haematological malignancies heavily relies on drugs, 
the field of haemato-oncology is markedly affected by this trend.45 Indeed, of all 88 newly 
approved oncologic therapies by the US Federal Drug Administration (FDA) between 2012 
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and 2018, approximately 32% (N =28) targeted haematologic malignancies.46 In contrast, 
these malignancies account for approximately 8% of the global incident cases of all cancers.47
In 2016, the first population-based cost analysis of malignant blood disorders across 
Europe estimated the total costs of these disorders to be 11.3 billion EUR in 2012.48 Ex-
penditure on drugs (i.e. antineoplastic drugs and endocrine treatment) accounted for 1.9 
billion EUR (17% of total costs).48 While “old” drugs such as cyclophosphamide are rather 
inexpensive, it seems that an increasing number of novel high-priced drugs for haematologic 
malignancies are flooding the market, especially in recent years.45 Examples for such treat-
ments are immunomodulatory agents such as lenalidomide with mean monthly therapy 
costs between 2,049 EUR (second treatment line; 2009 Euro) and 3,651 EUR (fourth treat-
ment line; 2009 Euro) per patient.49 More recently, chimeric antigen receptor (CAR) T-cell 
immunotherapies such as tisagenelecleucel with a list price of 320,000 EUR per patient 
received central marketing authorisation by the EMA.50,51
Determining the cost-utility of these treatments through formal CUAs is important to 
enable reimbursement decisions on scientific evidence.
IMPLICATIONS OF CUAS ON HEALTHCARE 
DECISION-MAkINg
Once the European Medicines Agency (EMA) has granted central marketing approval for a 
novel treatment based on the safety and efficacy profile of a novel treatment, pricing and 
reimbursement decisions fall within the competency of each Member State. This means that 
every payer (i.e. insurance companies or the state) needs to negotiate or set a price at which 
the respective treatment is reimbursed. HTAs play an important role in the reimbursement 
decision-making in many countries worldwide. Several European countries have therefore 
established institutions or organisational bodies dedicated to the evaluation of healthcare 
technologies. While national agencies operate differently across countries, they usually share 
a set of basic objectives and structures. Generally, they either take on an advisory or a regula-
tory role in the reimbursement decision-making process.52 By means of two example, the 
differences between these roles will be clarified below.
HTA advisory bodies: an example
In the Netherlands, the National Health Care Institute (Zorginstituut Nederland, ZIN) has a 
mandate to safeguard the accessibility, affordability and quality of healthcare. As such it has 
an advisory role and makes reimbursement and pricing recommendations to the Minister of 
Health, Welfare and Sport.
Since 2015 the Dutch government makes use of a lock (Dutch: sluis) system for novel 
and expensive treatments. Once a medicine is placed in the lock, it is temporary excluded 
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from the basic health insurance package and hence not reimbursed by the health insurance. 
The drug manufacturer can submit a reimbursement dossier to the ZiN which then assesses 
the medicine on the criteria of necessity (how high is the disease burden for patients?), 
effectiveness (how effective is the medicine?), cost-effectiveness (what is the price of the 
medicine with regards to its value for the patient?), and practicability (is the inclusion of 
the drug into the basic insurance package realistic in practice?).53 This assessment is based 
on a pharmacoeconomic dossier (commissioned) by the manufacturer. In case of a positive 
assessment, the ZIN advises the Minister of Health whether price negotiations with the 
drug manufacturer are necessary. Such price negotiations are usually confidential. Finally, 
the Minister of Health takes a definitive decision on whether the medicine shall be added to 
the basic health insurance package.
HTA regulatory bodies: an example
In the UK, the National Institute for Health and Care Excellence (NICE) has a regulatory 
role and is accountable to the Ministry of Health. It is responsible for conducting HTA on 
behalf of the National Health Service (NHS).52 In 2017, the NICE framed three strategic 
objectives.54 One of which is centred around providing evidence and guidance to provide 
high quality care that makes efficient use of resources.54 Following this objective, the NICE 
conducts so-called technology appraisals on the use of new and existing medicines and treat-
ments within the NHS. Such appraisals are based on both clinical and economic evidence.55 
Once the NICE has issued a positive recommendation, the NHS is legally obliged to fund 
and resource the respective medicine or treatment.55
As can be seen from the two examples above, jurisdictions tend to integrate evidence synthe-
sised through formal HTAs differently into their reimbursement processes. It is therefore im-
portant to interpret outcomes of such assessments (especially the cost and cost-effectiveness 
domain of HTA) within a country-specific context.
CHALLENgES IN ASSESSINg COSTS AND COST-
EFFECTIvENESS OF TREATMENTS IN HAEMATO-
ONCOLOgy
In the previous paragraphs, three key elements of HTA have been outlined and (potential) 
challenges in each of those were briefly sketched.
First, the evidence synthesis of clinical efficacy and health-economic information (in the 
form of costs and cost-effectiveness) are core components of each HTA. However, system-
atically searching published cost-effectiveness analyses has become more challenging since 
health economic databases seized to exist, and challenges in synthesising information on 
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the cost of healthcare based on hospital financial claims databases are not extensively docu-
mented. In addition, it is not fully explored in how far previously published phase II clinical 
data can be used to inform the building of a decision model that summarises this evidence.
Second, several novel and expensive haematological treatments such as tisagenlecleucel 
and lenalidomide demonstrated favourable efficacy results versus the studied comparator 
treatment and have recently received marketing approval by the EMA. However, results 
from cost-utility analyses are needed to make evidence-based reimbursement decisions.
Third, the advisory or regulatory role of HTAs in the reimbursement decision-making 
process in several European countries is well documented in its theory. However, to what 
extent specific assumptions made in CUAs can affect reimbursement decisions, or whether 
outcomes of CUAs on novel and expensive haematological treatments are actually used to 
form decisions is less known. In addition, the future financial impact of expensive haemato-
logical treatment options with potential curative effects on healthcare systems in Europe is 
not yet fully understood.
Identifying and addressing these issues and challenges were the motivation to write this 
dissertation.
OBjECTIvES AND OUTLINE
The aims of this dissertation are to identify and address several challenges arising in assessing 
costs and the cost-effectiveness of interventions in haemato-oncology. In addition, the cost-
effectiveness of two novel and expensive treatment options for haematological malignancies 
will be assessed.
To work towards these aims, this dissertation is structured into three parts. The first part 
addresses various challenges of the evidence synthesis for the costs and economic evaluation 
domain of HTA. The second part assess the cost-utility of two novel and expensive haema-
tological treatments. The third part describes challenges in the reimbursement decision-
making process based on HTA.
PART I includes Chapters 2 to 4 which explore and address challenges in the evidence 
synthesis for HTA. Chapter 2 addresses the challenge of systematically finding previously 
published economic evidence. It aims at determining a transparent and reliable methodol-
ogy for collecting published economic evidence for HTA. In the absence of evidence on 
the healthcare resource use and costs of paediatric patients with sickle cells disease in the 
Netherlands, Chapter 3 explores to what extent hospital financial claims data can be used 
to estimate these costs. Since phase II clinical data are increasingly used for reimbursement 
decision making, Chapter 4 assesses to what extent published phase II individual patient 
level data can be used in de novo decision models and CUAs.
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PART II comprises Chapter 5 to 6 and aims at providing evidence on the cost-utility of 
novel and expensive treatments in the field of haemato-oncology. In addition, it aims at 
examining the impact of expanding a societal perspective in CUAs to include future non-
medical consumption costs on the ICER. Chapter 5 assesses the cost-effectiveness of the 
CAR T-cell therapy tisagenlecleucel for the treatment of paediatric patients with relapsed or 
refractory B-cell ALL. Chapter 6 assesses the cost-effectiveness of rituximab in combination 
with lenalidomide for patients with previously treated follicular lymphoma. 
PART III of this dissertation includes Chapters 7 to 8 and describes implications of 
CUAs on healthcare decision-making. Furthermore, it investigates the impact of expensive 
immunotherapies for the treatment of cancer on (future) healthcare expenditures in Eu-
rope. Chapter 7 describes how results of CUAs can lead so-called “restricted decision” to 
reimburse novel and expensive anti-cancer treatments. Chapter 8 provides a forecast on 
healthcare expenditures of current and novel CAR T-cells therapies for the treatment of 
haematological cancers in Europe.
Finally, in Chapter 9 the main findings of this dissertation are summarised, discussed and 
interpreted in the context of research and policy. In addition, recommendations for further 
research and healthcare policy are provided.
Note that Chapters 2 to 8 are based on publications in, or intended for, international 
peer-reviewed journals and can therefore be read as independent papers.

PART I
Challenges in the evidence 




How to prepare a systematic review of 
economic evaluations for clinical practice 
guidelines: database selection and search 
strategy development (part 2/3)
FW Thielen, GAPG Van Mastrigt, LT Burgers, WM Bramer, HJM Majoie, 
SMAA Evers, J Kleijnen




Introduction: This article is part of the series “How to prepare a systematic review of eco-
nomic evaluations (EES) for informing evidence-based healthcare decisions”, in which a 
five-step approach is proposed.
Areas covered: This paper focuses on the selection of relevant databases and developing a 
search strategy for detecting EEs, as well as on how to perform the search and how to extract 
relevant data from retrieved records.
Expert commentary: Thus far, little has been published on how to conduct systematic review 
EEs. Moreover, reliable sources of information, such as the Health Economic Evaluation 
Database, have ceased to publish updates. Researchers are thus left without authoritative 
guidance on how to conduct SR-EEs. Together with van Mastrigt et al. we seek to fill this 
gap.
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INTRODUCTION
To support their decisions in health care, policy and decision makers need reliable informa-
tion on the cost-effectiveness of health care interventions.56 Systematic reviews of economic 
evaluations (SR-EEs) are a source of this information.57 However, although these reviews 
have become increasingly important, little has been published on how to perform SR-EEs.58 
Without such guidance, those who wish to perform SR-EEs are left with practice guid-
ance and recommendations that focus solely on medical efficacy research, which is usually 
concerned only superficially – if at all – with economic outcomes.
The vast amount of publications and their widely differing quality, together with sub-
jective components that may guide a searcher’s decision, call for standardized methods.59 
Therefore, a carefully planned strategy is essential when a thoroughly conducted SR is the 
goal.60 Moreover, SRs should be reproducible, verifiable, efficient, and accountable.57,61,62
With a five-step approach on how to perform SR-EEs of health-care interventions, van 
Mastrigt and colleagues make a first attempt to fill the gap that has occurred in the absence 
of both guidance and reliable and comprehensive economic databases.30 Their goal is to 
pave the way in establishing future guidance for SR-EEs. In the meantime, their approach 
can be used as a preliminary manual for performing SR-EEs in a sound scientific way. Their 
guidance aids users in employing efficient and transparent methods, which are central to any 
SR.57 Just as for part 1/3 of this paper series, this article’s main target audience is developers 
of clinical practice guidelines (CPGs) who need a point of reference on how to perform 
SR-EEs. Similarly, it can be a helpful tool for researchers in health technology assessment, 
systematic reviewers, and for students who seek to prepare an SR-EE. To illustrate the case, 
we will discuss our theoretical considerations alongside a recent example of an SR-EE that 
was part of developing a CPG for the treatment of epilepsy in The Netherlands.63
BACkgROUND
Typically, evidence for a CPG is gathered by systematically reviewing publications that are 
concerned with the effectiveness of different treatment options.64 In addition, it has become 
increasingly acknowledged that CPGs should also entail economic evidence.65,66(p7),67 This 
can be done in two, not necessarily independent, ways: (1) an SR and critical summary of 
the economic evidence already published is undertaken or (2) a decision analytic model is 
built to model economic effects.57 This article will focus solely on the former approach.
In general, most steps of an SR-EE involve the same stages that are needed to conduct an 
SR of evidence for clinical effectiveness.57 More specifically, any SR-EE will be based on the 
same two-stage process that has become the established standard for SRs of effects,57 namely: 
(1) developing a search strategy and (2) applying the search strategy to a set of specified 
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databases.68 However, some methods of SR-EEs diverge signifi cantly as economic outcomes 
replace eff ectiveness or safety outcomes that would be detected in SRs.57 As a result, database 
selection as well as the identifi cation of search terms and fi lters diff ers. However, guidance on 
how to extend a search strategy and what databases to use when seeking to incorporate EEs 
is scarce, fragmented, or not applicable to all cases. In this article, we will present solutions 
for overcoming these issues, based on published guidance in the fi eld and our experience.
THE FIvE-STEP APPROACH FOR PREPARINg AN SR-
EE
Following van Mastrigt’s approach for conducting SR-EEs, the fi rst step is to compose a 
multidisciplinary project team, frame the study, prioritize the topics, and write and publish 
the protocol. With regard to the subsequent steps, it should be noted that adding a medical 
information specialist or librarian to the search team adds great value to the quality of the 
searches.69 In the second step, EEs need to be identifi ed; this includes (1) selecting relevant 
databases, (2) developing an adequate search strategy, (3) performing the searches, and (4) 
selecting the relevant studies. Th is article will provide a more detailed description of these 
four parts of the second step, while step 3 is described by Wijnen et al.70 in more detail. An 
overview of all other steps and a detailed description of steps 1, 4, and 5 can be found in van 
Mastrigt et al.30 For an overview of the fi ve-step approach, see Figure 1.
 
Step 5: Discussion and interpretation of results*
Step 4: Reporting of results*
Step 3: Data extraction**
Step 2: Identifying full EEs
2.1 Select relevant datasources 2.2 Development of search strategy 2.3 Perform searches 2.4  Selection of studies
Step 1: Initiating a SR of EEs*
Figure 1 - An overview of the 5-step approach for preparing a systematic review of economic evalua-
tions to inform evidence-based decisions. *Described in detail by van Mastrigt et al.,30 **Described in 
detail by Wijnen et al.70
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STEP 2.1 OF THE OvERALL FRAMEwORk: 
SELECTION OF RELEvANT DATA SOURCES
Until recently, a large part of EEs in health care could be detected by searching databases that 
specifically focus on these evaluations, such as the U.K. National Health Service Economic 
Evaluation Database (NHS EED) and the Health Economic Evaluation Database (HEED). 
However, HEED ceased publication at the end of 2014 and is no longer accessible for 
searches.71 And, although still accessible through the Cochrane Library and the Centre for 
Reviews and Dissemination (CRD) website, the NHS EED has not been updated since 
March 2015.72
Many databases can be accessed via different search providers and platforms, and these 
pose varying requirements for a search strategy. Most end users will access well-known 
standard biomedical databases such as MEDLINE or Embase [1]. Apart from the question 
of whether all EEs are indexed in these databases, records can be indexed inconsistently, and 
there is no uniform interpretation of the definition of EEs [3]. In addition to electronic bib-
liographic databases, other resources such as gray literature, research registries, or web pages 
may contain useful information. Also, registries of unpublished studies can be searched, and 
researchers can be contacted for additional data.
No database is comprehensive enough to cover all relevant published research.73 Therefore, 
the general consensus for effectiveness is that at least several databases need to be searched 
for a comprehensive result.74–78 Guidelines for SRs recommend searching at least two bib-
liographic databases,79,80 although there is no agreed-on standard for how many should be 
searched.31 As the number of searched databases increases, database bias (referred to as the 
probability that the index of a record in a specific database is dependent on its results) and 
potential language bias can be reduced.81 Which databases should be selected for a review 
depends heavily on the study objectives,31 and there is no consensus about this either.82 Be-
ing aware of how each interface for searching databases works is essential, since search results 
might well vary if the same database is searched through different interfaces (e.g. searching 
MEDLINE via PubMed or via OVID).82
Electronic databases for searching EEs
Backed by an extensive amount of evidence,83–92 Mathes et al.93 recommend searching at 
least MEDLINE and Embase for SR-EEs. In addition, they suggest searching one health 
economic database, such as HEED or NHS EED. Also, the Cochrane Handbook92 and the 
manual for developing the National Institute for Health and Care Excellence (NICE) guide-
lines,64 together with the Campbell and Cochrane Economics Methods Group (CCEMG),94 
emphasize the use of the NHS EED on their website when searching for economic evidence 
for SRs. However, as HEED is no longer available and the NHS EED is no longer updated, 




Gray literature (i.e. technical reports, studies, or essays that are unpublished, have restricted 
distribution, and are therefore rarely included in bibliographic retrieval systems)95 has the 
potential to add valuable information to an SR-EE, especially when little is known about 
the topic under study. Although finding and including gray literature is particularly time-
consuming and difficult, it is regarded as necessary for minimizing bias in reviews.96 When 
possibly including gray trials, Hopewell et al.96 recommend contacting the authors of these 
trials for more information. Examples of missing information could, for instance, be values 
for the standard deviation or variance when only the mean or median is reported.
The CRD health technology assessment database identifies gray literature.97
Citation searching
In citation searching, the reviewers search for articles that have cited a set of relevant articles 
which have already been detected.31 For example, this can be done on the Science Citation 
Index Expanded™ (Thomson Reuters, United States),98 via the Web of Science™. Citation 
searching can also include reference checking. Here, the reviewers can scan the reference lists 
of useful records previously identified to see if they refer to as yet unknown articles.
Classification of databases
We classified several databases and websites into three categories, based on their ability to 
detect EEs in health care; these three categories are (1) basic, (2) specific, and (3) optional. 
For a complete but non-exhaustive list, see online Appendix 2A. The choice of databases is 
independent of whether the purpose is to conduct a multipurpose review or to develop a 
new CPG.
1) Basic databases: We refer to ‘basic databases’ as those that are recommended for use 
in any case when performing SR-EEs. Using a well-constructed search strategy, most 
relevant EEs will be detected.
2) Specific databases: For an SR on a topic for which a specific database is available, we 
recommend using it. Specific databases are those that provide information primarily in 
a particular research field. An SR on a mental health topic for instance would benefit 
Database selection: a practical example
Wijnen et al.63 sought to present an overview of published and ongoing full EEs of all health-care interventions 
for patients with epilepsy. The main search was conducted in March 2015. The following databases were searched: 
MEDLINE (via PubMed), Embase, NHS EED, EconLit, Web of Science, the Cost-Effectiveness Analysis Registry, 
the Cochrane Library of Systematic Reviews, the CRD Database of Abstracts of Reviews of Effects (DARE), and CRD 
Health Technology Assessment Database. With the first five databases, ‘basic databases’ were selected. Since the search 
was conducted up until March 2015, it can be expected that NHS EED was exhaustively searched. All other databases 
are classified as ‘optional database’ in this publication. It seems worthwhile mentioning that DARE also stopped its 
service in 2014.
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from searches performed on PsycINFO (American Psychological Association, United 
States).99,100
3) Optional databases and websites: Under the category of ‘optional databases,’ we 
grouped databases and web pages that may hold additional information relevant for 
a more comprehensive SR. For example, optional databases will identify Health Tech-
nology Assessment (HTA) reports (Canadian Agency for Drugs and Technologies in 
Health [CADTH] HTA database) and conference proceedings (International Society 
For Pharmacoeconomics and Outcomes Research (ISPOR) website or the Cochrane 
Colloquium). Furthermore, trial registries may provide an outlook on what studies are 
currently being performed and may provide further evidence in the near future.
Until a new EE database becomes available, we recommend searching at least the basic 
databases MEDLINE,101 Embase,102 NHS EED,97 EconLit (EBSCO),103 and Web of Sci-
ence,104 bearing in mind that the NHS EED stopped updating in March 2015. If applicable, 
a search on a more disease-specific database can be necessary. As many optional databases 
should be added as is feasible.
STEP 2.2 OF THE OvERALL FRAMEwORk: 
DEvELOPMENT OF A SEARCH STRATEgy
Developing an entirely new comprehensive search strategy (i.e. a string of search terms) is a 
time-consuming effort which highly depends on the reviewer’s experience. The time needed 
for developing and testing such a strategy is reported to be around 20 h for experienced 
reviewers.105 It needs to be noted that these estimates also entail the testing of such a strategy 
against a so-called ‘gold standard’ (i.e. a known set that entails all relevant publications).59 
However, it is not necessary to develop and test a search strategy from scratch for every new 
SR-EE. When designing a comprehensive search strategy, it is advised to ask the help of a 
biomedical information specialist, available at many universities.61,69,106 Considerable work 
has been done to support researchers in detecting relevant articles for SRs concerning the 
effectiveness of treatment and diagnostics. However, little has been published on empirically 
validated search strategies for EEs.56 In general, a successful search strategy is regarded as 
one that delivers a manageable amount of references with a searcherspecified balance of 
sensitivity and precision.76 The definition of what is regarded as being manageable obvi-
ously depends on the size and expertise of the review team. When making use of predefined 
methods for screening, researchers other than information specialists screened a median of 
296 articles per hour.107
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Important elements in a comprehensive search strategy
In searching literature databases, a search strategy typically makes use of different search 
terms that are related to elements in the research question. With a so-called ‘conceptual 
approach’ (also known as a ‘conventional approach’108), different information sources are 
used to identify relevant terms and their synonyms.109 Several databases offer the possibil-
ity to employ medical subject headings (referred to as MeSH® terms in e.g. PubMed®), or 
Emtrees® (Embase®). Both MeSH and Emtrees groups controlled vocabulary and hence serve 
as thesauri used to index biomedical literature in the respective databases. For a comparison 
of MeSH® and Emtree®, see 110.
Search filters are defined as a collection of search terms based on research and validated 
against a so-called ‘gold standard’ (i.e. a known set of relevant records),59 used to identify 
certain types of records, often for very broad topics.59,111 They are regarded as a time-saving 
‘ready-made solution’, leaving searchers ‘free to concentrate on the other aspects of the 
search’.73 Hence, they improve both the efficiency and effectiveness of searches.59
Although there seems to be no consensus on how to set up a good search filter, filters 
can be tested for their quality in terms of (1) sensitivity, (2) specificity, (3) precision, and 
(4) accuracy(see Table 1).59 Sensitivity is defined as the proportion of relevant citations that 
were retrieved; specificity is the proportion of low-quality (or off-topic) records not detected; 
precision is the proportion of articles that are of high quality; accuracy is the proportion of 
all articles that are correctly classified.112 While it should be the general aim to maximize 
sensitivity,68 a high level of precision is needed to meet the requirements of guideline de-
velopers and HTA researches and to prepare scoping or rapid reviews.113 It should be noted 
that achieving a high degree of sensitivity is often associated with a lowering of precision and 
vice versa.58,68,113–115
For identification of full EEs, we recommend choosing a sensitive rather than a precise 
filter.
Once all synonyms, MeSH/Emtree terms, and search filters are detected, they can be 
connected through the Boolean or proximity operators per Patient, Intervention, Compara-
tor, Outcome (PICO) aspect. All PICO aspects are then combined with AND. Finally, the 
complete search strategy can be pasted into the database search interface. It needs to be 
noted that each interface follows specific syntax rules.116
Boolean operators
Search terms within a concept (synonyms) should be combined with the Boolean operator 
OR. Aspects and filters can be combined into a search strategy with the use of the Boolean 
operator ‘AND.’ In addition, some search interfaces allow the use of proximity operators 
such as ‘NEAR’ or ‘ADJ.’ By searching for two (groups of ) words on a certain internal 
distance, the search achieves more specificity in comparison with combining terms with 
‘AND’ and more sensitivity in comparison with searching for specific phrases. The proximity 
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between the words can often be set by the user. This can be of particular value if one search 
term can be described in several ways. The Cochrane Handbook for Systematic Reviews of 
Interventions (hereafter: Cochrane Handbook)62 recommends using the ‘NEAR’ operator 
due to its higher degree of sensitivity and precision as opposed to ‘NEXT’ and ‘AND,’ 
respectively. It should be noted, however, that the proximity should be used only to combine 
words within one aspect (such as the disease or intervention aspect). Accordingly, it cannot 
replace the ‘AND’ between aspects. Theoretically, the Boolean operator ‘NOT’ can be used 
to exclude specific aspects. It should, however, be avoided in searches for SRs or used with 
great caution due to the possibility that it could unintentionally remove relevant records.68
Truncation
Most databases offer the use of truncation, which is a way to search for multiple words with 
the same word stem. Usually truncation is indicated with an asterisk (*) at the end of a word 
stem. Truncating effectiv* would for instance search for effective, effectiveness, effectivity, 
etc. Likewise, some databases offer a wildcard operator (such as ‘?’ in the Cochrane Library 
or ‘#’ in Ovid), which is meant to replace one single character Searching for wom?n will in 
this case search for women and woman.68 Truncation should be done carefully. Truncation 
of the word cost* for anything related to costs will for instance also search for costimulants 
which is not directly related to costs. In this example, truncation took place at a word stem 
that was too short.
Restrictions
Most databases allow different methods for restricting their search results. It is recommended 
that language restrictions not be included in the search strategy,68 although this is not always 
feasible. Likewise, restrictions on dates should not be applied except for specific reasons, 
such as when updating earlier reviews or when a certain technique being evaluated was not 
present before a certain date. Formats such as letters can add relevant additional information 
Table 1 - Calculation of sensitivity, precision, and specificity for the evaluation of search filters.
Manual filter (hand searching)
Relevant (gold standard) Not relevant
Search filter Retrieved A B
Not retrieved C D












that relates to trial reports; they can update them or may be intended to correct mistakes. 
Therefore, they should not be excluded per se.68
Selection of search terms and filters
Following the first steps of Mastrigt et al.,30 the eligibility criteria for studies to be included 
in the SR are already defined. These criteria will inform the four basic components of the 
PICO scheme: population (or participant, or population), intervention, control or compara-
tor, and outcomes;117 this is a helpful step in the conceptualization of the research question.93 
Other search tools such as PICOS (where the S refers to study design) seem to be less 
sensitive in comparison with PICO.118 Usually, not all PICO aspects are well covered by 
the title or abstracts or indexed key words of an article, and not all aspects are equally 
important.68 Therefore, the final search strategy for SREEs will often consist of the following 
three main key concepts of interest: (1) health/disease, 2b) intervention, and (3) economics. 
Search terms for each concept can be derived from the conceptual approach or by using 
already existing search filters. For each concept, it is advised to include a wide range of 
free-text terms separated by the Boolean operator OR, to make as much use of truncation 
and wildcards as possible (see below),68 and to use proximity operators if they are available in 
the interfaces used. Specifics of the three concepts will be discussed in the following subsec-
tion. Since February 2016, Embase provides a PICO search interface that can be useful for 
conceptualizing a first search strategy.119
Several databases offer the possibility of employing thesauri (also known as MeSH terms 
in MEDLINE or Emtree in Embase). These thesauri provide additional alternative terms 
that can be used as synonyms in the creation of the search strategy.
For English, it is recommended using both British and American spellings for the free-
term search.120
Health/disease and intervention concept
As both health/disease and intervention concepts share many features and are closely related 
to each other, they are discussed together. For both concepts, making use of an already 
existing search strategy or filters is recommended. These may be found in the appendices 
of Cochrane SRs, publications of the NICE,121 or other high-quality SRs. If the planned 
SR-EE is part of a CPG development process, information on the health- or disease-specific 
string can be taken from the search used to detect studies that evaluate the clinical effective-
ness of the intervention of interest.
As mentioned earlier, some search filters for specific topics already exist and sometimes 
are even partially integrated by database providers (e.g. clinical queries in PubMed). The 
InterTASC Information Specialists’ Sub-Group (ISSG) provides a list, updated monthly, for 
search filters grouped by study design and focus.122
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Economic concept
Search terms for the economic concept are dependent on the research question and on the 
type of EEs that are sought to be incorporated. If, for instance, economic modelling studies 
are considered for the SR, it is not enough to incorporate only economics-related search 
terms.
Most often, search filters and full search strategies are reported together with their respec-
tive sensitivity, specificity, precision, and accuracy. In 2009, Glanville and colleagues found 
that EEs cannot be identified efficiently using indexing terms provided by most databases.123 
Therefore, they tested the performance of available search filters for their ability to detect 
EEs in MEDLINE and Embase. They concluded that, while some filters are ble to achieve 
high levels of sensitivity, precision is usually low.123
Since a newly created search filter needs to be validated, its development is a challenging, 
time-intensive, and resource-consuming task. Some search filters for detecting EEs have 
been published in the literature. Although these filters have been translated to fit more 
than one database, the translation is not always optimal, so they are not easily transferrable 
between databases. The selection of an appropriate search filter depends on the scope set 
out for the SR, as well as on which databases are to be searched. Therefore, we refer to the 
regularly updated ISSG website which holds a list of published filters for finding EEs in the 
databases CINAHL, Embase, MEDLINE, and PsycINFO.124 If feasible, we advise choosing 
a sensitive rather than a precise search filter for SRs. This is because the former will most 
likely detect more records than the latter.
In 2016, the CADTH issued an update to the Peer Review of Electronic Search Strate-
gies (PRESS) guideline that aims to evaluate electronic search strategies.125 Originally, the 
PRESS guideline focused on librarians and other information specialists as primary users, 
but it can also be of great use for researchers undertaking SRs.
Recommendations for a complete search strategy – in a nutshell
When developing the search strategy, it is important to breakdown the research question 
into its main conceptual elements. The PICO scheme can help with this, although not all 
PICO elements might be useful.
A search strategy should encompass a wide range of freetext terms, make use of proximity 
operators when possible, and employ thesauri. Truncation should be used with caution, 
and for English, British and American spelling should be used. Restrictions of search results 
(e.g. language and time frame) should be used as little as possible when setting up a search 
strategy.
Already existing and validated search filters should be selected for being highly sensitive or 
highly precise or a combination of both. A soundly conducted SR will profit from a sensitive 
rather than from a precise search filter. Filters to find EEs can be found on the ISSG website.
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STEP 2.3 OF THE OvERALL FRAMEwORk: PERFORM 
SEARCHES
Once the search strategies for the selected databases have been created, the search can be per-
formed. Relevant studies that are already known should be included in the newly retrieved 
set of articles. If not, it needs to be determined why the search strategy could not detect 
them. Accordingly, the search strategy might have to be adapted. This triangulation method 
can serve as a sort of quality check.
A clear documentation of all searches (i.e. electronic database searches and hand and 
reference searches) is essential for the reproducibility and future updates of the study find-
ings.31,68,79,80,127 This means that the details of all searches performed (e.g. database selected, 
time frame covered, key words and restrictions used [i.e. the entire search strategy], number 
of records retrieved, etc.) should be collected systematically and added to appendices of the 
report (see online Appendix 2B for an example). Reference managing software (e.g. End-
Note, Refworks, etc.) can be used to manage bibliographic details and deduplicate results 
and prepare references for publications. This will ensure efficient handling of all references 
retrieved from different databases.68 The user should, however, be aware of how the reference 
manager used handles deduplication and the preparation of references for publication.128,129 
Reference information for gray literature and reports can be found on WorldCat®.130
After references from all databases have been downloaded into a reference software 
program, they can be deduplicated. Most reference management software programs have 
built-in deduplication options, but several methods have been published as well.131–133 De-
duplication is often considered time-consuming, even when using bibliographic software, 
because users feel the need to check the correctness of the selected duplicates. A safe and fast 
method has been developed in EndNote, where fields can be set upon which the duplicates 
are compared.131,134
Developing a search strategy: a practical example
Wijnen et al.63 constructed a total of eight different search strategies to cover all relevant aspects that the to-be-
developed CPG should cover. To keep this example comprehensible, we will focus on the search strategy for detecting 
publications concerning the ketogenic diet. A schematic overview on this search strategy is depicted in Figure 2. 
Applying the PICO strategy to this case would detect “individuals with epilepsy” as patients, “ketogenic diet” as 
intervention. As no specific comparator is mentioned, it is assumed that the authors searched for any comparator 
possible. For this part of the CPG development process, only economic evaluations were of interest as outcomes. For 
studies of effects, this would obviously be different.
For the example at hand, the important aspects for a database search would thus be patient, intervention, and outcomes 
(since no specific comparator was of interest). For the patient and intervention aspects, an experienced information 
specialist compiled a broad set of search terms. For the outcome aspect, an already published search filter designed for 
MEDLINE was used.126 This filter can be found on the ISSG website.124
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STEP 2.4 OF THE OvERALL FRAMEwORk: 
SELECTION OF STUDIES
Screening of potential relevant studies should be conducted in two stages.31,79 First, after 
removing the duplicates, all remaining records are screened, preferably by two indepen-
dent reviewers,135 on title and abstract. Studies should be selected based on the eligibility 
criteria stated in the published protocol (Steps 1.3 and 1.4). Second, the full-text records 
are screened for compliance with eligibility criteria.135 Often it is recommended that, 
ideally, all steps critical for study selection (2.3 and 2.4) and for data extraction (3.1 and 
3.2) should be done by two reviewers independently.31,80,135 However, as this is not always 
Figure 2 - Schematic overview on search strategy of Wijnen et al.70 Per PICO item, all synonyms and 
MeSH terms were combined with the Boolean operator OR. Truncation (in the form of an *) was used 
whenever possible. All search terms were restricted to be detected in title and abstracts only (see [TIAB] 
or [Title/Abstract]). Within one PICO item, different words can be combined with AND. For the 
intervention aspect, “ketogenic” was combined with “diet”. At this place a proximity operator could 
have been used. The same approach could also have been used for the search term “diet therapy”. To 
detect economic evaluations, a published search filter was copied.126 Finally, all elements of the PICO 
scheme were combined with the Boolean operator AND to produce a single search strategy that could 
then be pasted into a MEDLINE search interface (in this case PubMed).
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achievable, one reviewer can select and extract the data, with a second one checking this for 
completeness and accuracy.31 Pilot testing of these processes should be performed using a 
representative sample of studies.31,79,135 Accordingly, the inclusion criteria should be applied 
to a sample of records.79 Any discrepancies between the two reviewers should be resolved by 
consensus.31,79,135 In addition, a third reviewer may be consulted if any issues need further 
discussion.31,135 The review process can be done in different ways. As a formal measure of 
agreement, Cohen’s Kappa can be calculated,31,135 although not all guidelines regard this 
as necessary.79 The review process can be managed through EndNote,107 but many other 
programs are available as well. A compendium of different tools that also calculate Cohen’s 
Kappa automatically can be found elsewhere.136
All information on the abovementioned processes can be reported in the study protocol 
and in the methods section of the publication.31,79,135 If there are multiple records of the same 
study, these records should be linked together.68,79,85 This can be done by making a systematic 
numerical order for the studies and reporting this in the results section. This could be done 
as follows: for the oldest report, the number ‘1A’ (used further in SR-EE when reporting 
or discussing this study), ‘1B’ for the second report of that specific study (mentioned only 
once in the results section when discussing the number of included studies), ‘1C’ for the 
third publication, etc. A list of studies that were excluded from the SR at the full paper 
stage should be provided in the online appendices,31,135 to keep the study transparent and 
reproducible. This list needs to contain bibliographic details of the excluded studies and the 
reason for exclusion.31,79,135
A flowchart of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
statement on study inclusion should be used to show all details of the selection process in a 
systematic way.31,79,137
ExPERT COMMENTARy & FIvE-yEAR vIEw
As much as the development of the NHS EED and HEED databases was heralded as an 
improvement in providing access to EEs,113 the discontinuation of updating these databases 
has had a tremendous impact on how to conduct SR-EEs. The cessation of these databases 
created a gap, with no new database currently capable of replacing them. The scientific 
community seems to be reacting with procrastination. Renowned practice guidance such as 
the Cochrane Handbook,62 the NICE manual for developing NICE guidelines,64 and other 
reliable sources of information (e.g. the CCEMG website94) need to be revised and updated 
so that using these databases is no longer recommended. Without comprehensive economic 
databases, researchers need to rely on other information sources which are not specialized 
in EEs and must use more complex search strategies with specialized search filters to detect 
EE literature in available databases. Setting up a new health economic database might seem 
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Table 2 - Step-by-step plan on how to identify economic literature for a systematic review
Step 2: Identifying full economic evaluations
Step 2.1 Select relevant data sources
General databases Select at least Medline, Embase, NHS EED, Econlit, and Web of Science. Be aware 
that NHS EED has not been updated since May 2015.
Specific & optional databases Select specific databases according to your topic (if applicable).
Search optional databases for HTA reports and conference proceedings.
Grey literature Consider including grey literature; this can minimize bias and be a valuable source 
of information. Database noemen worldcat?
Citation searching Search for relevant citations in already known publications.
Make use of citation searching (i.e. identify articles that have cited a set of relevant 
articles already detected).
Step 2.2 Development of a search strategy
Search terms Make use of the PICO scheme to find relevant search terms for all important 
concepts/aspects of the research question.
Include a wide range of free-text terms.
Use proximity operators (e.g. ‘NEAR’, ‘ADJ’) if possible.
Employ thesauruses and synonyms.
Use truncation options for your search terms (beware not to truncate to short word 
stems).
For English, use British and American spelling.
Search filters Determine whether you want to use a more sensitive or precise search filter. SRs will 
profit from sensitive filters because precise filters will miss some articles.
Look for search filters that filter for publication types (e.g. economic or trial 
publications). Choose already developed and validated filters. The ISSG website122 
holds a regularly updated repository of such filters.
Combine search terms and filters 
with Boolean (AND, OR, NOT) 
operators
Carefully consider on what basis, and if at all, you want to restrict your search 
results. It is not recommended that restriction be made on the basis of language or 
within a narrow time frame.
Step 2.3 Perform searches
Document the search process Document and report all steps of the search, including the complete search strategy 
for every database.
Handle references Use bibliographic software to keep track of downloaded references and publications.
Deduplicate the downloaded records by using a reference management software.
Step 2.4 Selection of studies
Screen references Two reviewers should screen the references independently.
Screen titles and abstracts of the downloaded records based on the eligibility criteria 
that were set earlier.
Abbreviations: NHS EED: National Health Service Economic Evaluation Database; SRs: systematic 
reviews; ISSG: InterTASC Information Specialists’ Sub-Group; HTA: Health Technology Assessment.
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like a good solution. However, with regard to the tremendous amount of resources needed 
to build and maintain such information repositories, it is questionable if this will add value.
Based on several key guidelines for preparing SRs in effectiveness research and on major 
publications exploring methods for detecting economic publications, we issue our advice 
on how to identify EEs for SRs in data sources not specializing solely in health economic 
literature. All recommendations are compiled into a step by step plan that can be used as a 
checklist (see Table 2).
As yet there is no consensus on how many and which specific databases need to be searched 
to identify all relevant EEs. Also, there is no unanimous agreement by which methodology a 
solid search strategy should be developed (see for instance108,138). Our contribution can thus 
be seen as merely temporary guidance until more methodological research on this topic has 
been published or new databases for EEs have been set up. With an increasing amount of 
validated, reliable, and user-friendly search filters to detect health economic literature, the 
creation of a new database specialized on health EEs might become redundant.
Updating new and existing SRs is a key objective for future research in this area,139 par-
ticularly because many reviews are currently outdated or no longer accessible.140 On the one 
hand, surveillance systems could assess the need for updating SRs.141 On the other hand, 
Elliott et al.142 suggest initiating living SRs which should be high quality, up-to-date online 
summaries of health research that are continuously updated with newly available research.
In the years to come, researchers will have the possibility to (1) implement process 
parallelization, (2) use novel techniques and applications to automate the process, and (3) 
methodologically modify certain SR processes, in order to address the issue of timeliness in 
the compilation of SRs.143 Automation processes seem to be the most promising innovation 
in this regard,144 as they would make handcrafted SRs (at least in part) obsolete.145 The SR 
toolbox website holds a regularly updated compendium of available software tools to support 
the process of compiling SRs.136 With upcoming automation processes and the increasing 
availability of validated search filters, it is conceivable that the cessation of health economic-
specific databases will no longer be a misfortune for the scientific community. For the last 
decade, it seems that most research concerned with developing search strategies for detecting 
EEs focuses on the two major players, MEDLINE and Embase anyway.56,58,113,123,146,147 In the 
near future, a search of those two databases could possibly be sufficient to detect most EEs. 
However, an important step for this to become reality is that EEs must be correctly indexed. 
Concepts related to health economics are often broadly defined, and the mere definition 
of what constitutes important components of EEs differs among scholars and changes over 
time (see definitions of costs components in 148 and 149). Establishing new guidelines to 
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Background: While multiple studies have examined the cost of healthcare for one aspect of 
sickle cell disease care, few have focussed on the overall cost of comprehensive care for sickle 
cell disease.
Methods: We conducted a retrospective cohort study of children with sickle cell disease 
treated in a comprehensive care centre from 1 January 2015 to 31 December 2016. Health-
care utilisation of included patients was based upon data from two main sources. The clinical 
practice guideline was used to determine the expected resource use of routine comprehensive 
care (planned elective care) and the financial claims database was used to estimate real-world 
resource use associated with acute and inpatient care (additional care).
Results: A total of 125 children with sickle cell disease were analysed. Expenditures for these 
patients averaged 5,049 EUR (standard deviation [SD]: 1,634 EUR) per child per year. Total 
yearly costs per patient varied considerably, ranging from 669 EUR to 84,010 EUR, and less 
than 15% of patients were responsible for 50% of the healthcare costs. The majority (37%) 
of costs was associated with inpatient hospital care which increased by age group; 27% with 
diagnostics; 19% with treatment; 11% with outpatients’ visits and 6% with emergency care.
Conclusion: We have described real-world resource use and expenditures for children with 
sickle cell disease in a European comprehensive care centre. It seems that costs of a compre-
hensive approach with effective management in the outpatient setting is favourable when 
compared to episodic healthcare.
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INTRODUCTION
Sickle cell disease
Sickle cell disease is an autosomal, recessively inherited haemoglobinopathy characterised by 
chronic haemolytic anaemia, painful vaso-occlusive crises and progressive organ failure lead-
ing to decreased life expectancy. It is the most common monogenetic disease worldwide with 
an estimated 350,000 births annually and an important public health problem according to 
the World Health Organisation (WHO).150
Ninety percent of the global burden of sickle cell disease occurs in sub-Saharan Africa, 
where the majority of children with the disease do not live beyond five years of age.150,151 In 
contrast, life expectancy in well-resourced countries has significantly improved with almost 
all infants surviving into adulthood.152 Nevertheless, in these countries, life expectancy of 
patients with sickle cell disease is still 20 years shorter than the average life span of healthy 
adults.153
In the Netherlands, approximately 1,500 individuals currently have sickle cell disease, 
of which half are children and the carrier incidence is 0.4%.154,155 Most of those affected 
are from Surinam, Asian or African ancestry, with a minority being of Afro- Caribbean or 
Middle Eastern descent.156 More than a quarter of Dutch patients are treated in one of the 
largest comprehensive sickle cell centres in the Netherlands; the Erasmus University Medical 
Center – Sophia Children’s Hospital (Erasmus MC). To ensure consistency in comprehen-
sive care and reduce levels of morbidity and mortality,157 all children with sickle cell disease 
in the Netherlands are treated according to the national ‘Clinical Practice Guideline for 
Paediatric Sickle Cell Disease’ (CPG; Table 1).158
Cost of healthcare
Generally, sickle cell disease together with its related comorbidities and complications results 
in high utilisation of medical resources such as emergency room visits and hospitalisa-
tion.159–161 Knowledge of expenditures associated with sickle cell disease can be used to serve 
as an incentive for further improvement of prevention and management strategies for disease 
symptoms and complications, resulting in both better care and reduced costs. In addition, 
estimating cost of care is important as it may ensure appropriate allocation of resources and 
reimbursement tariffs. However, most cost-of care studies have focussed on only one or two 
aspects of care, such as hospitalisations and physician visits,162–165,166(p) and few studies have 
examined healthcare expenditures exclusively for children. Moreover, the majority of studies 
are based on data from Northern America,161,167–170 and due to large differences in healthcare 




Primary aims of this study were to (a) investigate overall cost of healthcare resource use for 
paediatric patients with sickle cell disease in a European country and to (b) identify major 
cost drivers.







5-1,3 yrs 13-19 yrs
Laboratory analyses
- Complete blood count 3x 4x 4x 6x
- Red blood cell indices 3x 4x 4x 6x
- Low Density Lipoprotein 2x 4x 4x 6x
- Bilirubin 2x 4x 4x 6x
- Liver and renal panel 2x 4x 4x 6x
- Iron status NA 4x 4x 6x
- Folic acid and cobalamin NA 4x 4x 6x
Haemoglobinopathy specific analyses
- Haemoglobin phenotyping 2x 1x NA NA
- Haemoglobin genotyping 1x NA NA NA
- Alpha thalassemia genetic mutations panel 1x NA NA NA
- Glucose-6-phosphate dehydrogenase enzyme deficiency 
testing
1x NA NA NA
Clinical geneticist outpatient visit 1x NA NA 1x
Paediatric haematologist outpatient visit 4x 8x 16x 12x




Transcranial Doppler NA 4x 13x 6x
Chest X-ray NA NA NA 1x
Electrocardiography NA NA NA 1x
Abdominal ultrasound NA NA NA 1x
Echocardiography NA NA 2x 1x
Ophthalmic screening NA NA NA 4x
Abbreviations: mths, months; NA, not applicable; yrs, years.
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METHODS
We retrospectively estimated healthcare costs of a paediatric cohort with sickle cell disease at 
the Erasmus MC by quantifying and valuing resource use for a period of 24 months.
Study population
All children with sickle cell disease visiting the Erasmus MC for routine or emergency care 
in 2017 were included in the study cohort. Individual patient-level data was retrospectively 
analysed from the period 1 January 2015 to 31 December 2016 (i.e. 24 months). Patients 
were categorised into four age groups; (A) < 1 year, (B) ≥1-5 years, (C) ≥5-13 years and 
(D) ≥13-19 years to reflect the categorisation of age used in the CPG. Unless patients were 
born during the observation period, they all contributed 24 months of follow-up time. To 
account for a shorter follow-up time of new-born patients and a possible switch between 
age groups during follow-up, we calculated the weighted average of all costs. Weights were 
based on the patient-months-at-risk during the retrospective study period (i.e. 24 months).
Resource use
Resource use per patient was quantified for five main resource use categories, based on two 
main data sources.
The two main sources of data included the national CPG, and the Erasmus MC financial 
claims database. The five resource use categories included: diagnostics, emergency room 
visits, inpatient care, outpatient care, and treatment.
The CPG was used to determine the expected resource use of routine comprehensive care 
(planned elective care) for the categories of diagnostics, outpatient visits and inpatient 
visits. This implied that every child with sickle cell disease follows recommendations for 
health maintenance and monitoring of disease-modifying therapy and therefore also uses 
all resources and generates all costs. Consequently, a full compliance to CPG was assumed. 
In addition to the resource use stated in the CPG, the Erasmus MC employs a specialised 
paediatric nurse practitioner (0.8 full-time  equivalent) for both inpatient and outpatient 
care coordination of children with sickle cell disease. We assumed 45 minutes of working 
time for the nurse practitioner per  planned outpatient visit for elective care (i.e. CPG). 
Remaining costs were distributed over all non-elective outpatient (90%) and inpatient visits 
(10%) as obtained from the financial claims database.
The Erasmus MC financial claims database was used to estimate real-world resource use 
associated with acute and inpatient care for all five resource use categories. This database 
contained all recorded hospital procedures and visits to the Erasmus MC and all inpatient 
visits at local hospitals. For the latter we had no access to detailed information about the 
inpatient episodes. Recorded resource use from the Erasmus MC financial claims database 
that exceeded the expected resource use in frequency, was regarded as resource use additional 
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to CPG. For instance, children below one year of age were expected to have five (routine) 
outpatient visits per year. In case a child in this age group had eight recorded outpatient visits 
in one year, only three were regarded as additional visits to the CPG.
The included items for the CPG and financial claims database per resource use category 
are summarised in Table 2.
Resource valuation
Prices for the resource use category ‘diagnostics’ were based on tariffs published by the Dutch 
Healthcare Authority (NZa) in 2019.171 Since prices for haemoglobin phenotyping and hae-
moglobin genotyping were not available from this source, they were based on local, internal 
prices. Medication prices were acquired from the Dutch Healthcare Insurance Board.172 
Prices for surgical procedures (e.g. cholecystectomy) were based on prices published in 2017 
by NZa.173 Costs for both outpatient and inpatient visits were calculated in accordance with 
the Dutch costing manual.174 The salary for a specialised paediatric nurse practitioner was 
taken from the Dutch collective labour agreement for hospitals (CAO).175
Prices for the resource categories of emergency room visits, outpatient care and inpatient 
care are summarised in Table 3.
Where relevant, prices were indexed to 2019 euros using the pertinent consumer price 
index (CPI) published by Statistics Netherlands (CBS).176 All statistical analyses were per-
formed in R (version 3.6.1) using R Studio (version 1.2.1335) (supplement A for loaded R 
packages). All variables were analysed using descriptive statistics. Categorical variables are 
presented in percentages and (total) numbers. Continuous variables such as resource use 
frequencies and costs are summarised by weighted means and standard deviations. Summary 
statistics are presented in an aggregated way (i.e. across all resource use categories) for the 
overall cohort. Weighted mean costs are presented per age group and resource use category.
Table 2 – Resource use categories and included items per data source
Resource use category Items CPg Items financial claims database
Diagnostics Diagnostic procedures (including 
laboratory and diagnostic imaging)
Additional diagnostic procedures (i.e. X-rays, 
abdominal ultrasound)
Treatment Standard medication and 
vaccinations
Additionally prescribed medication, surgery and 
blood transfusions
Emergency care NA Emergency room visits
Outpatient care Routine visits to the outpatient clinic 
and care by specialized paediatric 
nurse practitioner
Additional visits to the outpatient clinic or 
medical social work and additional care by 
specialized paediatric nurse practitioner
Inpatient care NA Inpatient visits (including ICU) and day patient 
visits
Abbreviations: CPG, clinical practice guideline; ICU, intensive care unit; NA, not applicable.
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RESULTS
A total of 125 patients were retrospectively analysed based on the Erasmus MC financial 
claim database. The mean age was 7.9 years (SD: 4.7 years) on 31 December 2015 (first year 
of observation) and 8.6 year (SD: 4.9 years) on 31 December 2016. Forty-three percent were 
female patients, five patients entered the cohort as new-borns in 2015 and 2016. Summary 
statistics for patient’s age, sex, haemoglobin genotype at the end of the observations period 
(31 December 2016) are shown in Table 4 (see online Appendix 3B for additional informa-
tion on the distribution of genotypes across age groups).
Overall, 52 of 125 patients (43%) had inpatient care during the study period. These 
patients had a total of 133 admissions with an average length of stay of 5.2 days (SD: 4.6). 
On average, children were seen on an outpatient basis 2.1 times per year and admitted as 
inpatients 3.1 times per year. Patients in age groups A and B had no additional outpatient 
visits to the planned visits according to the CPG. For age groups C and D, the average yearly 
additional outpatient visits were marginal. The number of patients per age group, their mean 
years at risk and summary statistics for inpatient and outpatient visits are presented in Table 
5.
Table 3 - Prices of emergency room visits, outpatient and inpatient care
Resource use 
categorya
Item Average yearly resource 
use frequency, per age 







Emergency room visit NA 277 Dutch costing manual 25
Inpatient care Inpatient day at academic 
hospital
NA 669 Dutch costing manual 25
Intensive care unit (ICU) visit NA 2309 Dutch costing manual 25
Inpatient day at local hospital NA 473 Dutch costing manual 25
Day patient visit NA 319 Dutch costing manual 25
Outpatient 
care






108 Dutch costing manual 25
Medical social work visit NA 69 Dutch costing manual 25
Specialised paediatric nurse 






25 Dutch collective labour 
agreement for hospitals 26
Abbreviations: CPG, clinical practice guideline; ICU, intensive care unit.




All patients (n = 125), accrued total cumulative costs of 1,205,919 EUR during the 2 years 
observed. For patients with a full follow-up time (i.e. 24 months), yearly total costs per pa-
tient varied considerably, ranging from 669 EUR to 84,010 EUR. Of the total expenditures 
for all patients, approximately 50% of the costs were induced by 18 children (i.e. 14% of the 
total patient population) and approximately 80% of the costs were induced by 65 children 
(i.e. 52% of all patients). The distribution of HbSS and HbSC genotypes in the 18 children 
inducing 50% of the total costs was 83.3% and 11.1%, respectively.
Average yearly expenditures for all 125 children were 5,049 EUR (SD: 1,634 EUR). The 
majority (37%) of costs was associated with inpatient care; 27% with diagnostics; 19% 
with treatment; 11% with outpatient care and 6% with emergency room visits. The average 
Table 4 – Patient characteristics
variable Entire retrospective cohort 
(values on 31 December 2016)
Patients (n) 125




Haemoglobin genotype, n (%)
HbSS 76 (60.8)
HbSC 31 (24.8)
HbSβ+ thalassemia 8 (6.4)
HbSβ0 thalassemia 4 (3.2)
Other (i.e. HbSdeltaβ0, HbArab β0) 6 (4.8)






































Totala 125 1.9 496 2.1 749 3.1 253 1.1
A 17 0.5 47 5.0 10 1.1 32 3.4
B 49 1.4 168 2.5 122 1.8 90 1.3
C 69 1.7 194 1.7 302 2.6 67 0.6
D 29 1.6 87 1.8 315 6.6 64 1.3
aThe sum of patients in each age group is not equal to the total number of patients studied, since chil-
dren were analysed in older age groups when applicable during the 24-month observation period. The 
mean number of visits was calculated by dividing the total number of visits (per stratum) by the total 
years at risk (not the total number of patients), as some patients did not contribute an entire 2 years to 
each age group (due to increasing age and switching between categories).
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yearly costs per patient and age group are depicted in Figure 1. Again, average costs vary 
considerably between age groups, which is mainly related to diff erences in the number of 
inpatient days. Major cost drivers for age group A and B were diagnostics and treatment, 
respectively. For age groups C and D, the major cost drivers were inpatient care, although for 
age group C, the average diff erence in costs between diagnostics (1,355 EUR) and inpatient 
care (1,488 EUR) could be regarded as marginal. Average yearly costs for inpatient care were 
higher in older age groups and nearly three times as high in age group D compared to group 
C. Only for age groups C and D, we observed stays at the intensive care unit (resource use 
category inpatient care) with a slight increase from age group C to D. More information on 
the distribution of inpatient care across age groups can be found in online Appendix 3C.
DISCUSSION
Healthcare utilisation and expenditures
Although healthcare utilisation and costs among children with sickle cell disease have been 
studied previously,161,167–170 studies from European comprehensive care centres are scarce 
and have only focussed on one aspect of care such as hospitalisations costs.163,177 To our 
Figure 1 - Th e average yearly costs per patient and age group. Green: Yearly mean costs according to 
the clinical practice guideline. Red: Yearly additional mean costs based on the Erasmus Medical Center 
fi nancial claims database.
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knowledge, this is the first study describing costs from a European comprehensive care 
centre combining standard treatment costs with real-world resource use.
The total yearly costs of healthcare for children with sickle cell disease, including inpatient 
care, outpatient care, diagnostics and treatment averaged 5,049 EUR (SD: 1,634 EUR) 
per patient per year. This is much lower when compared to cost of healthcare for paediatric 
patients with sickle cell disease in other studies. Kauf et al. calculated total costs of health-
care for children with sickle cell disease aged 0-9 years to be 10,704 USD (8,906 EUR) 
(SD: 24,696 USD [20,548 EUR]) per year, of which more than 75% were associated with 
inpatient care.161 In our study, inpatient care accounts for a much smaller proportion of total 
costs (i.e. 37%). As a consequence, this substantially reduces healthcare costs as inpatient 
care is generally more expensive compared to comprehensive healthcare at specialised out-
patient clinics. The study of Pizzo et al. is up until now the only cost of care study in sickle 
cell disease performed in Europe.163 They retrospectively assessed the cost of inpatient care 
for vaso-occlusive crises in the United Kingdom between 2010 and 2011. For children aged 
1-9 years they reported mean admission costs to be 1,732 GBP (2,379 EUR). Their analysis 
underestimates the real costs of inpatient care, as it only considers the cases with crises as a 
primary diagnosis.163 In our study, average yearly inpatient costs for children aged 1-5 (age 
group B) and 5-13 (age group C) years old was respectively 1,061 EUR and 1,488 EUR. 
However, care should be given to comparing costs, as factors such as healthcare financing, 
social and political structures as well as types of treatment regimen can vary greatly among 
different countries. For example, due to differences in expert opinion, the most recent guide-
line of the National Heart, Lung and Blood Institute advices transcranial Doppler screening 
every year, compared to twice a year in the Dutch CPG. Furthermore, most cost-of-care 
studies use the terms cost, charge and fees synonymously or confuse reimbursement with 
costs, making it even harder to compare international data.178
Sickle cell disease varies greatly in severity, with some children relatively asymptomatic 
while others are severely ill. As a consequence, substantial variation in healthcare costs is 
observed among children with sickle cell disease.162,167,168,170 We also observed this variation; 
a relatively small fraction of patients accounted for half of the total costs (i.e. 18 children 
generating approximately 50% of the costs). Although our study did not collect data on 
clinical heterogeneity (e.g. organ damage), these 18 patients are most likely patients with 
more severe symptoms. Furthermore, the majority of these 18 patients had HbSS sickle cell 
disease, which is often associated with a more severe phenotype. To establish and quantify 
the effect of disease severity on healthcare costs, further studies with larger samples sizes and 
longer follow-up periods need to be conducted.
Although the clinical features of sickle cell disease are heterogeneous, and therefore also 
the associated costs both within and across age groups, yearly additional mean costs based on 
the financial claims database seemed to increase with age for all resource use categories. This 
is consistent with previous research showing that age is an important determinant of disease 
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severity, since older patients are more likely to accumulate organ damage and dysfunction 
and have more frequent painful vaso-occlusive crises.179–183 However, yearly additional mean 
costs for emergency room visits follow a reverse trend (i.e. decrease between age groups A to 
C), while they increase for age group D again. A similar pattern is seen in the general pae-
diatric population, in which young children also constitute a disproportionately high share 
of paediatric emergency care, mostly due to respiratory infections.184,185 In addition, parents 
tend to be more anxious when their child has just been diagnosed with sickle cell disease (via 
the newborn screening program), possibly leading to more frequent hospital visits.
Estimating cost of care is important for appropriate allocation of resources and reimburse-
ment tariffs. Furthermore, specific to the healthcare system in the Netherlands, knowledge 
of healthcare utilisation and expenditures for patients with sickle cell disease may help to 
establish a diagnosis treatment combination (DBC) for (paediatric) patients with sickle cell 
disease. DBCs describe a complete care episode and are used as the basis for remuneration 
negotiations between hospitals and health care insurers. Currently, haemoglobinopathies 
(including sickle cell disease and thalassemia) do not have a separate DBC code and are 
declared by the DBC ‘anaemia not otherwise specified’. We hope this study will play a role 
in the authorisation of a DBC for paediatric sickle cell disease, by giving insight into overall 
cost of healthcare resource use for sickle cell disease patient in the Netherlands.
Limitations
This study is not without limitations which need to be considered when interpreting the 
results. Firstly, it is important to note that our analyses do not aim at deriving statistical infer-
ence and therefore our results are descriptive in nature. Secondly, sample size (125 patients), 
information about patient characteristics, and follow-up time (24 months) were limited. A 
further stratification into subgroups according to potential cost predictors was therefore not 
possible. Thirdly, a substantial proportion of patients were admitted to local hospitals. There 
are more than ten local shared care centres, all with their own medical databases, which are 
not linked to the financial claims database of the Erasmus MC. Although inpatient days 
were manually retrieved, detailed information about those care episodes, especially with 
regard to treatment and diagnostics, is missing. Hence, the estimated total costs reported for 
these items should be seen as lower limits of the actual costs. For example, although most 
complex care will have been given at the Erasmus MC, some children may have had a blood 
transfusion or imaging procedures during admissions at a local hospital. These interven-
tions remain unknown and are therefore not reflected in the total costs. Nevertheless, by 
including the major cost driver (inpatient days in local hospital) we believe that results will 
not be substantially different. The Sickle Cell Outcome REsearch (SCORE) consortium of 
the Netherlands is currently developing a multicentre database for (paediatric) sickle cell 
patients, which is an important step towards more detailed analysis of patient-related data. 
Fourthly, none of the patients in our cohort had a haematopoietic stem cell transplantation 
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(HSCT) during the observed time period. Although HSCT is still a relatively uncommon 
treatment, median total costs for children with sickle cell disease is around 413,000 USD 
(343,627 EUR) for inpatient care and 18,000 USD (14,977 EUR) for outpatient care,186 
which would consequently have increased total annual costs when performed. Finally, it is 
important to note that we have adopted a health care perspective approach, meaning that 
patients costs (i.e. patient’s time lost from school, transportation costs and parental loss of 
wage-earning capacity due to caretaking of a chronically sick child) were not accounted for 
in calculations. Further research is warranted to determine this important cost component.
CONCLUSION
In summary, we have described a detailed investigation of resource use and cost of healthcare 
for paediatric patients with sickle cell disease in the Netherlands over a 2-year period, retro-
spectively. Sickle cell disease is a chronic, complex and often unpredictable disease requiring 
life-long management. Our analyses suggest that costs of a comprehensive, multidisciplinary 
approach with effective management in the outpatient setting, is favourable when compared 
to episodic healthcare. Lower resource use and costs were observed for acute care and inpa-
tient facilities. However, care should be given with regard to comparing our data to other 
countries. Further studies including more patients with longer follow-up times are needed 
to confirm our findings. In addition, to enhance medical outcomes and decrease healthcare 
utilization and costs, further investigation of the small subset of children who consume a 
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Objective: No standard second‐line treatment exists for acute graft‐versus‐host disease 
steroid‐refractory (SR‐aGvHD), and long‐term outcomes remain poor. Mesenchymal stro-
mal cells (MSCs) have been evaluated as treatment, but no disease model (DM) exists that 
integrates and extrapolates currently available evidence. The aim of this study was to develop 
such a DM to describe the natural history of SRaGvHD and to predict long‐term outcomes.
Method: The DM was developed in collaboration with experts in haematology‐oncology. 
Subsequently, a model simulation was run. Input parameters for transition and survival esti-
mates were informed by published data of clinical trials on MSC treatment for SR‐aGvHD. 
Parametric distributions were used to estimate long‐term survival rates after MSCs.
Results: The newly developed DM is a cohort model that consists of eight health states. 
For the model simulation, we obtained data on 327 patients from 14 published phase II 
trials. Due to limited evidence, DM structure was simplified and several assumptions had 
to be made. Median overall survival was 3.2 years for complete response and 0.5 years for 
no complete response. Conclusion: The DM provides a comprehensive overview on the 
second‐line treatment pathway for aGvHD and enables long‐term predictions that can be 
used to perform a cost‐effectiveness analysis comparing any treatment for SR‐aGvHD.
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INTRODUCTION
Despite decades of research, acute graft‐versus‐host disease (aGvHD) is still one of the 
leading causes of death after haematopoietic allogeneic stem cell transplantation (HSCT) 
for both paediatric and adult patients.187,188 Immunosuppressive therapy with systemic cor-
ticosteroids is the first‐line treatment option. However, latest available studies estimate that 
about 50%‐70% of the patients do not respond to this therapy.189–191 Currently, there is no 
standard second‐line treatment available and outcomes in terms of morbidity and mortality 
remain poor.191–195
Since 2004, mesenchymal stromal cells (MSCs) are increasingly studied in phase II clinical 
trials as a therapeutic option, demonstrating positive treatment effects for steroid‐refractory 
(SR)‐aGvHD.196,197 However, most of these trials are single‐arm studies or case studies or 
include a limited amount of patients (<50 participants), making reliable and meaningful 
conclusions challenging. Ideally, the effectiveness of MSC should be tested through phase III 
randomised controlled trials (RCTs), but these trials are difficult to perform due to regula-
tory and patient population‐related issues.197–199 In 2010, results of one RCT (Prochymal; 
Osiris Therapeutics, Inc. Columbia, Maryland, United States) were released in the form of 
an unreviewed abstract.200 Further, a multicentre RCT is currently being conducted by the 
European Union Horizon 2020–funded research consortium RETHRIM (REgeneration 
THRough IMmunomodulation)201 (i.e. the HOVON 113 MSC trial202). The latter study 
aims to determine the efficacy and cost‐effectiveness of MSC as part of a second‐line treat-
ment for aGvHD.
In the absence of reliable and conclusive RCT data, several options exist to aggregate 
and synthesise currently available evidence of MSCs as a treatment option for SR‐aGvHD. 
These include metaanalyses, observational databases, the aggregation of expert opinion or 
decision analytic modelling.203 Thus far, four reviews that include currently available tri-
als testing MSC as treatment for SR‐aGvHD have been published,197–199,204 of which two 
are meta‐analyses.197,204 However, none of the reviews combine available patient‐level data 
(PLD) of the phase II trials to predict and model long‐term outcomes of MSC treatment.
The aim of this study was to develop a disease model (DM) to describe the natural history 
of SR‐aGvHD progression and its treatment pathways. The DM can be used to predict 
long‐term outcomes and cost‐effectiveness of current (eg, MSC treatment) and future treat-
ment options for SR‐aGvHD. To test the practicability of the model, we aimed to gather 
and implement PLD of a second‐line treatment option. Ultimately, our model may facilitate 
clinical decision‐making under conditions of uncertainty.205–207 When costs are added, this 




Part 1: designing and structuring the model
Model characteristics
The aim of the DM was 2‐fold. First, it needed to represent the natural history of SR‐aGvHD 
and its treatment pathways in a simplified manner. Therefore, the DM focusses on the SR‐
aGvHD only until patients either progress, relapse, develop chronic GvHD or die. Second, 
it needed to be easily adaptable to a cost‐effectiveness model at a later stage. Therefore, the 
DM was built based on clinical expertise, previously published literature189,191,196,208,209 and 
the R ETHRIM protocol.201 According to the ISPOR recommendations for good modelling 
practice,210 we consulted clinical experts to ascertain that the model represents the disease 
process and addresses the decision problem of determining which one second‐line treat-
ment option is (cost‐)effective when compared to another therapy option. We employed a 
convenience sample to include the clinical experts from the RETHRIM consortium. To be 
part of RETHRIM, consortium members needed to prove extensive research and treatment 
experience in the field of HSCT and work at a HSCT specialised treatment centre. All 
experts involved in this research thus have various professional backgrounds (e.g., internal 
medicine, haematology, oncology or transfusion medicine) and originate from five EU 
member states (Germany, Italy, The Netherlands, Spain and Sweden). A European perspec-
tive on the disease and treatment pathway(s) of SR‐aGvHD was hence ensured.
Involvement of experts
Experts were consulted via email, during several telephone conferences and consortium meet-
ings. This process was iterative until a final model version was regarded to fully represent the 
natural disease and treatment pathway. In addition to the several consultations, the experts 
were asked to give written feedback on an earlier model version by means of a semistructured 
questionnaire. Choosing the appropriate model type (eg, decision tree, Markov process) was 
also based on the ISPOR recommendations for good modelling practice.210
Part 2: model simulation
Model input parameters
As MSCs are widely studied in numerous phase II clinical trials and case studies since 
2004,196,199 we selected this treatment option to perform a model simulation. For the 
model input parameters, we identified relevant studies testing MSCs for the treatment of 
SR‐aGvHD from the recent reviews of Chen et al.,204 Munneke et al.,198 and Hashmi et al.197 
Additional PLD were obtained for studies whose principal investigator was a member of the 
RETHRIM consortium.
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Data were extracted using a prespecified extraction form aiming at capturing all available 
data that describe the disease and treatment pathway (see online Appendix 4A). The clinical 
effectiveness of MSC treatment was obtained from PLD of the reported first response evalu-
ation or reconstructed from the published Kaplan‐Meier curves. Studies not reporting these 
data were excluded.
To extrapolate the survival data beyond the observed time horizon, we followed the 2013 
updated NICE Decision Support Unit recommendations.211 Accordingly, considered para-
metric survival models for the DM included exponential, Weibull, Gompertz, loglogistic, 
lognormal and generalised gamma distributions. Parametric models were evaluated through 
visual inspection, Akaike’s information criterion (AIC) and Bayesian information criterion 
(BIC) tests as well as clinical validity according to the expert group.
Simulation
We ran a base‐case simulation with a hypothetical patient cohort comprising 100 patients 
with aGvHD grades II‐IV. Survival was modelled on a lifetime horizon, whereas it was as-
sumed that patients do not exceed the age of 99 years.212 Health outcomes of the simulation 
were expressed in life‐years (LYs). As future health effects are valued lower than immediate 
effects,19 we adjusted future health outcomes (LYs) to “present values” according to the 
Dutch guideline for economic evaluations in health care.213,214
All statistical analyses were conducted in RStudio (version 1.0.143, R version 3.4.1). 
Comprehensive R Archive Network (CRAN) packages used included survival, flexsurv, 
survminer and plyr.
RESULTS
Part 1: designing and structuring the model
Model characteristics
We opted for a cohort‐based Markov model, which represents the most relevant responses 
and outcomes to second‐line treatment for aGvHD in corresponding health states. A 
Markov model consists of mutually exclusive health states that are associated with different 
outcomes and costs and provides an efficient structure to simulate a group of patients over 
time. Patients can change from one health state to another (ie, transit) at specified time 
interval (ie, cycles). Outcomes and costs are calculated for the entire time horizon of the 
model, taking into account the distribution of patients amongst the states at each cycle.215,216 
Outcomes may entail clinical effectiveness outcomes (eg, response to treatment) as well as 
health‐related quality of life (HRQoL) measures.
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The DM comprises eight health states: (a) treatment for SRaGvHD II‐IV, (b) response 
to treatment (complete or partial response), (c) sustained response, (d) treatment failure 
(stable or progressive disease), (e) relapse/persistent aGvHD, (f ) third‐line aGvHD therapy, 
(g) relapse or adverse events of haematologic disease requiring reinitiation or intensification 
of immunosuppression and (h) death (see Figure 1 for the model diagram). These states 
were primarily based on the HOVON113 MSC treatment protocol and expert opinion (see 
section “Involvement of experts”). Four response categories are defined: complete response 
(CR) is defined as the absence of all sign and symptoms of aGvHD; partial response (PR) 
is the improvement of aGvHD by at least one grade; stable disease (SD) is no change in 
aGvHD; and progressive disease (PD) is the worsening of aGvHD by at least one grade. The 
cycle duration was set at 28 days according to the recommendation by Martin and colleagues 
on the standardised time period to evaluate aGvHD response.217 In addition, we applied a 
half‐cycle correction for the calculation of the model outcomes.
The model starts with treatment for SR‐aGvHD (a) at time 0 (T0). Within 28 days after 
treatment (T28), patients either respond [ie, transit to the response to treatment health state 
(b)] or have a treatment failure (d) or die (h). Responders (b) can have a sustained response 
(c), relapse or have a persistent aGvHD grade that requires the reinitiation or intensification 
of immunosuppression (e), or enter third‐line therapy (f ).
Patients with a treatment failure to the initial MSC treatment (d) will directly receive 
third‐line treatment (f ). Adverse events (AEs) of treatment are not defined as a separate 
health state, but are possible within health states (b), and (d)‐(f ). At any time and from any 
health state, patients can transit to relapse or experience of an adverse event of the underlin-
ing haematological disease (g), or death (h). Death is an absorbing health state, meaning that 
once entered, patients remain in this health state.
In the model, all health states are defined as mutually exclusive although in clinical prac-
tice patients may sometimes fit the criteria of multiple health states. In these cases, patients 
are assigned to the health state with the largest impact on outcomes and costs. For example, 
Figure 1 – Design of the deci-
sion model for MSC treatment in 
aGvHD
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patients with treatment failure [health state (d)] may experience a relapse of the disease 
[health state (g)]. These patients are assigned to the relapse health state (g) although they also 
fit the criteria for treatment failure. The increasing numbering of the model states indicates 
the expected increasing impact on both outcomes and costs, according to expert opinion.
Involvement of experts
The team of clinical experts consisted of eleven members from five different countries 
(Germany, Italy, the Netherlands, Spain and Sweden). A preliminary model based on the 
HOVON113 MSC treatment protocol was presented to all consortium members at the 
third RETHRIM consortium meeting. Because the structure of the model was deemed 
incomplete, alternative treatment pathways and additional health states were discussed in 
detail. This led to a refinement of the existing model states and to the addition of the fol-
lowing health states: relapse or adverse events of haematological disease, and adverse events. 
The new version of the model was then presented and discussed at the fourth RETHRIM 
consortium meeting. To allow for written feedback, experts were asked to fill out a semistruc-
tured questionnaire at the fifth consortium meeting. Subsequently, the model was amended 
and a final version was approved by all experts.
Part 2: Model simulation
Model input parameters
We detected 18 studies that reported on phase II trials and collection of case studies, 
190,218–234of which 9 reported PLD (see online Appendix 4B).218–223,225,228,233 Unpublished190,227 
and additional data230 were requested and received for three studies. Two studies could be 
integrated by reconstructing the published Kaplan‐Meier curves.232,234 Three studies were 
excluded because they did not publish survival data,224,231 or the proportion of patients in the 
response categories.41 Patients reported in the study by Ringdén et al229 were not included 
as they had been already included in the data presented by Le Blanc and colleagues.190 From 
Lucchini et al,233 only four patients with aGvHD stages II‐IV were included.
In total, we extracted data from 327 patients from 14 studies to estimate the proportion 
of individuals in the different health states and the proportion of patients changing between 
these states (ie, transition probabilities).31 Age and sex were only reported for 177 and 152 
patients, respectively, which made the originally planned subgroup analysis for age and sex 
impossible. All patients had aGvHD grades II–IV prior to MSC treatment; for 204 cases, 
the exact grade was known (18.6% aGvHD II, 45.6% aGvHD III and 35.8% aGvHD IV). 
Response categories in the underlying studies were defined heterogeneously. Whereas one 
study did not provide any definition for the response categories employed,37 only complete 
response (CR =the complete resolution of all aGvHD symptoms) was unanimously defined 
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in all other studies. Therefore, all response categories other than CR were grouped as “no 
complete response” (nCR).
Due to the lack of sufficiently detailed observational data, we were forced to use a 
simplified version of our model simulation. In this version, we could only model the first 
response to treatment (at day +28) and long‐term survival of patients after the first response 
evaluation to MSCs. The health states sustained response,190 relapse or persistent aGvHD,191 
third‐line therapy, chronic GvHD,193 relapse or adverse events of haematological disease,194 
and adverse events in general could not be modelled.
Transition probabilities for the first two model cycles
Reported mean and median time of first evaluation was 26.6 and 28 days, respectively (range 
= 2‐58). To integrate all available observations into the model, we assumed that all responses 
were evaluated within the first 28 days after MSC treatment. Based on this, we calculated 
a transition matrix showing the probability of response to MSC after day 28 (see Table 1).
Table 1 shows that 43.4% patients with aGvHD II‐IV had a CR at first response evalua-
tion whereas 43.7% had nCR, and 12.8% died within the first 28 days.
Long‐term survival estimation
To extrapolate survival estimates beyond study observations, survival data, available for 235 
patients (115 CR, 120 nCR), were used. For the excluded cases, the last time of follow‐up 
or time to death was not reported. Patients who died before day 28 were already included in 
the 28‐day transition rates to death. Median survival times were reached at approximately 
five years (1819 days) for complete responders and at approximately four months (115 days) 
for nCR.
Kaplan‐Meier curves and fitted parametric models for survival are depicted in Figure 2 for 
both response categories. AIC and BIC values are presented in online Appendix 4C. From 
a statistical point of view, the fit of the parametric models to the empirical data was similar. 
Nevertheless, the extrapolation after observation was different. For instance, the extrapola-
tion according to the generalised gamma function predicted that 40% of the CR patients 
survived more than 25 years after MSC treatment. This was not deemed plausible from a 
clinical perspective by the experts. Based on clinical expertise, the lognormal distribution 
would present the best balance between the statistical tests of fit and visual inspection for 
both CR and nCR.
Table 1 - Transition rates from pre‐ to post‐MSC treatment
To
CR nCR Death
From aGvHD II-IV 43.4% 43.7% 12.8%
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Results of the model simulation
At the 28‐day treatment evaluation, of the 100 simulated cases with aGvHD II‐IV, ap-
proximately 43 and 44 observations had a CR and nCR, respectively. The median survival 
time modelled for CR was 3.2 and 0.5 years for nCR. Overall median survival for all patients 
irrespective of their response category was 9.6 months. Average per‐person life‐years were 
Figure 2 - Empirical Kaplan‐Meier curves with parametric model estimations
Table 2 - Estimated overall survival probability in per cent
years after the first response evaluation
Response category 1 2 5 10 20 50 80 99
CR 73.1 59.6 40.1 26.7 16.0 6.8 4.1 0
nCR 25.7 11.4 2.6 0.6 0.1 0 0 0
All 43.0 30.9 18.6 11.9 7.0 3.0 1.8 0




estimated at 0.32 years (ie, 3.8 months). In Figure 3, modelling results are plotted on the 
empirical Kaplan‐ Meier curves for CR and nCR. Table 2 depicts the estimated overall 
survival probabilities for different years after the first response evaluation.
DISCUSSION
In this study, we present a DM for the second‐line treatment of aGvHD. In line with current 
recommendations for good modelling practice, we involved an international group of clini-
cal experts to develop this DM and used evidence available from the literature.189,191,208,210 
Consequently, we ensured that the model sufficiently represents current clinical practice.
The DM can serve manifold purposes. Updated with clinical evidence, it can be used 
by clinicians and researchers to estimate longterm health outcomes of different treatment 
alternatives. When costs are added to the clinical evidence, for example, from RETHRIM, 
economic evaluations can be performed to inform reimbursement decision‐makers on the 
implementation of treatment alternatives.
To run a first model simulation, we searched for available evidence on both costs and clini-
cal evidence on treatment alternatives for aGvHD. We found that MSCs for the treatment 
of SR‐aGvHD are widely studied. Therefore, we were able to integrate more than a decade of 
empirical data into our DM. Nevertheless, mainly due to the absence of randomised phase 
III studies, the number of patients included and the restricted follow‐up periods, we faced 
several challenges in integrating the collected information. Consequently, we had made a 
number of assumptions.
First, MSC products and their administration varied between the studies. With the excep-
tion of the study by Fang et al218 where MSCs were derived from human adipose tissue, 
all other studies used bone marrow–derived products. In addition, the number of MSC 
infusions (between 1 and 21 infusions) as well as the dosage of infused MSCs (between 0.6 
and 20 x106 cells per kg body weight) varied across the studies. In this regard, we assumed 
that type and administration of MSC products had no effect on transition probabilities or 
mortality rates. Whereas this made the integration of the study results possible, the data did 
not allow for further stratification to test potential MSC derivation–related or dose‐related 
effects on the response rates.
Second, there were not enough data available to estimate transitions between response 
categories after a first response evaluation. We had assumed survival can be predicted based 
on the initial response category at 28 days post‐MSC transfusion. However, in clinical 
practice response categories may change in any direction after the first evaluation. Of the 
included studies, only Prasad et al36 assessed response to MSCs in paediatric patients more 
than once. In this study, five of twelve patients further improved after day 32 to a complete 
remission. Future studies measuring response on several time points after MSC treatment 
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could inform our model on subsequent changes in response categories. Whereas this enables 
a better estimate for subgroups, the effect on the average survival of the entire population is 
most likely negligible.
Third, it needs to be noted that the simulation did not consider the underlying haema-
tological disease, nor the patients’ age or sex. This choice was made as not all studies did 
report on these variables and any further stratification would have resulted in a reduction in 
the population on which the different estimates are based. However, we acknowledge that 
the underlying haematological disease and age and sex can be important determinants for 
long‐term survival. Detailed reporting on patient characteristics and their diagnosis may 
help to enable further analyses for these subgroups.
Our modelling results, however, did show the expected longer survival after MSC transfu-
sion for patients that achieved CR at first response evaluation, when compared to patients 
with nCR. These estimates are in line with previous findings highlighting the importance of 
complete response for long‐term survival.235–240
To our knowledge, there are no long‐term survival results published for SR‐aGvHD 
patients treated with MSCs other than the two reports241,242 that are based on studies190,229 
included in our study. Therefore, we attempted to compare our results to survival estimates 
of studies that tested other second‐line treatment options for aGvHD. To find suitable stud-
ies, we consulted the most recent NHS England clinical commissioning policy on the treat-
ments for GvHD following HSCT.195 This guideline is based on an extensive and updated 
review of the literature and concludes that there is sufficient evidence only for extracorporeal 
photopheresis (ECP) to be routinely commissioned for the treatment of aGvHD. Therefore, 
we focussed on a comparison with ECP. For other treatment options such as infliximab, 
etanercept, inolimomab, alemtuzumab, pentostatin or MSCs, the reviewers found that there 
was no sufficient evidence available to propose the routine commissioning for aGvHD.
Regarding survival of aGvHD patients treated with ECP, the largest series was published 
by Greinix et al.238 in a phase II prospective study.195 Every week, 59 patients with steroid‐
refractory or steroid‐ dependent GvHD received two consecutive ECP treatments. CR and 
nCR was defined as in our study. The reported median survival was below 6 months after 
HSCT for patients with nCR, confirming our median survival estimations for nCR to MSC 
of approximately 6 months.238 In the study of Greinix et al,238 median survival for complete 
responders was never reached during the reported follow‐up period of 9 years after HSCT. 
For this study, this implies that the probability of surviving nine years after HSCT would be 
approximately 59% for patients with a CR With an estimate of approximately 27% at ten 
years post‐MSCs, our estimates for patients with a CR are significantly lower. This may be 
explained by differences in patient population before treatment (ie, Greinix et al. 238 included 
a higher number of patients with aGvHD grade II (61%)). In addition, the study by Greinix 
and colleagues was based on a limited amount of complete responders (n = 41).
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Although we were able to demonstrate longer survival for patients with CR when com-
pared to nCR, the relatively high mortality rate of SR‐aGvHD, even with MSCs, can still 
be regarded as unacceptably high. And although there were numerous studies reporting on 
MSCs as a treatment alternative for SR‐aGvHD, none of them included patient‐ reported 
outcomes (PROs) such as HRQoL. Updating our results with HOVON113 findings, in-
cluding HRQoL measures, might improve the current survival estimates and show favour-
able treatment outcomes in terms of quality of life for MSCs when compared to placebo. 
However, until these study results are presented, this remains subject to speculation and the 
search for alternative (pre)treatments helping patients to achieve a complete response will 
have to continue.
CONCLUSION
The designed DM provides a comprehensive overview on the second‐ line treatment path-
ways for aGvHD in general. The model simulation with data from previously published 
studies on MSCs as a second‐line treatment option for aGvHD presented outcomes match-
ing the literature as well as clinical expectations. This demonstrates the practicability and 
usefulness of the model. However, to date, only insufficiently detailed data are available to 
fully model all health states and to perform a cost‐effectiveness analysis. The yet restricted 
model simulation would therefore benefit from additional data, preferably from a phase 
III RCT. The integration of effectiveness results together with health‐related quality of life 
measures (e.g., from the EQ‐5D questionnaires) and different cost components derived from 
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Introduction: In several studies, tisagenlecleucel demonstrated encouraging rates of remis-
sion and lasting survival benefits in pediatric patients with relapsed/refractory acute lym-
phoblastic leukemia ALL. We assessed its cost-effectiveness (list price: 320,000 EUR) when 
compared to clofarabine monotherapy (Clo-M), clofarabine combination therapy (Clo-C), 
and blinatumomab (Blin) from both a healthcare and a societal perspective and considered 
future medical and non-medical consumption costs.
Methods: With a three-state partitioned survival model we simulated a cohort of paediatric 
patients (age: 12 years) through different disease states until death. Relevant outcomes were 
life years, quality-adjusted life years (QALYs), healthcare costs, societal costs and the incre-
mental cost-effectiveness ratio (ICER). Uncertainty was explored through deterministic and 
probabilistic sensitivity analyzes and several scenarios.
Results: Total discounted costs for tisagenlecleucel were 552,679 EUR from a societal, and 
409,563 EUR from a healthcare perspective. Total discounted societal costs for the compara-
tor regimens ranged between 160,803 EUR for Clo-M and 267,259 EUR for Blina. Highest 
QALYs were estimated for tisagenlecleucel (11.26), followed by Blina (2.25), Clo-C (1.70) 
and Clo-M (0.74). Discounted societal ICERs of tisagenlecleucel ranged between 31,682 
EUR/QALY (Blina) and 37,531 EUR/QALY (Clo-C) and were considered cost-effective 
with a willingness-to-pay (WTP) threshold of 80,000 EUR/QALY. None of the scenarios 
exceeded this threshold and more than 98% of the iterations in the probabilistic sensitivity 
analysis were cost-effective.
Discussion: At the current price tisagenlecleucel is cost-effective from both a healthcare and 
a societal perspective. Nevertheless, long-term effectiveness data is needed to validate the 
necessary assumptions.
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INTRODUCTION
With current first-line treatment protocols, survival in pediatric B-cell acute lymphoblastic 
leukemia (pALL) increased to 85-90% over the past years. Also in relapsed pALL, 40-60% 
of children can be cured with intensive chemotherapy regimens, often including allogeneic 
stem cell transplantation (alloSCT).243 The prognosis for patients with a second relapse, 
with a relapse after alloSCT or with refractory pALL remains however poor, ranging from 
10-30% two-year overall survival (OS).244,245 In this article, these patients are referred to as 
r/r pALL patients. Current regimens for r/r pALL include clofarabine monotherapy (Clo-
M), clofarabine combination therapy (Clo-C), and blinatumomab (Blina), although no 
clearly defined standard of care yet exists. In countries such as the US and the UK, salvage 
chemotherapy is also commonly used.
In several clinical trials, the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel 
showed high rates of remission246–250 and lasting survival benefits with 12-month event-free 
survival (EFS) rates between 45% to 51%.246,247,249 These promising results come at a high 
costs however. In the US tisagenlecleucel was made available at 475,000 USD (approx. 
414,000 EUR) which included an outcome-based commercial model.251 The stated list price 
in the UK is 282,000 GBP (314,000 EUR; 360,000 USD) and after a confidential discount 
it is currently available via the Cancer Drug Fund.252 In the Netherlands, the list price is 
320,000 EUR. Whether tisagenlecleucel is a cost-effective alternative to existing treatments 
is a pressing question for policymakers, payers, clinicians as well as patients, and can be 
explored by cost-effectiveness modelling approaches.253 Ideally, such a cost-effectiveness 
analysis is not limited to a healthcare (or payer) perspective, including only direct healthcare 
costs. This is because treatment for r/r pALL also affects both personal and professional lives 
of the patients and their caretakers. When other aspects such as travel costs, informal care 
costs and productivity losses or gains are incorporated, a cost-effectiveness study is referred 
to as being conducted from a so-called “societal perspective”. The Dutch EE guideline rec-
ommends such a perspective for all cost-effectiveness analyses in the Netherlands.42
To date, some economic evaluation studies have been performed estimating the cost-
effectiveness of tisagenlecleucel compared to Clo-M, Clo-C or Blin over a lifetime horizon 
(i.e. until all simulated patients died).254–258 All of them found tisagenlecleucel cost-effective 
in at least one scenario from a payer perspective255,257,258 and a societal perspective.254,256 
To employ a societal perspective, Sarkar et al.254 included cost of caregivers, patient time, 
transportation and parking, as well as meals. However, it remains unclear what specific cost 
items were considered with regard to caregivers and patient time. The initial manufacturer 
submission to the Canadian Agency for Drugs and Technologies in Health (CADTH) did 
not seem to include a societal perspective. Therefore, the CADTH considered travel and 
accommodation time for patients and caregivers, medical coinsurance amounts, copayment, 
and deductibles over a period of only three years for a scenario analysis from a societal 
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perspective.256 Assuming a lifetime horizon for the economic model, the considered total 
societal costs for tisagenlecleucel of approximately 16,500 CAD seem to be a drastic under-
estimation of the true societal costs that can be attributed to tisagenlecleucel in the lifetime 
of paediatric patients.
Our aim was to add to the existing evidence for tisagenlecleucel in r/r pALL patients 
by estimating the cost-effectiveness of tisagenlecleucel for pediatric patients with r/r pALL 
from a broad societal perspective when compared to Clo-C, Clo-M, and Blina, respectively. 
We are the first study to consider both medical and non-medical consumption costs in life 
years gained (i.e. future medical costs). Furthermore, we considered productivity losses for 
patients’ caretakers rather than for the paediatric patients and explored the inclusion of 
potential productivity gains for children with long-term EFS.
METHODS
The primary outcome of this analysis was the incremental cost-effectiveness ratio (ICER) 
of tisagenlecleucel for each comparator from two perspectives over a lifetime horizon.42 A 
healthcare perspective included costs and effects of pre-treatment, treatment, adverse events, 
follow-up period, subsequent HSCT and future medical costs. A societal perspective included 
all costs and effects of the healthcare perspective in addition to costs for travel, the stay of 
caregivers at a charity hotel during treatment, productivity losses of patients’ caregivers, and 
informal care. Lastly, we also considered non-medical consumption costs.259,260 Results of 
all perspectives are reported separately. The base-case is defined from a societal perspective, 
including future non-medical consumption costs as this represents the most conservative 
estimates.
To estimate the clinical effectiveness outcomes such as life years (LYs) and quality-adjusted 
life-years (QALYs) of each treatment, we modelled a fictive cohort of paediatric patients (12 
years of age) that receive tisagenlecleucel or either comparator treatment (i.e. Clo-M, Clo-C, 
or Blina). At any time, the modelled patients could be in one of the three health states: (i) 
EFS, (ii) progressive disease (PD) or (iii) death (see Figure 1). The proportion of patients 
per health state was estimated from standard parametric survival functions (i.e. exponen-
tial, Weibull, log-logistic, log-normal, Gompertz and generalised Gamma) with the best 
statistical and clinical fit to the observed OS and EFS.211 In addition, a set of flexible cubic 
spline models was considered to capture the potential curative nature of tisagenlecleucel.261 
Statistical fit was assessed with Akaike information criterion (AIC) and the Bayesian infor-
mation criteria (BIC), while clinical plausibility was validated by a clinical expert (PMH). 
For tisagenlecleucel, survival (EFS and OS) was based on pooled data (N=193) from the 
ELIANA (NCT02435849), ENSIGN (NCT02228096), and B2101J (NCT01626495) 
trials.262–264 Overall survival for Clo-M,265 Clo-C,266 and Blina245 was based on the literature. 
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Since EFS data were not available for the comparator arms, EFS was considered proportional 
to OS, using a validated ratio from the literature.267
Patients who remained in the EFS state after fi ve years were assumed to be long-term 
survivors of ALL (i.e. considered cured). Th is assumption was based on the observed plateau 
phase and validated by expert opinion. OS of these patients was modelled by applying the 
standard mortality rate (SMR) of 15.2 for 5-year ALL survivors.268 Th e initial proportional 
relationship of EFS to OS was assumed for the fi rst fi ve years of the model. After the fi fth 
year, the cumulative survival probabilities of EFS were assumed to fl atten up until they 
reached OS. In the model, EFS could not exceed OS at any time point. Furthermore, we 
assumed that relapses and leukaemia-specifi c deaths only occurred within the fi rst 5 years 
for all comparators.
Th e model cycle length was set to one month. To adhere to the Dutch guideline for 
economic evaluation research (Dutch EE guideline), costs and eff ects were discounted at a 
4% and 1.5% rate, respectively.42,269
Tisagenlecleucel was included as a one-time infusion costing 320,000 EUR and its dos-
ing schedule was according to the ELIANA trial.262 For the comparator treatments, dosing 
schedules were taken from the literature.245,266,270 Adverse treatment events (AEs) were con-
sidered for all treatments and included cytokine release syndrome and B-cell aplasia. After 
initial therapy, we assumed that a proportion of patients would receive HSCT (17%, 16%, 
40%, and 34% for tisagenlecleucel, Clo-M, Clo-C, Blina, respectively). For patients staying 
alive (i.e. in EFS or PD) we assumed follow-up costs for outpatients visits and laboratory 
test and procedures with diff erent resource use frequencies per model health state (see online 
Appendix 5H).
To calculate QALYs, health-state utilities for EFS and PD were derived from the EQ-5D-
3L data collected in the ELIANA trial and estimated with the Dutch tariff .262,271 Additional 
disutilities (i.e. for treatment and adverse events) and age-related utility decrements were 
based on the literature.272–274
Prices and costs for the societal perspective were based on the Dutch EE guideline and the 
literature (see Table 1 and online Appendix 5B).42,275 Future costs (medical and non-medical 
consumption) were based on the PAID tool (version 3.0).276 Furthermore, we explored 
Figure 1 – De novo model
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potential productivity gains due to the improved survival by assuming that 53% of the 
long-term survivors aged 18 years or older would be employed.277 These cost savings were 
explored in a scenario analysis to account for potential future productivity gains.
Lastly, we conducted deterministic sensitivity analyses (DSA), probabilistic sensitivity 
analysis (PSA) to address uncertainty of the model input parameters and estimates (see 
online Appendix 5A). Several scenario analyses were performed to explore the influence of 
different assumptions on the ICER.
A list of key input parameters to the model including their source is presented in Table 1 
and a more detailed description of the employed methodology can be found in the online 
Appendix.
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RESULTS
In the model base case, tisagenlecleucel yielded 14.01 discounted LYs and 11.26 discounted 
QALYs, which was much higher than any of the comparators. Undiscounted LYs and QALYs 
were 18.98 and 15.21, respectively. Figure 2 shows the observed EFS from the pooled data 
as well as the modelled EFS of all treatments. Figure 3 shows both observed and modelled 
OS of all treatments.
Th e total discounted treatment costs for tisagenlecleucel were 338,122 EUR and included 
costs for drug acquisition and administration as well as outpatient and inpatient days. Th ese 
costs were the highest when compared to any comparator regimen (Clo-M: 73,457 EUR, 
Clo-C: 39,745 EUR, Blina: 119,931 EUR). Th e main cost driver were the much higher drug 
acquisition costs for tisagenlecleucel (320,000 EUR), when compared to all other drugs (See 
table 1). Only for tisagenlecleucel was a pre-treatment regimen (i.e. lymphodepleting regi-
men) necessary. Total discounted costs for this pre-treatment were 6,821 EUR, with drug 
acquisition costs (i.e. for fl udarabine, cyclophosphamide, cytarabine, or etoposide) being 
the main cost driver. Considering both pre-treatment and treatment costs of tisagenlecleucel 
together, the total treatment costs amounted to 344,943 EUR (discounted). Discounted 
costs for adverse events were highest for tisagenlecleucel (24,731 EUR), when compared to 
Figure 2 – EFS extrapolated (and observed for tisagenlecleucel)
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Clo-M (4,269 EUR), Clo-C (8,085 EUR), and Blina (4,210 EUR). Th is was mainly due to 
the relatively high prevalence of B-cell aplasia and the associated high costs of IVIG.
From a healthcare perspective, considering all discounted cost for treatment (including 
pre-treatment for tisagenlecleucel), adverse events, follow-up period, subsequent HSCT and 
future medical costs of unrelated diseases, the total healthcare costs for tisagenlecleucel was 
409,563 EUR. Th is was nearly four times as much when compared to Clo-M (113,937 
UER) or Clo-C (136,069 EUR) and more than double the total healthcare costs of Blina 
(200,293 EUR).
For a societal perspective, we added costs of caretakers’ productivity losses, travel costs (for 
both caretakers and patients), informal care for patient below the age of 18 years, and care-
takers’ stay at a charity hospital during the treatment period to the healthcare perspective. 
Th e total discounted costs from this perspective were 488,340 EUR for tisagenleucel, and 
156,909 EUR, 182,496 EUR and 253,024 EUR for Clo-M, Clo-C, and Blina, respectively. 
Major cost drivers in all perspectives were the total costs of treatment for tisagenlecleucel, 
Clo-M, and Blina. Only for Clo-C, subsequent HSCT was more expensive than the treat-
ment costs. When non-medical consumption costs were added to the societal perspective, 
total costs increased for all treatment options. Total discounted costs for tisagenlecleucel, 
Figure 3 - OS observed and extrapolated
81
Cost-effectiveness of tisagenlecleucel for pediatric relapsed/refractory ALL
Clo-M, Clo-C, and Blina were 552,679 EUR, 160,803 EUR, 193,920 EUR, and 267,259 
EUR, respectively.
When comparing total discounted costs of the healthcare perspective to the societal per-
spective, costs increased most for tisagenlecleucel (78,777 EUR), followed by Blina (42,972 
EUR), Clo-C (46,427 EUR), and Clo-M (52,731 EUR). Considering future non-medical 
consumption as part of the societal perspective, the additional costs when compared to the 
healthcare perspective were 143,116 EUR, 66,966 EUR, 57,851 EUR, and 46,866 EUR for 
tisagenlecleucel,Clo-M, Clo-C, and blina, respectively.
The discounted ICERs per QALY gained, comparing tisagenlecleucel to Clo-M, Clo-C, 
and Blina from a healthcare perspective were 27,443 EUR, 28,611 EUR, and 23,229 EUR, 
respectively. When taking a societal perspective, the ICERs increased to 30,767 EUR/QALY, 
31,996 EUR/QALY, and 26,120 EUR/QALY comparing tisagenlecleucel to Clo-M, Clo-C, 
and Blina, respectively. When future non-medical consumption costs were added, ICERs of 
tisagenlecleucel compared to Clo-M, Clo-C, and Blina were 36,378 EUR/QALY, 37,531 
EUR/QALY, and 31,682 EUR/QALY. Assuming a WTP-threshold of 80,000 EUR/QALY 
gained, it can thus be concluded that tisagenlecleucel is a cost-effective treatment when 
compared to any comparator examined in this study.
The estimation of potential lifetime productivity gains could be 202,563 EUR, 482 EUR, 
8,884 EUR, and 12,658 EUR per patient for tisagenlecleucel, Clo-M, Clo-C, and Blina. 
However, its needs to be noted that these estimates are subject to substantial uncertainty as 
explained in the discussion and are therefore not considered for any presented ICER.
All deterministic results of the cost-effectiveness analysis are presented in Table 2.
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Deterministic sensitivity analyses demonstrated that the variation of the starting age of 
the simulated cohort was the most influential factor for the ICER in all three comparators. 
Figure 4 depicts the top 10 DSA results of ICERs per QALY for each comparator treat-
ment in so-called Tornado diagrams. Although the change in some parameters affected the 
ICER quite heavily, none of the calculation exceeded an ICER of 45,000 EUR per QALY 
gained. The impact of choosing different parametric survival models for OS and EFS and the 
impact of choosing different time horizons were tested in scenario analyses. Depending on 
the chosen parametric survival function for EFS, different proportions of cured patients were 
estimated. In this case, we refer to cured patients as those who stay in EFS five years after 
treatment until the end of life. The proportion of cured patients five years post-treatment 
varied between 8% (exponential distribution for EFS) and 40% (log-normal distribution). 
Choosing either parametric survival function (both for OS or EFS) did not cause the ICER 
to exceed the WTP threshold of 80,000 EUR per QALY gained.










Pre-treatment 6,821 - - -
Treatmenta 338,122 73,457 39,745 119,931
Adverse events 24,731 4,269 8,085 4,210
Follow-up 3,811 540 1,204 1,549
Subsequent HSCT 36,077 35,670 87,036 74,602
Patient and family 14,277 2,627 2,733 3,319
Productivity losses 28,301 25,868 26,857 30,696
Future medical costs (unrelated 
disease and consumption)
100,538 18,371 28,262 32,952
Total costs 552,679 160,803 193,920 267,259
Effects
Life years 14.01 0.74 2.46 3.17
Quality-adjusted life years 11.26 0.49 1.70 2.25
Increments (tisagenlecleucel versus each comparator)
Costs in EUR - 391,876 358,759 285,420
Life years - 13.27 11.55 10.84
Quality adjusted life years - 10.77 9.56 9.01
ICERs
Costs (in EUR) per life years gained - 29,535 31,052 26,334
Costs (in EUR) per quality-adjusted 
life year gained
- 36,378 37,531 31,682
aThe treatment costs entail drug/procedure costs, and costs for the inpatient and outpatient visits
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Results of the 5,000 PSA iterations (societal perspective, including future non-medical 
consumption) are depicted in the cost-eff ectiveness (CE) plane in Figure 5. Th e average IC-
ERs per QALY gained were in line with the deterministic results with 38,129 EUR, 42,289 
EUR, and 34,564 EUR when compared to Clo-M, Clo-C, and Blina, respectively. At a 
WTP-threshold of 80,000 EUR, the probability of all simulations being cost-eff ective for 
Clo-M, Clo-C, and Blina was 100%, 98%, and 100%, respectively.
Of the conducted scenario analyses, assuming a time horizon of twenty years had the 
highest impact on the ICER. In this scenario, the ICERs per QALY gained increased to 
60,859 EUR, 63,341 EUR, and 53,698 EUR for Clo-M, Clo-C, and Blina, respectively. 
Th is implies that tisagenlecleucel is less cost-eff ective with a shorter time horizon.
Assuming a plateau phase in EFS after three years (instead of fi ve years) decreased the 
ICER per QALY gained to 31,798 EUR, 33,641 EUR, and 29,219 EUR for Clo-M, Clo-C, 
and Blina, respectively. Th is suggests that the sooner patients can be considered cured with 
tisagenlecleucel, the more cost-eff ective the treatment is.
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Our analyses also show that the prevalence of B-cell aplasia substantially adds to the costs 
of the tisagenlecleucel treatment, mainly through the length of IVIG usage. Based on the 
literature, we assumed an average duration of B-cell aplasia of 11.4 months. Testing this 
assumption in a scenario analysis and considering IVIG cost for the entire duration of EFS 
among those without subsequent HSCT, increased the ICER to 49,969 EUR/QALY, 52,847 
EUR/QALY, and 47,932 EUR/QALY gained for Clo-M, Clo-C, and Blina, respectively. 
Hence, a longer treatment duration with IVIG negatively affected the ICER.
DISCUSSION
Our results showed that assessing the cost-effectiveness of tisagenlecleucel from a societal 
perspective as opposed to a healthcare perspective, increased all estimated total costs and 
ICERs. This was due to the relative higher increase in total costs for tisagenlecleucel when 
compared to Clo-M, Clo-C, or Blina. Nevertheless, we demonstrate that tisagenlecleucel is 
also cost-effective for pediatric patients with relapsed/refractory B-cell acute lymphoblastic 
leukemia from a societal perspective. Although all efficacy input parameters for the model 
stem from international clinical studies, background mortality and HRQoL data as well as 
all costs were analysed from a Dutch perspective. Transferability to an international setting 
needs therefore to be considered with caution.
Nevertheless, considering all assumptions made, our model results can be regarded as 
robust: all explored scenarios rendered tisagenlecleucel cost-effective with a WTP-threshold 
of 80,000 EUR per QALY gained. In addition, all 5,000 iterations of the PSA yielded a 
probability for tisagenlecleucel being cost-effective of more than 98%. The deterministic 
sensitivity analysis showed that the cohort starting age, together with the utility values for 
EFS and the assumed subsequent HSCT rates for the comparator treatment had the highest 
impact on the results. However, when any of these parameters were altered (i.e. increased or 
decreased in their estimated value), none of them had the potential to bring the ICER above 
48,000 EUR/QALY gained. Lastly, the conducted scenario analyses demonstrate an increase 
in the ICER with decreasing time horizons (i.e. follow-up time) and a considerable impact 
of the IVIG assumption (i.e. how long IVIG is given) on the ICER.
The favourable results for tisagenlecleucel in our analysis can mainly be explained by 
the extensive survival gains when compared to other treatment options. With a total of 
14.01 life years (discounted), tisagenlecleucel performed significantly better than any of 
the comparators. Since to date no randomized clinical trials for tisagenlecleucel in r/r ALL 
patients exist, the modelled effectiveness was based on single-arm studies. Furthermore, no 
information about EFS was available in the publications of the comparative treatments. 
Based on a high correlation between EFS and OS,280 we assumed that the missing EFS 
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data could be estimated based on the available OS data. This may have influenced the EFS 
estimates of the comparative treatments.
According to the currently available evidence, tisagenlecleucel is a potential curative treat-
ment thereby preventing young patients from premature death. Consequently, substantial 
life years and QALYs can be gained from a lifetime perspective. However, it needs to be 
noted that the long-term effects of tisagenlecleucel are not yet captured by any study, registry 
or clinical trial, because none of those have life-time follow-up data. We assumed no specific 
late side effects after tisagenlecleucel and regarded patients to be cured after five years. In our 
model, patients that remain in EFS for five years after treatment are considered being cured. 
This assumption helped to reduce some of the long-term uncertainties arising from long-
term survival extrapolation data beyond the observed trial data. The five-year cut-off was 
validated by clinical experts and our approach was similar to the one used for the National 
Institute for Health and Care Excellence (NICE) mock technology appraisal for chimeric 
antigen receptor T-cell (CAR-T) therapy as a treatment for r/r B-cell pALL.38 However, the 
exact time at which patients in long-term EFS may be considered cured is uncertain. In a 
scenario analysis we explored the impact of assuming three instead of five years as a cut-
off. Consequently, all ICERs decreased (ICER Clo-M: 29,628 EUR/QALY, ICRE Clo-C: 
31,459 EUR/QALY, ICER Blina: 27,110 EUR/QALY gained), meaning that the sooner 
patients can be considered cured, the more cost-effective tisagenlecleucel is. Irrespective of 
the time point at which patient may be considered cured, it is uncertain what fraction of 
patients can be considered disease free at that time. Up until the five years after treatment, 
the EFS in the model was based on parametric survival functions. Each of these functions 
estimated different probabilities for EFS five years after treatment start. These estimates 
ranged between 8% and 40% for EFS, but none of these scenarios exceeded an ICER of 
45,000 EUR per QALY gained. Nonetheless, empirical long-term follow-up data are vital to 
reduce uncertainty in effectiveness outcomes. Data from patient registries such as the EBMT 
(European Society for Blood and Marrow Transplantation) registry may play a vital role in 
collecting the necessary information.
The estimated favourable survival outcomes (both in EFS and OS) indicate significant 
benefits for both patients and society. These can best be captured by extending the healthcare 
perspective to a societal perspective. Assuming a societal perspective made it possible to cap-
ture costs from a broad economic angle, including the impact of the treatment on patients 
and their families. To include these additional cost components, health economic researchers 
can choose from an abundance of validated methodological approaches in the literature 
or health economic guidelines. However, most of the available approaches only focus on 
adult patient populations and children as well as young adults remain understudied.281–285 
Costs of productivity losses (i.e. the costs occurring when the productivity of individuals is 
affected by illness, treatment, disability or premature death) for instance, may be relevant to 
patients that already were (economically) productive before the onset of the disease.286 In the 
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case of most paediatric ALL patients, this is however not the case. Instead, patients’ parents 
or caregivers face these losses. Since Dutch-specific data were unavailable concerning the 
productivity losses of parents and informal care, we made assumptions based upon available 
information in the literature.
For economic evaluations conducted from a US or Dutch perspective, it is recommended 
to consider future medical costs. 42,287 While the US guidelines recommend the inclusion 
future non-medical (consumption) costs as well, the Dutch guideline does not mention its 
inclusion yet.42,287 Our study is the first to fully include both components in an evaluation 
of CAR-T cell therapy for pALL. Both aspects were added through the latest version of the 
iMTA PAID tool (version 3.0) which is available online (https://imta.shinyapps.io/PAID3/). 
The methodology of this tool is described elsewhere.259,260 Due to the favourable survival of 
patients with tisagenlecleucel, the discounted future costs of this treatment were extensive 
(i.e. 100,538 EUR), while these costs were significantly lower for Clo-M, Clo-C, or Blina 
(i.e. 18,371 EUR, 28,262 EUR, and 32,952 EUR, respectively). Long-term survivors of 
pALL may however not only induce costs in the future. Cured paediatric patients may be 
able to finish their school education and consequently join the workforce. We refer to these 
prospects as potential productivity gains, and made an attempt to quantify them in our 
analysis.
However, little is known about both educational and employment prospects of long-term 
survivors of childhood cancer. In addition, there is a lack of evidence and methodological 
guidance in how to integrate such gains in economic evaluations. Therefore, the inclusion 
of these cost savings in our model made use of rather simplistic assumptions and should 
be interpreted with caution. For instance, we assumed full and life-long employment of 
the modelled patients as from the age of 18 years. Future fluctuations on the job market 
or employment rates could not be reliably modelled and were beyond the scope of this 
research. Besides, it yet needs to be determined if patients in long-term EFS can or will start 
on the job market once they attain majority. It is apparent that patients who can potentially 
be cured from ALL may be enabled to finish their education and join the workforce in 
the future. However, the here modelled patients were all relapsed or refractory to previous 
treatment lines and non-attendance to school might have been significant during previous 
treatment lines. Research is needed to determine in how far the absence from school affects 
the job starting age and shapes future employment opportunities in this patient popula-
tion. Furthermore, resulting from the uncertainty of the long-term effectiveness, no future 
productivity losses for the modelled patients were assumed that might result from long-term, 
disease-related absenteeism. Nevertheless, our approach may be seen as an illustration of 
the magnitude of potential economic gains resulting from improved survival, especially 
in pediatric diseases. Further research could quantify the potential productivity gains by 
elucidating how this aspect can be captured and integrated into cost-effectiveness analyses in 
a sound methodological manner.
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Although this study is not the first to estimate the cost-effectiveness of tisagenlecleucel, it 
is the first to adopt a full societal perspective. Following a ‘mock appraisal’ commissioned by 
the UK National Institute for Health and Care Excellence (NICE) to assess whether changed 
to its methods and processes were needed,38 several cost-effectiveness analyses were published 
in the US and Canada. Two studies had considered societal aspects in a scenario analysis, 
but none of them had considered productivity losses of caregivers, travel and hotel costs for 
patients and caregivers, informal care costs, and future medical costs including consumption 
costs altogether.254,256 In addition, input parameters and outcomes of the societal perspective 
were either not reported,256 or not clearly defined and point to evidence of adult patients, 
while paediatric patients are studied (see patient time in Sarkar et al.(2018)).254
When comparing our results to the other cost-effectiveness studies we found some dispari-
ties. Differences in incremental costs were highest between our study and Sarkar et al.254 for 
Clo-C, followed by costs for Clo-M when compared to the NICE mock appraisal.38 The 
reason for these discrepancies can be explained by major differences in several cost input 
parameters. For instance, costs for tisagenlecleucel are higher in the US when compared 
to the Netherlands (475,000 USD [426,000 EUR] versus 320,000 EUR). Similarity, the 
NICE mock appraisal assumed even higher one-off costs for tisagenlecleucel of 528,600 
GBP (587,697 EUR) per patient.38 In addition, estimated costs for HSCT in all US studies 
were significantly higher when compared to our study. Sarkar et al.254 assumed HSCT costs 
ranging between 299,987 USD (267,456 EUR) for successful HSCT and 459,682 USD 
(409,834 EUR) for failed HSCT. Lin et al.255 estimated the HSCT costs to be 555,000 
USD (483,904 EUR), which was similar to the estimates of Whittington et al.257 (560,000 
USD [488,264 EUR]). For every modelled patient that received subsequent HSCT, our 
model considered one-time costs of 217,590 EUR per HSCT31 and no distinction was made 
between successful or failed treatment.
With the exception for Whittington et al.257, incremental effects in LYs could be regarded 
as similar between all studies. Incremental QALYs differed to a greater extend and were 
highest for the study of Lin et al.255 We hypothesize that this is mainly do the use of different 
utility estimates. Lin et al.255 used a variety of utility estimates ranging between 0.56 to 0.92, 
depending on the health state or time. Our utility estimates were based on the ELIANA trial 
and ranged between 0.68 and 0.83, depending on the health states. Although we accounted 
for disutilities during any treatment, the stay at an intensive care unit, and graft-versus host 
disease, our utilities were consistently higher when compared to Lin et al.255
Finally, the divergent ICERs per QALY between the studies are a result of the difference 
in both costs and outcomes as explained above.Despite the several assumptions made in 
this study, we conclude that our results are robust (as tested through several sensitivity and 
scenario analyses) and that the conclusion of tisagenlecleucel being cost-effective is in line 
with all other cost-effectiveness studies for paediatric patients with r/r ALL. Furthermore, 
total costs from a societal perspective were higher for each treatment option when compared 
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to costs from a healthcare perspective. Although the increase in these costs was higher for 
tisagenlecleucel when compared to Clo-M, Clo-C, or Blina, none of the ICERs exceeded the 
WTP threshold of 80,000 EUR per QALY gained.
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Introduction: The National Institute for Health and Care Excellence (NICE), as part of the 
institute’s single technology appraisal (STA) process, invited the company of obinutuzumab 
(Roche Products Limited) to submit evidence of the clinical and cost-effectiveness of the 
drug in combination with chemotherapy, with or without obinutuzumab as maintenance 
therapy for adult patients with untreated, advanced follicular lymphoma (FL) in the UK. 
Kleijnen Systematic Reviews Ltd (KSR), in collaboration with Erasmus University Rotter-
dam, was commissioned to act as the Evidence Review Group (ERG). This paper describes 
the company’s submission, the ERG review, and NICE’s subsequent decisions.
Methods: The clinical evidence was derived from two phase III, company-sponsored, 
randomised, open-label studies. Most evidence on obinutuzumab was based on the GAL-
LIUM trial that compared obinutuzumab in combination with chemotherapy as induction 
followed by obinutuzumab maintenance monotherapy to rituximab in combination with 
chemotherapy as induction followed by rituximab maintenance monotherapy in previously 
untreated patients with FL (grades 1-3a). Long-term clinical evidence was based on the 
PRIMA trial, studying the benefit of two years of rituximab maintenance after first-line 
treatment in patients with FL. The cost-effectiveness evidence submitted by the company 
relied on a partitioned survival cost-utility model, implemented in Microsoft® Excel.
Results: The base case incremental cost-effectiveness ratio (ICER) presented in the company 
submission was below 20,000 GBP per quality-adjusted life-year (QALY) gained. Although 
the ERG concluded that the economic model met the NICE reference case to a reasonable 
extent, some errors were identified and several assumptions made by the company were chal-
lenged. A new base case scenario produced by the ERG suggested an ICER that was higher 
than the company base case, but still below £30,000 per QALY gained. However, some ERG 
scenario analyses were close to or even above the threshold. This was the case in particular for 
assuming a treatment effect that did not extend beyond trial follow-up.
Discussion: These results lead to an initial negative recommendation by the appraisal com-
mittee. Subsequently, the company submitted a revised base case focusing on patients at 
intermediate or high risk of premature mortality. Simultaneously, a further price discount 
for obinutuzumab was granted. In addition to the company’s revised base case, the ERG sug-
gested a restriction of the treatment effect to five years and implemented biosimilar uptake 
and cheaper prices for rituximab. All of these adjustments did not exceed £30,000 per QALY 
gained and therefore the use of obinutuzumab for patients with advanced FL and a FLIPI 
score of two or more could be recommended.
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INTRODUCTION
Within the United Kingdom (UK) National Health Service (NHS), the National Institute for 
Health and Care Excellence (NICE) may recommend the use of new and existing medicines 
and treatments through single technology appraisals (STAs).322 During such appraisals, the 
NICE Appraisal Committee (AC) reviews clinical and economic evidence on the technology 
under investigation based on the company submission (CS) taking into account the critique 
of a report from an appointed independent Evidence Review Group (ERG) as well as advice 
from other consultees (e.g. patients, experts and other stakeholders). After consideration 
of all the relevant evidence, the AC formulates preliminary guidance in the form of the 
Appraisal Consultation Document (ACD) as to whether or not to recommend the technol-
ogy. The stakeholders are invited to comment on this ACD and the submitted evidence. 
A subsequent ACD may be produced or a Final Appraisal Determination (FAD) is issued. 
Once recommended by NICE, the NHS is legally obliged to fund and resource the appraised 
technology so that the patients’ right to access these technologies is ensured.322 This paper 
presents a summary of the ERG report and the development of the NICE guidance based 
on the AC’s findings for the STA of obinutuzumab in combination with chemotherapy as an 
induction therapy followed by obinutuzumab maintenance monotherapy, for the first-line 
treatment of patients with advanced follicular lymphoma. Full details of all the relevant 
appraisal documents can be found on the NICE website (TA513).323
THE DECISION PROBLEM
Arising from lymphocytes, lymphomas are a heterogeneous group of malignancies of which 
about 90% are diagnosed as non-Hodgkin lymphomas (NHL).324 In the UK, NHL are the 
sixth most common type of cancer.325 With an annual incidence rate of 3.2 per 100,000, 
follicular lymphomas (FL) constitute the third most common subtype of NHL in UK.325 
The median age at diagnosis for FL in the UK is about 65 years with a five-year relative 
survival rate of 86.5%.326,327 Survival of patients with FL can be predicted with either the 
Follicular Lymphoma International Predictive Index (FLIPI),328 or its revised version, 
known as FLIPI2.329 The FLIPI comprises a set of five predictive parameters (age, Ann Arbor 
stage, haemoglobin, serum LDH level, and number of nodal sites), discriminating patients 
into three risk groups (low, intermediate and high).328 FLIPI2 builds on five parameters as 
well, but only haemoglobin and age are shared with the FLIPI (β2-microglobulin, longest 
diameter of the largest involved node, and bone marrow involvement are the other three).329 
The lower the FLIPI/FLIPI2 score, the better the prognosis as well as overall survival (for 
FLIPI) and progression free survival (for FLIPI2) of patients with FL. A FLIPI score of 0 
to 1 is regarded as low risk while a score of 2 or above signifies intermediate to high risk. 
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Due to the indolent nature of the disease, most patients present with advanced stages at first 
diagnosis and therefore require systemic treatment.326,330
In the UK, patients with advanced, symptomatic FL, receive rituximab-containing treat-
ment regimens as first-line therapy options, followed by two years maintenance therapy. 
However, despite receiving immunochemotherapy, an estimated 20% of patients with FL 
experience disease progression within two years from diagnosis.331 Treatment for patients 
with advanced stage targets to control the disease, which is typified by a chronic course 
comprised of repeated relapses, treatment and progression.
As a Type II anti-CD20 antibody, obinutuzumab received marketing authorisation from 
the European Medicine Agency (EMA) for previously untreated chronic lymphocytic 
leukaemia (CLL) in July 2014.332 In April 2016 and July 2017, the EMA extended the 
indication for obinutuzumab to FL.333,334 The scope for this STA set by NICE was to assess 
the use of obinutuzumab in combination with chemotherapy, with or without obinutu-
zumab as maintenance therapy (obin-chemo+obin) for people with untreated advanced 
FL in the UK. Mentioned comparators were rituximab monotherapy (although there was 
no marketing authorisation in the UK for this indication at time of appraisal), rituximab-
based chemotherapy, with or without rituximab maintenance treatment, and bendamustine 
monotherapy (no marketing authorisation in the UK at the time of appraisal).
THE INDEPENDENT EvIDENCE REvIEw gROUP 
(ERg) REvIEw
Kleijnen Systematic Reviews Ltd (KSR), in collaboration with the Erasmus University 
Rotterdam constituted as the ERG and reviewed the evidence on the clinical and cost-
effectiveness of obin-chemo+obin treatment for the first-line treatment of patients with 
advanced follicular lymphoma.
The ERG critically reviewed the evidence in the CS, the company’s responses to clarifica-
tion questions (RCQ) from the ERG, and the evidence provided after the publication of the 
ACD. Furthermore, the ERG explored the impact of assumptions on the incremental cost-
effectiveness ratio (ICER), revised the economic model and explored additional scenario 
analyses.
Summary of the clinical evidence
The company conducted a systematic review to identify published and unpublished ran-
domised clinical trial (RCT) evidence on the use obinutuzumab in previously untreated 
FL. Searches were carried out in June 2015 via PubMed, Embase and the Cochrane Central 
Register of Controlled Trials (CENTRAL). Update searches were reported for March and 
June 2017. At each time, separate supplementary searches of congress proceedings, clinical 
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trial registries, cancer association networks, and HTA agency websites were conducted to de-
tect relevant unpublished and grey information. Ultimately, only one study was considered 
relevant to the decision problem. Therefore, the evidence on the efficacy of obinutuzumab 
was entirely based on GALLIUM, a phase III, open-label, multicentre RCT (BO21223, 
NCT01332968).335
GALLIUM was conducted at 177 trial centres in 18 countries with 21% of the participants 
(n=293) being from the UK. For this study, 1401 adult patients (≥18 years) with previously 
untreated, advanced iNHL were randomly assigned to two treatment arms. All analyses were 
based on the 1202 patients in the FL subpopulation, which included those with FLIPI scores 
from 0 upwards. One group received rituximab in combination with chemotherapy (R-
chemo) as induction followed by rituximab (R) as maintenance. The other group received 
obinutuzumab in combination with chemotherapy (obin-chemo) as induction, followed by 
obinutuzumab (obin) as maintenance.
The primary outcome was investigator-assessed progression-free survival (INV-PFS). Sec-
ondary outcome measures included independent review committee-rated progression-free 
survival (IRC-PFS) and overall survival (IRC-OS), response rates at induction, maintenance 
and follow-up, adverse events (AEs), as well as health-related quality of life (HRQoL). The 
latter was assessed using the disease-specific Functional Assessment of Cancer Therapy for 
Patients with Lymphoma (FACT-Lym) instrument and the European Quality of Life (Euro-
Qol) ED-5D-3L questionnaire.
Data reported in the CS were taken from the primary analysis of GALLIUM with a 
clinical cut-off in January 2016. Since the updated cut-off data were marked as academic 
in confidence, all data presented in this publication focus on the FL subpopulation at the 
January 2016 cut-off of the GALLIUM trial only.
The median age of the FL population in GALLIUM was 59 years (range: 23-88 years) 
with a female ratio of 53.2%. Of the three different chemotherapy regimens permitted, 
the most frequently used was bendamustine (57%), followed by CHOP (33%) and CVP 
(10%). Induction therapy was completed for 598 and 594 patients in the R-chemo and 
obin-chemo arm respectively. Subsequently, 527 patients in the R-chemo and 539 patients 
in the obin-chemo arm received maintenance therapy. These patients had achieved either 
a complete response (CR) or a partial response (PR) at this stage. Stable disease (SD) was 
achieved by 17 patients who therefore underwent observation. Patients in both maintenance 
and observation were followed clinically on a two-monthly basis for two years. A total of 
341 patients in the R-chemo arm and 361 patients in the obin-chemo arm completed main-
tenance therapy. The reported overall median observation time was 34.4 months (range: 
0.1–54.5 months) in the R-chemo arm and 34.8 months (range: 0.0–53.8 months) in the 
obin-chemo arm. The proportion of patients who had been observed for at least 2 and 3 
years at the clinical cut-off was 87.7% and 44.1% in the R-chemo arm and 91.3% and 
45.1% in the obin-chemo arm, respectively.
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At the January 2016 cut-off, median INV-PFS as well as OS were not reached in both 
treatment arms. While the IRC-PFS was also not reached for the obin-chemo arm, it was 
reported with 51.2 (95% CI: 47.1 – not estimated) months for the R-chemo arm. Hazard 
ratios (HRs) comparing obin-chemo+obin to R-chemo+R were consistent and in favour 
for obin-chemo+obin in both INV-PFS (HR 0.66 [95% CI: 0.51, 0.85; p = 0.0012]) and 
IRC-PFS (0.71 [95% CI: 0.54, 0.93; p = 0.0138]). In the subgroup analyses, only low risk 
FLIPI scores showed a HR greater than 1.00 (HR 1.17 [95% Ci: 0.63, 2.19]), while HRs of 
all other FLIPI scores ranged from 0.40-0.86.
Treatment-related AEs were observed in 94.8% of patients in the obin-chemo+obin 
arm and in 91.6% of patients in the R-chemo+R arm. Two System Organ Classes were 
more commonly observed (≥ 10%) in the obin-chemo+obin arm when compared to the 
R-chemo+R: general disorders and administration site conditions (50.8% vs. 60.8%) as well
as injury, poisoning and procedural complications (49.1% vs. 59.2%). In addition, a higher
incidence of severe adverse event (SAEs) could be observed in the obin-chemo+obin arm
than in the R-chemo+R arm (46.1% vs. 39.9%).
For both FACT-Lym questionnaire subscales and EQ-5D-3L scales, no notable differences 
between the treatment arms was detected at any time.
It is worthwhile mentioning that data for the late progressive disease states were taken 
from the PRIMA study, a phase III RCT of rituximab maintenance therapy in patients 
with high tumour burden FL that responded to rituximab plus chemotherapy induction. 
Characteristics of the PRIMA trial are reported elsewhere.336,337
Critique and conclusion of the clinical evidence and interpretation
Regarding the systematic review, the ERG concluded that the population of the review was 
in line with the scope but the comparators were not. This was because the company had 
only included studies with a rituximab arm. As a deviation from the scope set by NICE, 
the company chose to consider only one comparator: rituximab in combination with che-
motherapy, followed by rituximab maintenance treatment in patients achieving a response, 
which was criticised by the ERG. In addition, the ERG criticised that both data extraction 
and quality assessment of the studies retrieved by the literature search were not conducted 
by two reviewers independently. However, the ERG acknowledged that the GALLIUM 
trial was appropriate for the decision problem at hand due to its relevant population and 
reasonable proportion of UK patients (21%). The attention of the AC was drawn to the 
exclusion of grade 3B lymphoma in GALLIUM, which was found to be in line with the 
anticipated treatment with obinutuzumab. Although three different types of chemotherapy 
were offered in the trial, GALLIUM was not designed to investigate differences between 
these regimens. Therefore, the ERG could not decide whether the breakdown of regimens in 
the trial would reflect UK clinical practice. Due to GALLIUM being an open-label trial, the 
ERG concluded that the results of the IRC would be less prone to bias than the investigator 
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results. Furthermore, although the follow-up duration of the trial was reasonable, data were 
judged not fully mature for the main outcomes.
In its clarification response the company acknowledged that the GALLIUM cohort 
might on average be younger than the average UK patient population with FL which was 
confirmed by clinical experts consulted by the company and data of the Haematological 
Malignancy Research Network (HMRN)338 The ERG therefore adjusted the age at baseline 
in its own base case model.
Summary of the cost-effectiveness evidence
The company conducted several literature searches to detect studies on cost-effectiveness, 
health effects, as well as on cost and healthcare resource use. For the cost-effectiveness search, 
none of the retrieved references were considered relevant. Therefore, the company conducted 
a de novo economic evaluation of obinutuzumab in combination with chemotherapy com-
pared with rituximab in combination with chemotherapy for the first-line treatment of 
patients with advanced FL.
For this purpose, the company developed an Excel-based five-state cohort transition 
Markov model with following health states: two progression-free survival (PFS) states for 
on and off treatment, two progressed disease states (PD) for early and late PD, and death. 
All simulated observations start in the PFS health state on treatment (obin-chemo+obin or 
R-chemo+R). Only patients responding to induction received maintenance (as per licence 
indication), which was only offered until progression or for a maximum of two years. Pa-
tients are considered ‘off-treatment’, when they complete or discontinue treatment in the 
PFS state. From the latter state, patients can remain in either PFS (on- or off-treatment) or 
transition due to a progressive disease or death. It is assumed that the time to progression 
after initial treatment is predictive for post progression mortality and overall survival. In 
particular, patients progressing within the first two years of initial treatment have signifi-
cantly worse survival outcomes than those who did not progress that early.331,339 To account 
for different outcomes and costs to the cohorts of patients who experience an early or a late 
progression, two progressed disease (PD) states were introduced. Once patients enter any 
of the two PD states, they can only remain in this state until death. The cumulative deaths 
from PFS and early as well as late PD states were used to calculate overall survival in the 
model. Survival estimates beyond the observed trial duration were extrapolated using several 
parametric functions. The population considered in the de novo analysis was equal to the 
GALLIUM cohort in terms of average age, body weight, height und Body Surface Area 
(BSA) (see Table 1).
The company argued that, based on the observed long-term follow-up in the PRIMA 
study and the expert opinion from clinical advisors, there was no evidence of a finite dura-
tion of treatment effect in treatments of FL (including obin-chemo+obin and R-chemo+R). 
However, for the base case analysis a treatment effect duration of 9.75 years was assumed, 
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based on the PRIMA study. This assumption was tested in the sensitivity analysis for its 
robustness with a minimum and maximum assumed treatment effect duration of five years 
and an infinite time duration, respectively.
The transition probabilities between the different model states were estimated from 
parametric survival functions fitted to the relevant data for the time to treatment discontinu-
ation (TTTD), PFS, and post progression survival (PPS). Considered distribution were: 
exponential, Weibull, log-logistic, log-normal, gamma, and Gompertz. Their goodness of fit 
to the GALLIUM data was assessed with both the Akaike/Bayesian Information criterion 
(AIC/BIC).
In the model, OS was calculated as the sum of the time spent in both PFS and the two PD 
health states (early and late). For the PFS and early PD mortality estimates, the company 
relied on the investigator assessed (INV) data of the GALLIUM trial. Since in GALLIUM 
no PPS events in late progression were observed, late PD mortality estimates were based on 
the PRIMA study.
For the CS base case model, long-term PFS and early PD were modelled with an exponen-
tial distribution. The monthly probability of transitioning from PFS to death was based on 
the UK age-specific all-cause mortality rate or the PFS death rates in GALLIUM (whichever 
occurred first). The same method was applied for the post progression survival probabilities; 
except that late PD mortality rates were estimated using data from the PRIMA trial (instead 
of GALLIUM). This was necessary because the GALLIUM data was premature.
HRQoL utilities for the PFS states were based on EQ-5D values collected in the GAL-
LIUM trial. However, since long-term EQ-5D values from this trial were considered im-
mature, the utility inputs for the progressed model states were based on utilities elicited in 
another study that had originally been commissioned by Roche.340 Health state related costs 
used in the model consisted of costs for medication (induction and maintenance), supportive 
care, subsequent treatment in PD, transportation, and adverse events. Relevant medication 
costs included those of obinutuzumab, bendamustine, CHOP, CVP, and rituximab. The 
latter were based on 2017 UK reference prices.341,342 No vial sharing was assumed.
For both costs and utilities, a 3.5% discount rate was applied. In addition, the company 
conducted a one-way deterministic sensitivity analysis, several scenario analyses and a proba-
bilistic sensitivity analysis (PSA) to explore parametric and structural uncertainty.
Table 1 – Patient baseline characteristics used in the company’s de novo economic evaluation
Patient characteristic Baseline value Source
Age (years) 57.9 GALLIUM trial data335
Body weight (kg) 75.7
Height (cm) 168.3
Calculated Body Surface Area (m2) 1.86
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In the RCQ, the initial 40-year time horizon of the model was set to 50 years, following 
the ERG’s request.
In the final model submitted by the company, the base-case ICER (cost per quality-
adjusted life-year [QALY] gained) was lower than 20,000 GBP, the threshold set by NICE 
being somewhere between 20,000 GBP and 30,000 GBP, depending on plausibility of the 
evidence.343 In addition, in the PSA results, it was observed that the ICER never reached this 
threshold. Scenario analyses revealed that different assumptions on the length of treatment 
effect (no finite duration versus five years), discount values (3.5% vs. 1.5%), and the choice 
of the parametric survival curve (exponential vs. Weibull) for the PFS states had with the 
highest impact of the ICER but did not exceed the NICE threshold. In general, all ICERs 
presented by the company (base case, PSA, and scenario) were below 30,000 GBP per QALY 
gained.
Critique of the Cost-Effectiveness Evidence and Interpretation
After assessing the company’s submitted evidence and model, the ERG concluded that, 
although the cost-effectiveness searches were well documented and reproducible, there were 
concerns regarding inclusion of a Line of Treatment facet that was overly restrictive. Revised 
searches were provided during the clarification process, which retrieved additional refer-
ences. Despite the revision of the strategies, errors in the Cochrane Library search syntax 
were still present. The additional studies identified were not found to be relevant for the 
decision problem and were not included.
The economic model met the NICE reference case to a reasonable extent. Nevertheless, 
the ERG found that deviations might have occurred in both measurement and valuation of 
HRQoL. Other deviations included the company’s choice of the intervention and the com-
parator. In general, the model was in line with the company’s formulated decision problem 
but only partially in line with the scope. While the intervention in the scope was described as 
“obinutuzumab in combination with chemotherapy, with or without obinutuzumab maintenance 
therapy”,344 the company assessed the obinutuzumab induction therapy with obinutuzumab 
maintenance therapy only. Hence, the cost-effectiveness of obinutuzumab in combination 
with chemotherapy induction without maintenance therapy was not explored in the submis-
sion. In terms of comparators, the company focussed on rituximab in combination with 
chemotherapy but did not include other relevant comparators listed in the NICE scope 
(such as rituximab mono-therapy or bendamustine mono-therapy).
For the model structure, the ERG concluded that the one used in the CS was slightly dif-
ferent from other, commonly used partitioned survival models in oncology.345,346 The transi-
tions between the health states were explicitly modelled, and in addition to other models, 
the company had also incorporated early and late PD states, which was seen by the ERG as 
a valid addition for modelling FL patients. With regards to the analysis and extrapolation of 
the survival data, the company had followed the guidance from the NICE Decision Support 
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Unit (DSU).306 Nevertheless, the ERG criticised the choice of the exponential distribution 
for the PFS survival probabilities. Although the company had argued that the exponential 
distribution would result in a more conservative estimate when compared to the log-logistics 
distribution, the ERG considered the Weibull distribution would represent an even bet-
ter estimate with similar AIC and BIC values. This was because the Weibull distribution 
predicted a 10-year PFS probability of 30.2%, which was in line with clinical expert opinion 
suggesting that approximately 60-70% of patients relapse in the first 10 years after treatment.
Furthermore, due to few mortality events in the GALLIUM study, the company had based 
the transition probabilities from PFS to death on pooled estimates between the treatment 
arms. Consequently, the probability of dying in PFS was assumed equal for both treatment 
arms. Yet, the number of observed deaths between the treatment arms differed and showed 
higher mortality in the obinutuzumab arm (although not statistically significant). Therefore, 
the ERG recommended applying different transition probabilities per arm for both PFS and 
post progression survival (early and late PD).
Another point of criticism by the ERG was the assumption of a finite duration of the treat-
ment effect on PFS, which was the main driver of the cost effectiveness results. This assump-
tion was made solely on data from the PRIMA trial, as long-term data from GALLIUM was 
lacking. In the model base case of the CS, a 9.75-year treatment effect was assumed although 
the longest follow-up in the GALLIUM trial (at the time of the submission) was five years. 
Therefore, the ERG considered a finite treatment effect of five years as a more conservative 
approach to model the cost effectiveness.
Similar to the critique of the clinical evidence, the ERG criticised the used on INV-PFS 
data instead of the IRC-PFS data.
Additional Exploratory Analysis Conducted by the ERg
After careful consideration of all input parameter assumptions in the company’s base case, 
the ERG defined a new base-case scenario, including multiple adjustments to the company’s 





ence case, scope or best practice has not been adhered to)
•	 Matters	of	judgement	(amending	the	model	where	the	ERG	considers	that	reasonable	
alternative assumptions are preferred)
Ultimately, the ERG corrected five errors, three violations, had four matters of judgement, 
and tested four alternative scenarios (see online Appendices 7A and 7B for a complete list 
of all items). The most influential adjustments to the company’s base case model were: (1) 
choosing the IRC-PFS data together with a Weibull distribution for the PFS extrapola-
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tion, (2) applying age dependant utility decrements, (3) increasing the population’s age at 
baseline, and (4) considering different mortality rates per treatment arm.
The ERG revised base-case ICER did not exceed the 30,000 GBP threshold per QALY 
gained. Simultaneously, in more than 50% of the PSA results, obin-chemo+obin was cost-
effective when compared to R-chemo+R at a 30,000 GBP per QALY-gained threshold. For 
all but one scenario analyses, the estimated ICER remained below the 30,000 GBP threshold 
per QALY. Only assuming a treatment effect duration of five years (scenario 1a) yielded an 
ICER above 30,000 GBP per QALY gained. Choosing different sources for utilities in PFS 
and PD had a substantial impact on the ICER but did not exceed the mentioned threshold.
Conclusion of the ERg Report
The ERG concluded that the GALLIUM trial is a good quality RCT even though a number 
of limitations were found. For instance, the breakdown of chemotherapy regimens (CHOP, 
CVP, and bendamustine) received in the trial may not reflect UK clinical practise. Likewise, 
the median age of included individuals in GALLIUM was not reflective of the UK FL 
population. In addition, although the trial had a reasonable follow-up, data were not fully 
mature for the main outcomes. Consequently, the ERG expressed major concerns regarding 
the implementation of the treatment effectiveness. More specifically, choosing a shorter 
duration of the treatment effect than in the CS was a major driver for bringing the ICER 
close, or even above the 30,000 GBP per QALY-gained threshold. Choosing either INV-PFS 
or IRC-PFS data had a substantial impact on the ICER as well, although none of two 
scenarios exceeded the mentioned threshold. Other remaining concerns were related to PFS 
probability distributions, and choosing the same mortality rate for both treatment arms. In 
addition, the ERG could not verify the source of the stated utility values for the PD states 
since they were referenced with an abstract that did not present any EQ-5D values.340
Nevertheless, the ERG preferred base-case analysis resulted in an ICER lower than the 
30,000 GBP per QALY threshold. Although the ICER seemed to be robust to most struc-
tural changes explored by the ERG, the scenario analyses conducted by the ERG showed 
that with different choices for the treatment effect duration or the utilities for the PD health 
state, the ICER could exceed the 30,000 GBP per QALY threshold.
ERG research recommendations
Most notable, the cost-effectiveness analyses could benefit from long-term follow-up results 
from GALLIUM. The results could validate some of the key assumptions made in the model 
such as the extrapolation of the PFS parametric survival functions, the duration of the treat-
ment effect and the early/late mortality in the progressed disease state. Different mortality 
assumptions in the progressed disease state would lead to different PFS/OS surrogacy impli-
cations, which might have substantial impacts on incremental results as elaborated in other 
first-line treatment submissions in oncology.348 In addition, a more recent and transparent 
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measure of utility values for the PD health state would increase both validity and reliability 
of the HRQoL estimates. Future research should include a comparison of obinutuzumab 
with different chemotherapy regimens such as CHOP, CVP, and bendamustine to generate 
more reliable estimates for direct treatment comparisons.
Key methodological issues
Three issues were expressed by the ERG.
First, the company’s assumption of a finite duration of treatment effect on PFS was a major 
driver for the ICER. The treatment effect duration was implemented by setting the hazard 
ratio of the modelled intervention to the comparator to one (i.e. no difference in treatment 
effect), once the end of the treatment effect was assumed. Although, the ERG deemed the 
technical realisation of the limited treatment effect duration appropriate, some methodical 
concerns on its duration were expressed. The company had based its assumption on the 
PRIMA study, where no finite duration of treatment effects between rituximab maintenance 
treatment compared with ‘observation only’ could be observed until the longest follow-up 
period of 9.75 years. Likewise, the assumption of proportional hazards between interven-
tion and comparator arm seemed to hold throughout the PRIMA study. This was backed 
by clinical advisors who had suggested that there is no evidence of finite treatment effect 
in FL treatments, and that this might hold true for the comparison of obin-chemo+obin 
versus R-chemo+R. The ERG by contrast doubted the generalisability from the PRIMA 
results and their transferability to GALLIUM. A visual inspection also suggested that the 
log-cumulative hazard plots for PFS from GALLIUM converged. Hence, the proportional 
hazards assumption most likely did not hold. Based on the available evidence, no robust 
estimate alternative for a treatment effect duration could be given. On these grounds, the 
ERG proposed a duration of five years for the treatment effect, as this also reflected the 
longest follow-up time of the GALLIUM study.
Second, due to the immaturity on the GALLIUM data, the company used PRIMA data 
to model the late PD health states. This combination of evidence was done without any kind 
of adjustments. However, since patient characteristics between the two studies might not be 
comparable, an unadjusted use of these data might bias the model estimates.
Third, the company’s assumption of no biosimilar uptake for rituximab was deemed 
implausible.
NICE gUIDANCE
key issues Considered by the Appraisal Committee
Regarding the clinical evidence, the AC concluded that the population of the GALLIUM 
trial would reflect people with advanced FL receiving treatment within the NHS to a reason-
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able extent. However, the trial was judged to be underpowered to show a difference in OS. 
In addition, the presented trial data was considered highly immature. Consequently, the AC 
could not conclude whether obinutuzumab could prolong overall survival when compared 
to rituximab. Although it was acknowledged that obinutuzumab delays disease progression 
in the short term, there was still uncertainty about a long-term effect on progression-free 
survival. Furthermore, the AC concluded that obinutuzumab is associated with higher bur-
den of adverse events when compared to rituximab. In terms of HRQoL, the AC regarded 
the difference in the EQ-5D scores between the GALLIUM trial arms as not statistically 
significant.
For the cost-effectiveness analysis, the AC considered several key issues.
First, it recognised substantial uncertainty in the evidence base and ICER in terms of the 
treatment effect duration, extrapolation of progression free survival, resource use and the 
immaturity of the clinical data. In addition, the company’s assumption on the treatment 
effect duration was criticised.
Second, the AC doubted the company’s assumption of a 0% uptake of biosimilars for 
rituximab and was aware of two biosimilar versions of rituximab that had a market authori-
sation. In addition, the AC was informed that the current uptake was increasing and at 
around 40%.
Due to the substantial uncertainty in the evidence base and ICER, the AC concluded that 
an acceptable ICER threshold would not lie towards the upper part of the 20,000 GBP to 
30,000 GBP per QALY gained range specified in the NICE’s guide to the methods of tech-
nology appraisal.343 Other factors that could substantiate a 30,000 GBP per QALY gained 
such as the innovative nature of obinutuzumab or special consideration as a ‘life-extending 
treatment at the end of lie’ were ruled out as well.
Ultimately, the ERG updated its base case analysis incorporating the ACs findings. This 
yielded an expected increase in the ICER, rendering the intervention not cost-effective at the 
threshold of 30,000 GBP per QALY gained.
Preliminary guidance (First Appraisal Consultation Document [ACD])
For the first ACD, NICE had considered the initial evidence submitted by the company, 
the testimony of professional groups and other stakeholders, as well as the ERG report. In 
September 2017, NICE’s first ACD did not recommend obinutuzumab within its market-
ing authorisation for untreated advanced FL in adults. This recommendation was however 
not intended to affect patients that had already started treatment with obinutuzumab before 
the guidance was published. For these patients no change in funding arrangements would 
take place. A second appraisal committee meeting was planned for October 2017. Until 
then, all consultees had the possibility to react to the previously presented evidence.
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Response to Preliminary Guidance (First ACD)
In reaction to the first ACD, the company provided an updated version of its model includ-
ing alternative assumptions and a revised base case population. The company argued that, 
although the trial was not powered for individual FLIPI subgroups, an analysis focussing 
only on intermediate and high FLIPI subgroups would result in sufficient PFS events for the 
modelling task. This was in line with the EMA requirement to include a statement in the 
obinutuzumab Summary of Product Characteristics that the “[…] efficacy in FLIPI low risk 
(0-1) patients is currently inconclusive […]”,349
With regard to the duration of treatment effect, the company retained its earlier argumen-
tation and assumed an infinite duration of treatment effect for obinutuzumab. Furthermore, 
the new model assumed independent PFS extrapolations for high and intermediate FLIPI 
subgroups (thus using a non-proportional hazards assumption) and implemented vial shar-
ing.
Biosomilar uptake for rituximab was not considered for the base case but in scenario 
analyses. The company had based this assumption on the recent availability of biosimilar 
rituximab, claiming that the branded product would currently constitute the majority of IV 
rituximab used.
This new analysis yielded an ICER below £20,000 per QALY gained, whereas scenarios 
considering different proportions of market shares and price reductions for biosimilar ritux-
imab showed an ICER above £20,000 per QALY.
In reaction to the new company model, the ERG proposed a new (final) base case that 
assumed a treatment effect duration of five years, independent PFS extrapolations for high 
and intermediate FLIPI subgroups (thus using a non-proportional hazards assumption), no 
vial sharing, and a 65% update of biosimilar IV rituximab.
In the meanwhile, the company had also agreed on a new patient access scheme that 
would provide a further discount to the list price of obinutuzumab. The level of the discount 
is, however, commercial in confidence. The new ERG base case (including the new patient 
access scheme) yielded an ICER below £30,000 per QALY gained.
Final Appraisal Determination (FAD)
Due to the revised economic analyses focussing on higher-risk subgroups and a further 
discounted price for obinutuzumab and rituximab, the ICER was estimated to be below 
£30,000 per QALY gained. Hence, the AC issued new guidance. In March 2018, the FAD 
recommended obinutuzumab as an option for untreated advanced FL in adults, restricted 
to patients with a FLIPI score of 2 or more (as intended by the company’s revised model), 
provided that the company would grant the negotiated simple price discount in the revised 
patient access scheme. Just as in the ACD, the recommendation was not intended to affect 
patients that had already started treatment with obinutuzumab before the guidance was 
published. For these patients no change in funding arrangements would take place.
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CONCLUSIONS
This STA demonstrates that even an ICER of below £20,000 per QALY gained, as in the 
first company submission, is no guarantee for a positive recommendation by NICE. In fact, 
a high degree of uncertainty in the evidence base of the cost-effectiveness model might lead 
to a negative decision by NICE, even when the ERG’s base case is below the £30,000 per 
QALY gained threshold. Instead, NICE is also valuing the degree of uncertainty that, in this 
case, was expressed by some initial ERG scenarios yielding and ICER close to and above the 
£30,000 threshold.
For this submission, the AC’s major concerns were on the degree of uncertainty of the 
various cost-effectiveness model input parameters, particularly the treatment effect duration. 
Although in this STA most of these parameters were based on an RCT, the immaturity of its 
results did not allow for robust estimates concerning the long-term effects of obinutuzumab 
on progression-free survival. Furthermore, the AC acknowledged both cheaper prices and 
higher uptake of rituximab biosimilars. This was based on the 2017-2019 prescribed services 
commissioning for quality and innovation (CQUIN), issued by NHS England, encourag-
ing the use of biosimilar products to reduce the costs for medicines.350 Consequently, the 
AC had assumed that most commissioners in England would prefer to purchase cheaper 
biosimilar versions rather than branded drugs.
Narrowing down the treatment indication to patients with a FLIPI score of 2 or higher, as 
well as providing a further discount on the price for obinutuzumab could reduce the degree 
of decision uncertainty to the extent that the AC could issue a positive recommendation. 
This final decision deviates from the originally intended patient group proposed by the 
company (no FLIPI score thresholds). Hence, when considering the scope of the first CS, 
NICE adopted a ‘restricted’ or ‘optimized’ decision to provide access to obinutuzumab while 
concomitantly reducing the decision uncertainty.351,352

Chapter 8
Health Economic Aspects of Chimeric 
Antigen Receptor T-Cell Therapies for 
Haematological Cancers. Present and Future
R Heine*, FW Thielen*, M Koopmanschap, MJ Kersten, H Einsele, U Jaeger, 
P Sonneveld, J Sierra, C Smand, CA Uyl-de Groot





Introduction: Since 2018, two chimeric antigen receptor (CAR) T-cell therapies received 
approval from the European Medicine Agency, with list prices around 320,000 EUR per 
treatment. These high prices raise concerns for patient access and the sustainability of health 
care systems. We aimed to estimate the costs and budget impact associated with CAR T-cell 
therapies for current and future indications in hematological cancers from 2019 – 2029.
Methods: We focused on the former EU-5 and the Netherlands. We conducted a review 
of list prices, health technology assessment reports, budget impact analysis dossiers, and 
published cost-effectiveness analyses. We forecasted the ten-year health expenditures on 
CAR T-cells for several hematological cancers in selected EU countries.
Results: Nine cost-effectiveness studies were identified and list prices for CAR T-cell 
therapies ranged between 307,200 EUR and 350,000 EUR. Estimated additional costs for 
pre- and post-treatment were 50,359 EUR per patient, while the incremental costs of CAR 
T-cell therapy (when compared to care as usual) ranged between 276,086 EUR and 328,727 
EUR. We estimated market entry of CAR T-cell therapies for chronic mantle cell lymphoma 
(MCL), follicular lymphoma (FL), lymphocytic leukemia (CLL), multiple myeloma (MM), 
and acute myeloid leukemia (AML) in 2021, 2022, 2022, 2022, and 2025, respectively. Cu-
mulative expenditure estimates for existing and future indications from 2019 – 2029 were 
on average 28.5 billion EUR, 32.8 billion EUR, and 28.9 billion EUR when considering 
CAR T-cell therapy costs only, CAR T-cell therapy costs including pre- and post-treatment, 
and incremental CAR T-cell therapy costs, respectively.
Discussion: CAR T-cell therapies seem to be promising treatment options for hemato-
logical cancers but the financial burden on health care systems in the former EU-5 and the 
Netherlands will contribute to a substantial rise in health care expenditure in the field of 
hematology.
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INTRODUCTION
It took almost 40 years from the time chimeric antigen receptor (CAR) T-cell therapy was 
first described in the 1980s to the approval of tisagenlecleucel (Kymriah®) and axicabtagene 
ciloleucel (Yescarta®) by both the Food and Drug Administration (FDA) and the European 
Medicines Agency (EMA) in 2017 and 2018, respectively.353 Thus far, the EMA approved 
tisagenlecleucel for the treatment of pediatric and young adult patients up to 25 years of age 
with B-cell acute lymphoblastic leukemia (ALL) that are refractory, in relapse post-transplant 
or in second or later relapse as well as for adult patients with relapsed or refractory diffuse 
large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Axicabtagene 
ciloleucel is currently approved by the EMA for the treatment of adult patients with relapsed 
or refractory DLBCL and primary mediastinal large B-cell lymphoma (PMBCL), after two 
or more lines of systemic therapy. Both therapies are autologous treatments and second-
generation CAR Ts.
After novel drugs receive central approval by the EMA, each European member state 
handles its own approval and reimbursement procedure. With list prices of approximately 
289,550 EUR (373,000 USD) in the US and 320,000 EUR in Europe, CAR T-cell therapies 
belong to the most expensive cancer treatments at the moment. This has consequently raised 
concerns regarding patient access to these therapies and the financial sustainability of health 
care systems in general. CAR T-cell therapies are expected to bring substantial health benefits, 
but also exposes healthcare systems to very large expenditures. Simultaneously, an increase 
in trial activity heralds an expansion of CAR T-cell therapies to many more indications in 
the near future, of which hematological cancers currently play the most significant role.354 
Therefore, these therapies may have a considerable incremental budget impact on healthcare 
expenditures, especially in the field of hematology-oncology. Moreover, the costs associated 
with these therapies are not limited to acquisition costs alone. Other costs that will have a 
substantial impact on healthcare expenditures are hospitalization, intensive care unit (ICU) 
stays, as well as other costs related to the treatment of adverse events and laboratory work. 
Furthermore, patients who live longer will also incur future medical costs unrelated to their 
condition for which they received CAR T-cell therapy. Conversely, longer survival may also 
lead to a return to productive work of survivors in remission.
In addition, substitution effects may reduce the financial impact of CAR T-cells such as 
avoiding the current standard of care treatment and a potential reduction in the numbers of 
autologous and/or allogeneic stem cell transplantation following treatment.
Overall, the application of CAR T-cell therapies may result in higher overall healthcare 
spending and opportunity costs –money can only be spent once– leading to a change in the 
allocation of the available healthcare budget. Without any formal assessment with regards to 
the financial aspects of these therapies, their costs remain intangible and vague. Even though 
economic evaluations and budget impact analyses can shed light on the economic burden 
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of new therapies in general, such assessments are not formally required in most countries 
(in Europe and elsewhere) for drug reimbursement decision making and therefore such data 
are scarce.
The European Hematology Association (EHA) is concerned about the sustainability of the 
pricing of new oncological treatments, and in particular of CAR T-cell therapy, possibly ex-
posing health systems to very large expenditures. Therefore, the EHA has commissioned the 
Institute for Medical Technology Assessment (iMTA) to forecast future health expenditures, 
based on the adoption of CAR T-cell therapies in hematological cancers.
This study aimed to estimate the costs and budget impact associated with CAR T-cell 
therapies for current and future indications in hematological cancers in Europe from 2019 
to 2029. The results of this study can be used by health care decision-makers in their budget-
ary planning as they elucidate the future economic burden of CAR T-cell therapies in several 
European countries.
METHODS
We followed a four-stepped approach and focused on six European member states: the for-
mer EU-5 (i.e. Germany, Spain, France, United Kingdom, and Italy) and the Netherlands. 
First, we conducted a review of list prices, health technology assessment (HTA) reports, 
budget impact analysis (BIA) dossiers, and published cost-effectiveness analyses (CEA). 
Second, we identified potential future indications and estimated the eligible patient popula-
tion for both registered and selected upcoming indications. Third, we validated our findings 
with international clinical experts in the field of hematology-oncology. Finally, based on the 
gathered information in the previous steps, we predicted the ten-year health expenditures on 
CAR T-cells for several hematological cancers in the selected EU member states. The forecast 
entails different cost calculations namely: i) costs of CAR T-cell therapies only; ii) costs of 
CAR T-cell therapies and costs of care, as well as iii) incremental costs associated with the 
substitution of former therapies by CAR T-cell therapies.
Review of list prices and cost-effectiveness publications
We retrieved list prices for tisagenlecleucel and axicabtagene ciloleucel from HTA/BIA reports 
published by national reimbursement authorities. In addition, we searched for published 
CEA studies to complement potential missing or unpublished data. These publications were 
searched through EMBASE on 09-05-2019 with an update search on 20-04-2020 (see one 
Appendix 8A for the full search strategy). Only economic evaluations for hematological 
diseases were included.
133
Health economic aspects of CAR T-cell therapies
Identification of future indications and estimation of the eligible 
patient population
To identify future indications for CAR T-cells, we searched clinictrials.gov for all registered 
studies on CAR T-cell therapies (search term: “chimeric antigen receptor”) for hematological 
cancers on 03-05-2019. This search included early phase 1, phase 1, phase 2, phase 3, and 
phase 4 trials. All studies were ranked according to the indication studied (most to least often 
studied indication). Through a semi-structured interview, several clinical experts were asked 
to validate this ranking and to (re)arrange it according to the sequence of expected market 
entry.
To estimate the eligible patient population for CAR T-cells, we focused on the two indica-
tions for which CAR T-cells already have market authorization (pALL and DLBCL) and the 
top five potential future indications identified by the clinical experts. The eligible patient 
population was calculated based on previous population forecasts by using two data sources, 
namely Eurostat and Globocan.7
In the Eurostat forecast, several assumptions were made on the future development for 
fertility, mortality, and net migration to predict the population of European member states 
to the year 2080 (based on the population in 2016).355 We assumed a linear trend between 
the 2016 and 2080 Eurostat data and calculated the yearly population per country of inter-
est. For our purpose, we defined the disease incident population by estimating the yearly 
crude incidence rate (IR) per 100,000 for each disease and country of interest. For pALL 
and DLBCL, the yearly disease IRs were taken from HTA/BIA reports. For future indica-
tions, or in the absence of published data from HTA/BIA reports, we used data from the 
European Cancer Information System (ECIS).356 Subsequently, the crude IRs were applied 
to projected population data by Eurostat.355
The online database GLOBOCAN offers information on projected IRs of different cancer 
types for the time between 2018 and 2040 for several countries.357 To derive the number 
of patients for each cancer subtype of interest, we applied proportions based on the litera-
ture.358–361
Both forecast approaches are depicted in Figure 1.
The proportion of patients eligible for CAR T-cell therapy per country was calculated based on 
HTA/BIA reports. Most publications stated the yearly number of incident cases and the total 
number of patients eligible for CAR T-cell therapy. From these numbers, we calculated the 
proportion of eligible patients and applied this rate to all incident cases to derive the total 
yearly number of eligible patients for CAR T-cells per disease and country. The CAR T-cell 
therapy eligible patient population for all future indications was based on expert opinion.
validation with clinical experts
Clinical experts in the field of hematology-oncology were asked to validate our intermediate 
findings via semi-structured interviews. Respondents were asked about their experience with 
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CAR T-cell therapies, possible future hematological indications, resource use during pre-
treatment, treatment, and post-treatment with CAR T-cell therapies in their own country, 
and the plausibility for CAR T-cell therapies to be manufactured within specialized hospitals 
(point-of-care manufacturing).
Expenditure estimation of CAR T-cell therapies for current and selected 
future indications
Expenditures were estimated for three scenarios. In Scenario 1, the CAR T-cell therapy eli-
gible patient population was multiplied with the average list price for the currently approved 
CAR T-cell therapies in the former EU-5 and the Netherlands. For all new indications, the 
costs for CAR T-cell therapies were assumed to be similar to the average list price.
For Scenario 2, we added costs for pre-treatment, concomitant medication, adverse events 
(AEs), and hospitalization (including follow-up) to the price of CAR T-cell therapy. Infor-
mation on resource use (i.e. medication dosage and the number of hospital days etc.) were 
taken from available HTA/BIA reports or based on expert opinion. Prices for medication, 
hospitalization (including ICU admission), and AEs were based on costs reported in HTA/
BIA reports or the literature.307,362–367 In case country-specifi c prices could not be found, the 
average of available prices was used. Finally, clinical experts were asked to validate these data.
For Scenario 3, we calculated the incremental costs of CAR T-cell therapy, i.e. the costs of 
Scenario 2 minus the costs of care as usual. Th ese incremental costs were derived from the 
published CEAs identifi ed for this study. Th ereafter, we multiplied the eligible patient popu-
Figure 1: Flowchart of forecast approaches
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lation with incremental costs of CAR T-cell therapy. Average incremental costs observed in 
DLBCL were used to estimate incremental costs for future indications.
For all scenarios and indications, we assumed a market penetration rate of 45% in the first 
year after registration and 90% thereafter.368
RESULTS
Results of list prices and cost-effectiveness publications
HTA reports and BIA dossiers were found for Germany,369–371 France,372–374 the UK375–377 
the Netherlands378–380 and Spain. Only in German publications, list prices were stated for 
all indications. In France, all prices were marked as confidential, and in the UK, prices 
were stated for all indications treated with tisagenlecleucel. The UK price for axicabtagene 
ciloleucel was marked confidential, i.e. it was concealed in the report. Dutch prices were 
available for axicabtagene ciloleucel and tisagenlecleucel.
For Italy and Spain, HTA/BIA reports were not publicly available. List prices for these 
countries were retrieved from documents of the Italian Medicines Agency (AIFA),381,382 and 
the Spanish Ministry of Health.383,384 Table 1 presents an overview of all list prices.
The initial literature search detected nine cost-effectiveness analyses,385–388,388–392 and 
the search for grey literature found three HTA reports393–395 and one report from an ERG 
(Evidence Review Group) for a NICE STA.388 Two publications were added following the 
update search.389,396 The publication by Walton et al. (2019)25 presented results from the 
ICER HTA report and is therefore included in the following summary, instead of the HTA 
report. Most studies focused on pALL patients, while three publications391,392,397 studied 
relapsed/refractory (r/r) DLBCL as indication. The ICER report393 presented results for both 
r/r pALL and r/r DLBCL.
The results are summarized in Table 2.
Table 1: Overview of list prices
Country






France 350,000 EUR 320,000 EUR 320,000 EUR
Germany 327,000 EUR 320,000 EUR 320,000 EUR
Italy 327,000 EUR 300,000 EUR 300,000 EUR
The Netherlands 327,000 EUR 320,000 EUR 320,000 EUR
Spain 327,000 EUR 320,000 EUR 320,000 EUR






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Identification of future CAR T-cell indications
The search on clinicaltrials.gov resulted in a total of 246 studies, of which most were attrib-
uted to non-Hodgkin’s lymphoma (N = 97), followed by ALL (N = 84), multiple myeloma 
(MM) (N = 38), chronic lymphocytic leukemia (CLL) (N = 22), acute myeloid leukemia 
(AML) (N = 19), and others (N = 35). Several studies addressed multiple indications and 
targets. The three most studied target antigens were CD19 (N = 161), followed by BCMA 
(N = 19) and CD22 (N = 20).
The clinical experts expected that mantle cell lymphoma (MCL), follicular lymphoma 
(FL), MM, CLL, and AML, would be the first indications for which CAR T-cell therapy 
would become available in the near future. Based on phases of the clinical trials and clinical 
expert opinion, we estimated market entry of CAR T-cell therapies for MCL in 2021. For 
the indications of MM, CLL, and FL market entry was estimated for the year 2022. Finally, 
it was expected that CART T-cell therapies for AML would be available in 2025.
Estimation of the eligible patient population
Reported yearly IRs varied not only across but also within countries. Although targeting 
the same indication, HTA/BIA reports for DLBCL stated different yearly incidences for the 
same indication and hence different numbers of eligible patients within the same country. 
For our analysis, we used country averages for pALL and DLBCL in case more than one 
estimate was available. IRs for MCL, FL, AML, MM, and CLL were taken from ECIS (see 
online Appendix 8G).
The proportion of eligible patients for CAR T-cell therapies were available for pALL in 
Germany, France, and the Netherlands and varied between 6% (FR) and 11% (DE). For 
DLBCL the proportions were known for Germany, France, the UK, and the Netherlands, 
varying between 12% (FR) and 22% (UK). Missing data for these indications (i.e. pALL 
and DLBCL) in all other countries were imputed with the mean proportion from countries 
with available data (see for details online Appendix 8G).
To estimate the number of patients for the different cancer sub-types from Globocan, we 
used US figures, since European data were not available. As proportions were not available 
from one single source, data for pALL were based on the Surveillance, Epidemiology, and 
End Results Program (SEER) of the US National Cancer Institute.398 Most recent data for 
ALL and CLL were taken from the 2019 facts and figures sheet published by the American 
Cancer Society,358 and DLBCL estimates were based on Li et al.399 Proportions of MCL and 
FL patients from non-Hodgkin lymphoma were taken from Sandoval-Sus et al.360 (2017) 
and Cerhan et al.359, respectively.
For the period 2019-2029, we estimated a total average of 103,750 patients being eligible 
for CAR T-cell therapies, ranging from 95,954 patients (Eurostat forecast) to 111,545 
patients (Globocan forecast) for the indications pALL, DLBCL, MCL, FL, AML, CLL, 
and MM.
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Expenditure estimation of CAR T-cell therapies for current and selected 
future indications per scenario
Scenario 1 estimation based on list prices
Multiplying costs for CAR T-cell therapies with the number of eligible patients in the former 
EU-5 and NL resulted in average cumulative expenditures varying between 1.4 billion EUR 
for the Netherlands to 6.7 billion EUR for Germany. Cumulative expenditure estimates in 
our base-case for pALL, DLBCL, MCL, FL, AML, CLL, and MM for all included countries 
from 2019 to 2029 were on average 0.8 billion EUR, 13.5 billion EUR, 2.3. billion EUR, 
6.4 billion EUR, 1.2 billion EUR, 0.9 billion EUR, and 3.5 billion EUR, respectively (total 
average: 28.5 billion EUR). Figure 2 depicts the yearly average forecasted expenditure per 
country for scenario 1 across all indications.
Scenario 2 Total CAR T-cell therapy costs, including pre- and post- costs
Resource use and prices for the cost items considered for scenario 2 could partly be retrieved 
from sources for the Netherlands, the UK, Germany, and France (see Table 3 for an overview 
of the average resource use and cost prices). Th e additional costs for CAR T-cell therapy 
amounted to 50,359 EUR for each patient receiving CAR T-cell therapy, with a substantial 
amount necessary for lymphodepletion and administering CAR T-cells, namely 26,615 
Figure 2: Total average costs per country in scenario 1 (all indications)
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EUR EUR. In Table 4, these costs are shown. Cumulative expenditure estimates in our 
base-case for pALL, DLBCL, MCL, FL, AML, CLL, and MM for all included countries 
from 2019 to 2029 were on average 0.9 billion EUR, 15.7 billion EUR, 2.5 billion EUR, 
7.4 billion EUR, 1.4 billion EUR, 1.1 billion EUR, and 4 billion EUR, respectively (total 
average: 32.8 billion EUR).
Multiplying the total costs of pre- and post- CAR T-cell care with the number of eligible 
patients per indication and country resulted in total cumulative expenditures between 7.7 
billion EUR (DE) and 1.6 billion EUR (NL). Figure 3 depicts average forecasted costs (all 
indications) per country for scenario 2.
Table 3: Cost components and resource use of pre- and post- CAR T-cell therapy
Item Type value in EUR
Leukapheresis and cryopreservation Costs 4,947
CAR T-cell administration + Lymphodepletion Costs 15,033
ICU stay (per day) Costs 1,444
Hospital stay at hematology/oncology ward (per day) Costs 628
Intravenous immunoglobulin IVIG (per dose) Costs 2,032
Tocilizumab (per event) Costs 1,483
Treatment of febrile neutropenia (per event) Costs 4,953
Treatment of anemia (average costs per event, incl. transfusion) Costs 2,961
Treatment of thrombocytopenia (per event) Costs 2,417
Oncologist/hematologist (per visit) Costs 145
Neurologist (per visit) Costs 103
MRI scan (per scan) Costs 214
PET-CT scan (per scan) Costs 1,110
Percentage of patients receiving tocilizumab Resource use 60%*
Percentage of patients receiving IVIG Resource use 24%
Assumed average number of days in hospital (including pre- and post-treatment) Resource use 14
Assumed average number of ICU days (including pre- and post-treatment) Resource use 2
Percentage of patient admitted to ICU Resource use 20%*
Probability of patients with cytokine release syndrome (CRS) ≥3 Resource use 18%
Probability of patients with febrile neutropenia (FN) Resource use 23%
Probability of patients with neurological events ≥3 Resource use 20%
Probability of patients with anemia Resource use 27%
Probability of patients with thrombocytopenia Resource use 19%
Duration of follow up (in years) Resource use 15*
* = based on clinical experts
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Table 4: Average total costs pre- and post- CAR T-cell administration in former EU-5 and NL
Item value in EUR
Average cost of care pre- CAR T-cell administration 7,147
Average cost lymphodepletion and administering CAR-T 26,615
Average cost of care managing AE’s 10,524
Average cost of follow up 6,074
Total cost of pre and post- CAR-T care 50,359
Scenario 3 Incremental costs of introducing CAR T-cell therapy
Of all CEA studies reviewed, the total average incremental costs of CAR T-cell therapies 
when compared to care as usual were 276,086 EUR and 328,727 EUR for patients with 
pALL and DLBCL, respectively. Cumulative expenditure estimates in our base-case for 
pALL, DLBCL, MCL, FL, AML, CLL, and MM for all included countries from 2019 
to 2029 were on average 0.7 billion EUR, 13.8 billion EUR, 2.3 billion EUR, 6.5 billion 
EUR, 1.2 billion EUR, 0.9 billion EUR, and 3.5 billion EUR, respectively (total average: 
28.9 billion EUR).
Figure 4 depicts the average expenditure across all countries and indications of all three 
scenarios. Th e upper and lower bounds are the estimates based on the Globocan and Euro-
stat approach, respectively.




In our analysis, we estimated future expenditures associated with CAR T-cell therapies for 
a set of hematological indications in six European member states between 2019 and 2029. 
The average cumulative costs in all six countries for all included indications were estimated 
at 28.5 billion EUR (scenario 1) with a steady increase in yearly average costs across the time 
range studied. Average yearly costs increased in a step-wise manner which can be explained 
by the assumed drug penetration rate and predicted new indication launches. For the year 
2019, we assumed penetration rates of 45% for current CAR T-cell therapies for DLBCL 
and pALL. This penetration rate peaks in 2020 (90%) and remains stable thereafter. For the 
year 2021 we assumed new product launches for MCL and in the year 2022 new launches 
for FL, MM, and CLL. Even with an initial penetration rate of 45% for the first year of the 
product launch, this is a major cost driver that more than doubled the yearly average costs. 
Finally, the product launch for AML was estimated for the year 2025 and is responsible for 
another stepwise increase in predicted yearly cumulative costs.
It seems obvious that new product launches have a considerable impact on any expendi-
ture. Therefore, the methodology for estimating the expenditure of these launches is crucial. 
However, there is no reliable way of knowing at what time exactly new CAR T-cell therapies 
will be available for treatment. For product launches of future indications, we used data on 
available clinical trials on clinicaltrials.gov and estimated their future availability based on 
the time between the trial start date and the published date of the respective HTA reports 
for tisagenlecleucel and axicabtagene ciloleucel. In case several trials were currently running, 
Figure 4: Expenditure forecast per scenario (all countries and indications)
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we selected studies from the biggest sponsor in terms of market capitalization. However, this 
approach neglects the possibility of failing trials that would not lead to market access of a 
drug, the possibility of smaller companies to be the first to receive market access for their 
drug, or the possibility of postponing market access due to internal decisions. Therefore, we 
validated our findings with clinical experts who suggested CAR T-cell therapy launches in 
the years 2021 and 2022 for MCL and FL, respectively.
The eligible patient population for CAR T-cell therapies in the different EU member states 
was based on the population projection by Eurostat355 with fixed incidence rates, and the 
incidence projection from Globocan, over the period 2019 to 2029. Both strategies were 
used to congregate an average patient population. The factual eligible patient population 
could deviate from our projection due to unforeseen events and assumptions. Our assump-
tions and results were validated by clinical experts, but forecasts are sensitive to changes in 
outcomes and business strategies. Besides, future clinical pathways may also change, ac-
commodating for new treatments that are currently in the pipeline. Advancements in other 
immunotherapies and targeted therapies could affect future uptake of CAR T-cell therapies 
as well. Currently, available CAR T-cell therapies (i.e. tisagenlecleucel and axicabtagene 
ciloleucel) are being investigated for the second-line treatment of patients with DLBCL 
(NCT03570892, NCT03391466) which will make those therapies available to an even 
larger patient population. Moreover, lisocabtagene maraleucel is also being investigated in 
a second-line setting for patients with B-cell non-Hodgkin lymphomas (NCT03575351). 
If CAR T-cell therapies are utilized in second-line settings, this would considerably increase 
the eligible patient population.
Besides the uncertainties regarding the number of patients eligible for CAR T-cell 
therapies, the price of the therapy itself is associated with a high degree of uncertainty. For 
our analysis, we used list prices whenever available. However, actual prices for CAR T-cell 
therapies are mostly subject to confidential negotiations. Hence, the actual price per country 
is unknown. For our analysis, the price of CAR T-cell therapies for future indications was 
assumed to be 323,500 EUR per treatment, based on an average of the known list prices for 
DLBCL patients. This estimation could be inaccurate, due to existing and future competing 
treatment options. Moreover, clinical experts already reported a new and lower price for 
tisagenlecleucel in Germany of 275,000 EUR per treatment. Such a price reduction could be 
the result of the two CAR T-cell therapies (i.e. tisagenlecleucel and axicabtagene ciloleucel) 
currently competing for DLBCL. The expected approval of lisocabtagene maraleucel400 (Cel-
gene) could drive up competition even more. To allow competition with the two existing 
CAR T-cell therapies, could lead to an even further reduction in prices. Per contra, Celgene 
might price lisocabtagene maraleucel higher than its competitor considering the possibility 
of being best-in-class.401 Yet another scenario that could affect prices of CAR T-cell therapies 
is the point-of-care production within hospitals, leaving health care payers with only the 
manufacturing costs. Specialized hospitals in several countries are exploring the possibility 
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to make their own CAR T-cell treatments in the future. We have asked clinical experts 
whether they think it would be an option for lowering the price and improving the access 
to CAR T-cells for patients. In Germany and the Netherlands, the probability was estimated 
above 50% and the cost of own production was estimated to be 50,000 EUR – 70,000 EUR 
per CAR T-cell treatment. This means that one treatment may cost approximately 80,000 
EUR (including pre- and post-care costs) instead of 375,000 EUR. In the literature, the 
manufacturing costs have been estimated at 65,000 USD.402 Moreover, companies such 
as Cellectis or Servier are currently working on the development of allogeneic CAR T-cell 
therapies (NCT03190278, NCT02808442). These off-the-shelf CAR T-cell therapies could 
be manufactured in batches instead of on-demand, resulting in economies of scale, and 
possibly lower cost for health care payers. Lastly, the possibility of in vivo reprogramming of 
T cells, to e.g. be active against CD19 positive cells, could potentially reduce treatment costs 
by circumventing ex vivo manufacturing of T cells.403
While the price for CAR T-cell therapies may be subject to changes, the cost of care 
associated with CAR T-cell therapy could also decrease over time. This may be due to pos-
sible reductions in side-effects or different adverse event profiles with future CAR T-cell 
therapies. Likewise, our forecasted incremental costs may differ. Our estimates are based on 
relatively scarce cost-effectiveness data on both tisagenlecleucel and axicabtagene ciloleucel. 
For future indications, we assumed an average of the known costs. However, according to 
clinical experts, the incremental costs associated with CAR T-cell therapies for MM could 
be much lower when compared to DLBCL for instance. This may be caused by the chronic 
nature of MM and its current high costs for the standard of care, which could be redundant 
after CAR T-cell therapies.
Other cell and gene therapies that have regenerative or curative potential are currently 
being developed for various indications.404 The limited duration of clinical trials, is coin-
cidentally accompanied by uncertainty in long-term effects. Moreover, the possibility to 
cure patients with a single administration presents a new challenge for pricing and reim-
bursement of these therapies.405 Current pricing of gene therapies ought to reflect expected 
long-term effects and its curative potential. For instance, Novartis has priced Zolgensma, a 
gene therapy medication used to treat spinal muscular atrophy in children less than 2 years 
old, at approximately 1.887 million EUR (2.125 million USD), which makes it the most 
expensive drug currently available.406 Spark Therapeutics Inc’s Luxturna gene therapy for 
patients with inherited retinal disease, was priced at approximately 754,817 EUR (850,000 
USD) for both eyes. One aspect these cell and gene therapies share is their high prices which 
are often justified by significant treatment effects. However, long-term efficacy results are 
not yet available, and some patients may need subsequent CAR T-cell therapies or allogeneic 
stem cell transplantation. In addition, some patients might need additional (other) gene 
therapies in the future. It remains unclear who should bear the financial risk stemming from 
the uncertainty in the clinical value. Consequently, reimbursement decision-makers in many 
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EU member states seem to be reluctant in applying “standard” reimbursement criteria to 
CAR T-cell therapies.
Several EU member states and the UK adopted various pricing and reimbursement 
schemes. While France and the UK opted for coverage with evidence development schemes, 
both Italy and Spain negotiated outcomes-based staged payment agreements. Outcomes-
based rebates were negotiated in Germany, and in Austria, different cost-sharing agreements 
are in place, varying between provinces. In the Netherlands tisagenlecleucel for pALL, 
patients is reimbursed through standard criteria, since its estimated budget impact was 
found to be relatively low (approximately 10 children per year were estimated to be eligible). 
Axicabtagene ciloleucel for DLBCL patients on the other hand was placed in the so-called 
‘lock’ for 421 days, before being reimbursed. The different reimbursement schemes for the 
former EU-5 are analyzed and discussed in depth elsewhere.407
At the 2020 EHA/EBMT CAR T-cell congress in Sitges, manufacturers signaled a willing-
ness to further cooperate with payers reaching reimbursement agreements. Presented options 
were discounts of list prices, price-volume agreements, outcome-based agreements based on 
patient-level outcomes, value-based agreements based on additional clinical evidence, or 
a price by indication. Despite this, CAR T-cell therapies are still not affordable for many 
countries.
We limited our study to the former EU-5 and the Netherlands, all of which are already 
reimbursing CAR T-cell therapies. However, difficulties regarding reimbursement are even 
greater in Eastern Europe, resulting in many patients currently lacking access to these prom-
ising treatments.
future market of CAR T-cell therapies has been studied previously, although not with a 
specific focus on hematology-oncology. The decision resources group (DRG) for instance 
published a report on CAR T-cell therapies in the pipeline and a forecast snapshot. Without 
revealing the employed methodology, the DRG estimated the CAR T-cell therapy market 
at approximately 1.5 billion EUR (1.7 billion USD) by 2026 for the hematological ma-
lignancies. It is not clear whether these figures ought to reflect the US, European, or a 
global market. Our estimation exceeds the DRG figures by far but since the methodological 
approaches cannot be compared, it remains open which forecasted aspects differ.
Another study estimated 114,737 cumulative treated patients in the US between the 
years 2019 and 2029 for all hematological cancers.368 This is relatively close to our estimate 
considering a fundamentally different methodological approach and the inclusion of dif-
ferent cancer types. In terms of costs, Quinn et al.408 mention a range between 11.1 billion 
EUR (12.5 billion USD) and 88.8 billion EUR (100 billion USD) for all hematological 
cancers. Our estimates fall within this range. However, it needs to be noted that although the 
US population is comparable to the studied population in terms of size (US population is 




Finally, we conclude that, although current and future CAR T-cell therapies seem promis-
ing in hematological cancers, with the current price-setting the financial burden on health 
care systems in former EU-5 and the Netherlands is considerable. Some European countries 
are struggling with associated costs of pre- and post- care for CAR T-cell therapies as these 
costs are reimbursed insufficiently. Further, the pricing of CAR T-cell therapies is high and 
it can be expected that new and commercial CAR T-cell therapies will be in a similar price 
range. Combined with the expected expansion of indications, the financial burden on health 
care systems will increase substantially with direct effects on patient access to these new 
treatment options. Specialized hospitals could produce CAR T-cell treatments themselves 
in the future at lower costs, which could drive procurement costs down. Stimulating this 
development may contribute to better patient access but future research and development 








Cancer is the second leading cause of death after cardiovascular diseases in Europe, account-
ing for 26% of all death in 2016.2 During the last three decades, the worldwide incidence 
of cancer increased by 50%, while mortality due to cancer increased with 20% during the 
same time frame.2
Novel treatment options such as chimeric antigen receptor (CAR) T cells are on the 
verge of revolutionising the field of haemato-oncology as they have the potential of actu-
ally curing certain types of cancer.409 Nevertheless, prices for novel cancer drugs in general 
and for haematologic malignancies in particular, are high and increasing throughout the 
last decades.45 To keep healthcare systems affordable, decision makers have adopted several 
measures to control the price at which novel treatments are reimbursed. Through a formal 
Health Technology Assessment (HTA), the value that patients and health systems perceive 
for the particular treatment can be assessed, and a price for reimbursement can be set ac-
cordingly.7 Although the concept of HTA is already used since the 1980’s, various challenges 
persist to this day.
Recently, the European Network for Health Technology Assessment (EUnetHTA) defined 
nine domains of HTA. This dissertation mainly focussed on identifying and addressing 
challenges in the domain of costs and economic evaluation. In addition, the domains of safety, 
clinical effectiveness, as well as patient and social aspects were taken into account. More spe-
cifically, this dissertation explored several challenges in assessing costs and cost-effectiveness 
of treatments in haemato-oncology. Several aims were defined in Chapter 1 which were 
analysed in three parts. PART I explored challenges in the evidence synthesis for HTA. 
PART II aimed at providing evidence on the cost-utility of novel and expensive treatments 
in haemato-oncology. PART III described implications of these cost-utility analyses (CUAs) 
on healthcare decision making and investigated the impact of expensive immunotherapies 
for the treatment of cancer on the (future) healthcare expenditure in Europe.
This final chapter discusses various aspects and findings of this dissertation and ends with 
recommendations for future research and healthcare policy.
PART I: CHALLENgES IN THE EvIDENCE SyNTHESIS 
FOR HTA
Three distinct challenges in synthesising evidence for HTA were identified and addressed in 
this dissertation.
Synthesising evidence from existing economic evaluations
In the context of evidence-based medicine (EBM), health decision making should be based 
on so-called “evidence to decision frameworks”, meaning that all relevant factors for a deci-
sion are assessed and considered both systematically and transparently.410 To answer research 
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questions in the costs and cost-effectiveness domain of HTA, previously published economic 
evidence should therefore be reviewed systematically.17
To this end, researchers and decision makers could make use of specialised databases that 
focus on indexing published economic evaluations such as the U.K. National Health Service 
Economic Evaluation Database (NHS EED) or the Health Economic Evaluation Database 
(HEED). However, since funding had ended, the HEED is no longer accessible for searches 
since the end of 2014, and the NHS EED is no longer updated since March 2015.71,72 
Hence, finding all relevant economic information on a specific health topic has become a 
challenging and (more) time consuming task. Today, researchers and policy makers need to 
search economic evidence through databases that primarily index biomedical literature. Ide-
ally, the resumption of the former specialised databases on economic evaluations could solve 
this issue. However, the reasons that led to their cessation might probably still persist and 
therefore these solutions seem unlikely. Simultaneously, no authoritative guidance on how to 
conduct systematic reviews of economic evaluations in biomedical databases was available.
To fill this gap, Chapter 2 aimed at supporting researchers to prepare systematic literature 
reviews of economic evaluations for informing evidence-based healthcare decisions. As such, 
Chapter 2 details the second step of a five-stepped approach of this process. The full five 
steps include (1) initiating a systematic review of economic evaluations, (2) identifying full 
economic evaluations (see Chapter 2), (3) data extraction, risk of bias and transferability 
(see Wijnen et al., 201670), (4) reporting of results, and (5) discussion and interpretation of 
results. The entire approach including a brief summary of all steps is described elsewhere.30
Generally, this guidance was well received in the scientific community which is reflected 
in several citations of this work. More specifically, the WHO-INTEGRATE (INTEGRATe 
Evidence) framework version 1.0, advised to gather evidence related to the review of eco-
nomic analyses following the guidance provided in Chapter 2.410 This can be viewed as some 
sort of validation of the guidance.
Nevertheless, the guidance may become (partly) futile or outdated in the future. This 
may be due to several reasons. For instance, the way databases can be searched is constantly 
refined. In 2016, the biomedical research database Embase integrated a new search form 
enabling the database searcher to enter search terms separately for the different aspects of 
the PICO (Patient, Intervention, Comparator, Outcome) scheme.411 The user interface then 
automatically suggests synonyms and combines those into a full search query.412 This feature 
facilitates an instant conceptualisation of the PICO scheme for the respective research ques-
tion. While this might save time for the user, important synonyms could still be missed, 
and truncated search terms are not added. Our guidance offers suggestions to incorporate a 
variety of search terms and is therefore still relevant. Also, other databases do not yet provide 
such elaborate user interfaces. Searching Embase with the integrated PICO search tool might 
thus be a good starting point in designing a new search strategy. Subsequently, the query 
could be critically assessed with the guidance presented in Chapter 2. However, such a 
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process is not covered by the current version of the guidance and an update in this regard 
is warranted. For all other databases this guidance still offers useful resources for building a 
search query with a desired level of specificity and sensitivity.
The evolution of biomedical research databases may call for another update of the guid-
ance soon. Not only because user interfaces are increasingly refined and tailored to the 
researchers’ needs. Novel, intelligent and automated search algorithms are at the verge of 
changing the way literature is searched in general. Machine learning algorithms and tools 
are promising approaches to reduce the workload of systematic literature reviews and can 
be applied to inform evidence synthesis already today.413,414 However, such tools are still 
under development and may require an extensive background in information technology or 
biomedical informatics.414,415 Until such approaches have become fully mature and available 
to a broader audience, Chapter 2 may serve as a practical guidance to undertake “hand-
crafted” systematic searches for economic evaluations.
Synthesising evidence on effects
Data from randomised controlled trials (RCTs) are often referred to as the “golden standard” 
of collecting clinical evidence on safety and efficacy of a drug.36 Consequently, evidence on 
effects for HTA is preferably collected through such studies.17,19,416 However, these studies are 
not per se designed to inform economic evaluations. RCTs are for instance primarily powered 
to detect differences in clinical outcomes. Since variables related to costs have higher variance, 
the required sample size to detect differences in costs is considerably higher when compared 
to the needed sample size to detect differences in clinical effects.417,418 Furthermore, clinical 
studies have limited follow-up times. Consequently, desired clinical benefits such as overall 
survival (OS) can often not fully be captured. Therefore, so-called surrogate endpoints 
are often chosen as primary trial endpoints. In the field of haemato-oncology, these often 
include event-free survival, freedom of treatment failure, or progression-free survival (PFS). 
Surrogate endpoints such as PFS do not usually reflect better health-related quality of life 
(HRQoL) or overall longevity.45 Outcomes of the study in Chapter 6 seem to confirm the 
former, since HRQoL for patients in progression-free disease did not differ from patients in 
progressive disease. This aspect is discussed in more detail in Part II of this Chapter.
Patient selection in accordance with the decision problem
The decision to reimburse a novel treatment is usually taken for a (sub-)group of patients 
with a specific disease. Therefore, it is important that economic evaluations clearly define the 
target patient population including all relevant subgroups. When data from RCTs are used 
to inform efficacy parameters of economic evaluation, challenges may arise. This is because 
RCTs are conducted under strictly controlled and idealised conditions. The selection of a 
narrowly defined patient population can hence potentially affect external validity, which is 
need when (reimbursement) decisions need to made on a more general level.419 A recent 
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literature review showed that the majority (71.2%) of included RCTs in cardiology, mental 
health, and oncology reported that their samples were not broadly representative of real-
world patients.420 More specifically, patients enrolled in oncological studies were found to 
be often younger, less likely to be female, have better performance status, and better disease 
prognosis than real-world cancer patients.420
This issue poses a general challenge to the generalisability of all economic evaluations 
making use of RCT data, especially when the (reimbursement) decision problem focusses on 
specific patient subgroups of the gathered evidence.
In Chapter 7 for instance, evidence on effects were used for a subgroup of the trial 
population in the final analysis. In this way the decision uncertainty for the reimbursement 
authority could be reduced to an extent that the treatment could be accepted for reimburse-
ment. However, initially, the trial was not designed to detect differences in efficacy between 
the novel treatment and its comparator for the relevant subgroup. Consequently, post hoc 
subgroup analyses were necessary for the economic evaluation.
While post hoc subgroup analyses are possible for clinical trial data, the Consolidated 
Standards of Reporting Trials (CONSORT) initiative strongly criticised such approaches.421 
To allow for more robust estimates, subgroups analyses should be pre-specified and it is 
suggested that such specifications could be made mandatory, at least for publications.422
In Chapter 6, the relevant subgroup for the reimbursement decision problem were pre-
stratified. Therefore, using evidence from this subgroup for the CUA did not introduce ad-
ditional uncertainty. This was however only possible since patient-level data were available. 
Usually, such subgroups analyses cannot be perform since the relevant empirical survival 
data is often not published.318
To tackle the issue of low external validity of RCT data, adapting trial designs to include 
more representative patient samples or supplementing RCT data with evidence from sup-
portive studies could be a solution.420 Regarding evidence of specific subgroups, clearly 
defined and pre-specified subgroups could offer more valid and reliable outcomes, relevant 
for economic evaluations. In addition, such evidence should be published so that relevant 
cost-effectiveness studies can be conducted without having access to patient-level data.
Estimating long-term efficacy
Since clinical studies usually have restricted follow-up times and most jurisdiction prefer a 
lifetime horizon for economic evaluations,19,26 there is a need to extrapolate the empirical data 
to a longer time horizon. Researchers can choose between several techniques, and parametric 
survival models are often used for this purpose. The literature refers to the exponential, 
Weibull, Gompertz, log-normal, and log-logistic models as “standard” parametric models.306 
These models are frequently used in economic evaluations and their employed methodol-
ogy including their strength and weaknesses is well documented.211,306,423 When parametric 
models are used to extrapolate patient data of clinical studies, both internal and external 
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validity need to be verified. Internal validity is commonly assessed through visual inspection 
of the fitted curves to the observed survival. In addition, model fit criteria such as the Akaike 
Information Criterion (AIC) and the Bayesian Information Criterion (BIC) are used for this 
purpose. External validity is subsequently assessed by comparing the extrapolated survival to 
data from other studies (when available) or the general population mortality (extrapolated 
data should not exceed this mortality). In addition, the plausibility of the extrapolated long-
term survival should be validated by clinical experts.211
Chapters 5 and 6 employed such standard parametric survival models to extrapolate the 
empirical survival data of the respective clinical studies. The results showed that the internal 
validity of the extrapolated curves was high since all parametric survival curves visually fit 
the empirical data well and both AIC and BIC values did not differ to a great extent. While 
internal validity could be established, long-term estimates differed considerably. This aspect 
of survival extrapolation is long recognised in the literature.306 To ensure external validity 
in Chapters 5 and 6, clinical experts were consulted to validate the long-term estimates. 
However, as of yet, standard methods for the elicitations of expert opinion for HTA are 
scarce,424 and although some tools exist to aid in this endeavour, none of them focus of the 
external validation of parametric survival models.425–427 This may introduce some uncertainty 
in the elicitation process. For the studies presented in Chapters 5 and 6, clinical experts 
were asked to validate long-term survival by means of a semi-structured questionnaire in 
combination with subsequent telephone interviews. This may be a possible solution in the 
absence of a clear methodological guidance. However, depending on the complexity of the 
disease, renowned clinical experts may be difficult to find. For Chapter 5 for instance, only 
one clinical expert could be included. This was because paediatric and young adult patients 
with relapsed or refractory B-cell acute lymphoblastic leukaemia (pALL) are only treated 
in one specialised centre in the Netherlands. Consequently, the number of clinical experts 
available to consult about this particular indication is limited. Although for Chapter 6 more 
clinical experts could be included, expert opinion in general may be biased with regard to 
the experts’ experience, training, mood or motivation.428,429
Due to these limitations, there is an expressed need to improve parametric survival ex-
trapolations to incorporate external (long-term) data.430–433 Recently, Vickers (2019) evalu-
ated several survival curve extrapolation techniques using long-term observational cancer 
data.434 The author generally concluded that long-term survival predictions can be improved 
by directly using such mature long-term data and recommends different methodological 
approaches to extrapolate survival data and to integrate long-term data, depending on the 
observed treatment benefit. Nevertheless, several limitations where stated with regard to the 
data used in the study. Most importantly, the different techniques were assessed using data 
from patients ≥80 years old, which might have led to biased results.434 This is particularly 
important to acknowledge when the suggested methodology is used to extrapolate data of 
patients with haematological malignancies, since in Europe, their average age at initial diag-
Chapter 9
156
nosis is considerably lower (i.e. approximately 64 years; median: 69 years; standard deviation 
[SD] or range not reported).435
Extrapolating empirical survival of cancer patients remains a challenging task. And al-
though guidance exist to support researchers in employing “standard” parametric models,211 
the plethora of alternative modelling approaches such as for instance model-averaging 
techniques,436,437 hybrid models,438,439 or cure models440 show that this is an evolving field of 
research. Therefore, it seems that a definitive guidance cannot yet be issued. Future research 
should focus on validating promising modelling techniques to enable robust long-term esti-
mates of survival data for the use in economic evaluations. Simultaneously, existing guidance 
for such methodologies should frequently be updated to incorporate newest findings and 
recommendations.
Choosing an appropriate treatment comparator
Since economic evaluations are comparative studies, any novel treatment that will be as-
sessed for its cost-utility needs to be compared to at least one other course of action.
The importance of choosing an appropriate comparator for any economic evaluation is 
highlighted by the Drummond checklist for assessing economic evaluations.19 The second 
question of this checklist focusses on whether a comprehensive description of the com-
peting alternatives was given and whether relevant alternatives were omitted. Already in 
1998, Mullins and Ogilvie, concluded that most pharmacoeconomic guidelines agreed on 
an appropriate comparator being either a therapy currently used in standard practice, or a 
therapy that is most likely to be replaced by the novel treatment.441 More recently, reviews 
of country-specific economic evaluation guidelines came to similar conclusions.442,443 Con-
sequently, the EUnetHTA stated in its 2015 guideline that comparators should “reflect most 
relevant alternative intervention(s) used in clinical practice”.443
Despite such clear and longstanding preferences for comparators in economic evaluations, 
choosing a relevant comparator was challenging for Chapters 5 and 6. Although several 
treatment alternatives existed for the patient population studied in Chapter 5, no standard 
of care was yet defined. Therefore, all commonly administered treatment alternatives in the 
reference country, for which survival data were available, were selected for the evaluation. 
Similarly, no clear standard of care was defined for patients studied in Chapter 6. And 
although clinical experts indicated several treatment options for the reference country, reli-
able survival data of these treatments were not available.
Using phase II clinical data
Conducting pivotal phase III trials is a time-consuming effort and it can take decades until 
such studies are concluded. To improve a timely access for patients to new medicines, the 
European Medicine Agency (EMA) established the so-called PRIME scheme to “enhance sup-
port for the development of medicines that target an unmet medical need”.444 Consequently, 
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evidence from phase II clinical trials is increasingly used by the EMA to decide on the 
marketing approval of new (cancer) treatments.445 The question arises to what extent phase 
II clinical data can be used to inform early HTAs.
Following the ISPOR Good Research Practices in Modelling Task Force, conceptualising 
(decision) models for economic evaluations is an iterative process, involving several steps 
and stakeholders.210 To keep the time between marketing approval and the possible reim-
bursement of novel and expensive treatments as short as possible, a timely beginning of 
conceptualising the model is warranted. Chapter 4 demonstrated that evidence from previ-
ously published phase II studies can be used to conceptualise such a model and to simulate 
long-term survival outcomes. Such simulations make a de novo decision model transparent 
and discussable within the scientific community. In addition, the simulation results already 
indicate the magnitude of the efficacy that can be expected from the novel treatment. The 
proposed model in Chapter 4, together with its results was generally accepted by scientific 
peers, supporting its credibility.446,447 Complemented with clinical evidence from a compara-
tor treatment and input parameters on costs, this model could be used for a model-based 
CUA. In such a case, an early HTA could be conceivable, accelerating later reimbursement 
procedures. In case results of such an analysis show that the novel treatment would result in 
a significantly unfavourable cost-effective ratio when compared to the pertinent willingness-
to-pay (WTP) threshold, the use or development of the novel treatment could be halted. 
Nevertheless, the analysis of Chapter 4 needs to be interpreted as an indication for the long-
term survival of the studied patient population which needs to be validated through phase 
III clinical data. Currently, the multi-centre, international phase III clinical trial RETHRIM 
aims at creating such needed evidence. However, issues with patient accrual have delayed 
the end of the study extensively. This is due to several reasons such as improved preventive 
measures to develop the disease (acute graft-versus-host-disease [aGvHD] in this case) and 
the relatively small indication (aGvHD can be considered as rare448).
In Chapter 5, phase II clinical data was used to perform a formal CUA for a Dutch 
reimbursement dossier. Previously, the studied therapy (tisagenlecleucel) had received mar-
keting approval following the EMA’s PRIME scheme based on phase II clinical data.50,449 
Consequently, evidence from an RCT were not available at the time the economic evalua-
tion was conducted. With the evidence available, CUAs could be conducted in several ju-
risdictions, including the one of Chapter 5.254,256–258,389,450,451 Nevertheless, most European 
Member States did not opt for a “classic” reimbursement of the therapy. All (former) EU-5 
Member States (i.e. France, Germany, Italy, Spain, and the UK) have adopted some kind of 
outcomes-based reimbursement scheme (OBR).407 Reasons for this included the high costs 
of the treatment but also the considerable amount of decision uncertainty stemming from 
restricted efficacy data.407 In the Netherlands, the decision to reimburse the treatment was 
based on a simple budget impact analysis (BIA) instead of making use of the available results 
of the CUA in Chapter 5 (more about this in Part II of this discussion). Consequently, the 
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novel treatment was reimbursed following a standard procedure in the Netherlands and no 
OBR was negotiated.
Similar to the findings of Chapter 4, the results of Chapter 5 need to be validated with 
long(er)-term efficacy data, preferably from phase III clinical data.
Synthesising evidence on costs
When economic evidence is not available or transferrable to the setting of interest, new 
evidence needs to be generated. Chapter 3 can be seen as a case study to estimate healthcare 
costs based on two distinct approaches.
First, healthcare costs of paediatric patients with sickle cell disease were based on the 
pertinent clinical practice guideline (CPG). These costs could quickly be estimated since 
the expected resource use frequency was described in sufficient detail and could be valued 
with reference prices. However, such an approach only considers the standard resource use 
of patients. Consequently, it does not provide insights into real-word resource use. As such, 
it neglects any additional or emergency visits to the hospital for instance. Depending on the 
studied disease, such visits can be relatively frequent (e.g. in the case of sickle cell disease452) 
and should therefore be considered when costs are estimated.
Therefore, a second approach was explored. For this, available patient level data of a hospi-
tal financial claims database was used to gather information of real-world resource use. This 
approach was significantly more challenging when compared to the first one due to several 
reasons. For instance, receiving access to the financial claims database was complicated. 
Since hospital claims data are generated for billing purposes,453 they are usually managed by 
the financial department of a healthcare institution whose primary aim is not the support 
of scientific research. Also, claims data hold less information on patients than for instance 
medical records. While this makes them easily de-identifiable,453 it is not always clear which 
of the recorded measures are most useful to represent utilisation.454 This can only be resolved 
in a dialogue with the healthcare professionals and the data administrator.
In conclusion, hospital claims databases are not designed to support research endeavours on 
costs. In addition, such databases are subject to frequent updates and changes. The respective 
Dutch reimbursement system for instance was introduced in 2005 and profoundly revised 
in 2012.455 It can therefore still be considered as a system under development. Especially at 
the time data for the initial analysis of Chapter 3 was requested (2017). Enhancements and 
updates of hospital information systems under development are necessary and important. 
However, such changes may render previous or newly collected data incompatible and hence 
not useful for data analyses. Nevertheless, claim-based studies are conducted at least since 
the 1980’s for manifold purposes in the US.456 A review of such studies between 2000 and 
2005 in five healthcare journals found that the majority used claims data to study aspects 
of access to healthcare (49%), followed by quality of healthcare (24%), and interventions, 
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therapies, or treatments (13%).457 Studies on healthcare costs were not mentioned, although 
some studies exist.458,459
Generally, the literature suggests that using claims data to estimate the cost of illnesses 
is feasible and may provide access to a relatively large sample size while avoiding selection 
bias.458–461 This is in line with the findings reported in Chapter 3. In addition, Chapter 3 
demonstrated that hospital financial claims data can be used for the estimation of real-world 
healthcare costs. Supplemented with patient characteristics such as age, sex, and diagnosis, 
such databases can be a powerful and reliable source of information that is readily available 
and frequently updated. Alternatively, as mentioned in Chapter 1, information on resource 
use could be synthesised from patient questionnaires, although this may be related to some 
bias.43 Future research could compare either approach (i.e. collecting resource use data 
from financial claims databases versus patient questionnaires) to establish the comparative 
evidence on the validity of either method.
PART II: COST-UTILITy OF NOvEL TREATMENTS IN 
HAEMATO-ONCOLOgy
Costs of novel cancer treatments for haematological conditions are high and can put the 
affordability of other new treatments at risk. Therefore, reimbursement decisions need to 
be made in a transparent and systematic way. CUAs can provide the needed information to 
make evidence-based decisions in healthcare and are therefore a vital part of the reimburse-
ment decision process. This dissertation assessed the cost-utility of two novel and expensive 
treatments that entered the European market in 2019.
The cost-utility of tisagenlecleucel when compared to clofarabine monotherapy (Clo-M), 
clofarabine combination therapy (Clo-C), and blinatumomab (Blina) in paediatric patients 
with relapsed/refractory acute lymphoblastic leukeamia (pALL) was assessed in Chapter 5. 
Based on the disease burden and applicable willingness-to-pay (WTP) threshold, tisagenle-
cleucel could be considered cost-effective from all perspectives studied. Several other CUA 
assessed the same therapy in Canada,389 the US,254,257,451 and the UK.258 All of these studies 
came to the same conclusion of tisagenlecleucel being cost-effective in the base-case analysis.
Similarly, Chapter 6 assessed the cost-effectiveness of lenalidomide plus rituximab versus 
rituximab monotherapy for previously treated follicular lymphoma (FL). Based on the 
selected WTP-threshold for the base-case analysis, lenalidomide could be considered cost-
effective. However, the probabilistic sensitivity analyses indicated some uncertainty in the 
results. In addition, some scenarios exceeded the chosen WTP-threshold for the base-case 
analyses, rendering the treatment not cost-effective. To this date, two other studies are avail-
able that assessed lenalidomide in previously treated FL in the UK and China.316,318 While 
the treatment was considered cost-effective in a UK setting, the Chinese study concluded 
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that lenalidomide was not cost-effective. Several reasons could have led to the conclusion of 
the latter. Most importantly, Zhang and colleagues assumed a rather restrictive time horizon 
of ten years.318 In such a short time frame, differences in both effects and costs of the two 
studied treatments could not fully be captured. Assuming a similar time horizon in our study 
would also lead to an ICER above the assumed WTP-threshold.
Including future non-medical costs in a societal perspective
As described in Chapter 1, two main perspectives used in CUAs stand out: the healthcare 
perspective and the societal perspective.21 For either perspective, most pharmacoeconomic 
guidelines prefer a lifetime horizon on costs.26 Consequently, the inclusion of future costs 
should be considered as well. A systematic review published in 2015, found that the number 
of publications to include future costs in general increased by 40% (to 70.8%) between 2008 
and 2013.27 While most of the studies detected (i.e. 49%) incorporated future medical costs 
related to the studied disease (also referred to as related future costs), only 4.2% included 
future medical costs not related to the studied disease (also referred to as future unrelated 
medical costs). None of the studies included in the review considered future non-medical 
(i.e. productivity or consumption) costs. A reason to not include the latter may be that most 
pharmacoeconomic guidelines do not yet explicitly mentioned their inclusion.26,27 Some 
guidelines (e.g. in the US) however already do so and it seems that the scientific debate on 
whether to include these costs settles in favour of the US approach.26,27,259,287 Regardless 
this ongoing debate, the impact of including future non-medical costs in CUAs remains 
understudied.26,27
Both Chapters 5 and 6 assessed the cost-utility of a novel treatment in haemato-oncology 
from a healthcare and a societal perspective. In addition, future non-medical costs were 
included to determine the impact of this component on the ICER. The inclusion of the 
latter costs was possible due to a recent update of the iMTA Practical Application to Include 
Disease Costs (PAID) tool.276 Hence, the studies presented in Chapters 5 and 6 were the 
first to incorporate these costs in their assessment and can therefore be seen as case studies 
to examine the impact on the ICER when these costs are added to a societal perspective.
Including future non-medical consumption costs in a societal perspective, lead to an 
increase in the ICER between 17% and 21% in Chapter 5, when compared to the societal 
perspective alone. When future non-medical costs were included in a societal perspective 
in Chapter 6, the ICER increased by approximately 22% when compared to the societal 
perspective alone. However, despite these rather large increases in the ICER, the results of 
these two studies showed that considering future non-medical consumption costs within 
a societal perspective does not necessarily influence the decision to consider a treatment 
cost-effective. Whether or not this holds true for other studies as well depends on the mod-
elled efficacy of a treatment, its costs, and the assumed WTP-threshold. When incremental 
effects (i.e. life years or QALYs) are relatively high for the novel treatment, considering 
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future non-medical costs might not influence a positive reimbursement (as seen in Chapter 
5). However, when the ICER from a societal perspective is already close to the assumed 
WTP-threshold, considering future non-medical costs might lead to an ICER exceeding the 
WTP-threshold (as seen in Chapter 6).
It needs to be noted that especially the results of the study presented in Chapter 5 are 
related to some uncertainty. Since the patient population of interest were children and 
young adults, the modelled time horizon was substantially longer when compared to pa-
tients included in Chapter 6. This not only introduces uncertainty in the modelling of 
long-term efficacy but also in modelling cost items such as productivity losses or gains. 
Typically, economic evaluations from a societal perspective consider future production costs. 
These are usually referred to as productivity losses when adults are the patient population 
of interest. When children and young adults are the patient group of interest however (as in 
Chapter 5), they are usually not yet part of the workforce and hence productivity losses can-
not not be considered. Instead, disease survivors might be able to work in the future. Hence 
productivity gains should be considered for this group. Modelling potential productivity 
gains in this population is challenging since little is known about both educational and 
employment prospects of long-term survivors of childhood cancer. Also, the estimation of 
potential productivity gains should account for future fluctuations on the job market for the 
jurisdiction of interest which introduces additional sources of uncertainty.
The decision as to whether or not future non-medical costs should be considered in eco-
nomic evaluations should not be driven by the impact of these costs on the ICER. It is rather 
a fundamental methodological question within health economics that needs to be answered 
through scientific discourse. While this debate is currently ongoing, clear recommendations 
put forward through pharmacoeconomic guidelines have probably the biggest potential 
to resolve this uncertainty. The recommendations issued by the US Second Panel on Cost 
Effectiveness in Health and Medicine in 2018 were a first step in this direction.287 Whether 
other countries will follow is not yet clear. However, given the potential of exceeding the 
WTP-threshold when future non-medical costs are considered, their impact should at least 
be explored in sensitivity analyses of economic evaluation already now. Especially, since the 
recent update of the iMTA PAID tool facilitates the inclusion of these costs, at least for the 
Netherlands.259 Arguably, this tool should be extended to also include cost estimates from 
other countries to allow for a more seamless implementation in different jurisdictions. Efforts 
to do this are already underway as a recent publication of a separate PAID version to include 
future unrelated medical costs for economic evaluations in England and Wales show.462 It is 
unfortunate that this version does not include future non-medical costs altogether.
The need for accurate health state utility values
Health state utility (HSU) values are an integral part of CUAs as they allow the calculation 
of quality-adjusted life years (QALYs). Since most contemporary clinical trials collect health-
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related quality of life (HRQoL) data, they can be an important source for synthesising such 
evidence.463 Nevertheless, HSU values are regarded as one of the most uncertain input 
parameters of cost-utility models which simultaneously have the potential to heavily impact 
both accuracy and precision of the model results.464
Despite their relative importance to economic modelling studies, HSU estimates of 
haematological malignancies seem to be rarely reported in the literature. For the indication 
of FL for instance, utilities from a study of Wild et al.340 are commonly used for CUAs in 
this field.465–472 Similarly, studies examining HRQoL of patients diagnosed with multiple 
myeloma were found to be scarce.473
Results from the widely cited study of Wild et al.340 are only available in form of a con-
ference abstract and therefore the employed methodology is not fully disclosed. For the 
study in Chapter 6, patient level HRQoL data were available and therefore HSUs for the 
economic model were estimated based on the most recent ISPOR guideline.464 Outcomes 
of this analysis suggested no statistically significant difference between either administered 
treatment in the clinical study. This was in line with the analysis of the same data conducted 
by the principle investigator of the trial.300 More importantly however, our analysis also did 
not find any differences in HRQoL between the health state of progression-free and progres-
sive disease. This finding is at least counterintuitive as a recent cohort study including more 
than 2,000 patient with metastatic breast, pancreatic, lung, or colorectal cancer found that 
disease progression is related to worse outcomes in many HRQoL scales.474 It needs to be 
noted that this study did not include patients with haematological cancers, nor did the study 
include a generic HRQoL questionnaire such as the EQ-5D.299 For economic evaluations 
in healthcare, such generic questionnaires are generally preferred as they allow a comparison 
of outcomes across different diseases.19 Currently, a comprehensive overview relevant HSUs 
for haematological diseases is lacking. A systematic summary in the form a literature review 
could shed light on this. Alternatively, a cohort study including patients with haematological 
malignancies could reveal HSUs for this patient group. In this way, findings on the HSU 
used in Chapter 6 could be validated.
PART III: IMPLICATIONS OF CUAS ON HEALTHCARE 
DECISION-MAkINg
Implications of CUAs on reimbursement decisions in haemato-
oncology
As stated in Chapter 1, economic evidence generated from CUAs can guide reimbursement 
decision-making in healthcare. In this dissertation, the policy implications were studied for 
the three CUAs described in Chapters 5 to 7. All three analyses assessed the cost-utility of 
novel, expensive treatments in haemato-oncology and provided the first economic evidence 
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on the treatment of interest for the pertinent jurisdiction. To understand the implications 
of the CUA results on policy and decision making, Chapters 5 to 7 need to be interpreted 
in the context of the respective jurisdiction. While Chapters 5 and 6 were conducted to 
primarily inform Dutch reimbursement decision, Chapter 7 was performed for a UK 
perspective.
The relevance of CUAs when the estimated budget impact is low in the 
Netherlands
In the Netherlands, CUAs are required to inform reimbursement decisions for novel and 
expensive treatments. To keep the time between marketing authorization and the decision 
for reimbursement as short as possible, manufacturers often commission independent re-
search institutes to perform the CUA for the eventual submission of evidence to the National 
Health Care Institute (Zorginstituut Nederland, ZIN). Studies presented in Chapters 5 and 
6 are both examples of this process as they were both submitted for the reimbursement 
decision process of the treatment studied. Nevertheless, results of neither Chapter seemed to 
have played a role in the decision to reimburse the novel treatment.
Despite its relatively high list price of 320,000 EUR per patient, the budget impact of 
tisagenlecleucel (Chapter 5) was seen as “low” and below the threshold that requires a full 
cost-effectiveness analysis. After all, the ZIN estimated that approximately 9 patients per 
year would receive the drug. When compared to the current standard treatment of blinatu-
momab, the ZIN estimated that this would lead to incremental costs of 2.1 million EUR 
per year, considering treatment, administration and monitoring costs. Nevertheless, results 
of Chapter 8 show that these costs are likely to increase in the future due to an increase in 
eligible patients.
Although the Dutch EE guideline prefers discounted, societal costs from a lifetime per-
spective to support evidence-based decisions in healthcare,314 the estimates from the budget 
impact analysis (BIA) for tisagenlecleucel only considered undiscounted direct medical 
healthcare costs for one year. Such an analysis neglects several aspects that are specific to 
CAR T-cell therapies and influence both costs and patient outcomes.
CAR T-cell therapy is a particularly complex treatment requiring an extraction of the 
patient’s own T cells.475 These cells are then transported to a specialised facility where they 
are genetically engineered to become CAR T-cells that target the desired cancer cells.476 After 
the CAR T-cells are amplified by several million-fold, they can be transfused back into the 
patient.477 This is a time consuming process with a median manufacturing time of 23 days 
(range, 21-37 days) from receipt of the material at the manufacturing facility to return to 
the clinical facility.478 It needs to be noted that these figures are only valid for US which 
holds at least two centralised manufacturing facilities.478 For the European market the first 
manufacturing facility is currently built in Switzerland and estimated to be functional by 
the year 2021.479 Until then, shipment of patients’ own T cell and CAR T-cells between 
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Europe and the US is necessary, adding to both costs and wait time. Only recently a study 
on the impact of increased wait times on overall mortality of CAR T-cells in large B-cell 
lymphoma (DLBCL) found that even a modest delay in the therapy significantly impacts its 
effectiveness negatively.409 There is little reason to believe that this impact might be different 
in other indications. In addition to the high costs of pre- and post-treatment, some patient 
might not survive such wait times and decease before receiving the final product. All such 
(potential) negative impacts on both effect and costs of the novel treatment were not and 
cannot be considered in a BIA and hence its value of information to the reimbursement 
decision can be questioned.
In a similar case, the results of the CUA presented in Chapter 6 showed a considerable 
level of uncertainty of the novel treatment (R-LEN) being cost-effective in a Dutch setting. 
Nevertheless, the Dutch Minister of Health described the reimbursement negotiations with 
the manufacturer as an “exceptional” case, for which the ZIN was not asked for advice.321 
He argued that the treatment was originally placed in the lock due expected high costs for 
the treatment of another indication (multiple myeloma). Once in the lock, the treatment 
would automatically be exempted from the basic insurance package for all new indications. 
For the recent extension of marketing authorisation, a previously conducted horizon scan of 
the ZIN had expected no more than 10 to 15 patients on a yearly basis for the indication at 
hand.321 Therefore, total healthcare costs for the new indication were expected to not exceed 
the amount of 1 million EUR per year.321 Specifics of this calculation were not disclosed but 
it can be assumed that these estimates were based on a BIA.
Although the budget impact for novel treatments studied in Chapters 5 and 6 were seen 
as too low to require a full HTA for the reimbursement assessment by the Dutch authorities, 
it needs to be noted that both treatments currently have marketing authorisation for several 
indications in the EU. Tisagenlecleucel (Chapter 5) holds central marketing authorisation by 
the EMA for children and young adults with B-cell acute lymphoblastic leukaemia (pALL), 
and diffuse large B-cell lymphoma (DLBCL).50 Lenalidomide (Chapter 6) is authorised 
by the EMA for the treatment of multiple myeloma, myelodysplastic syndrome, mantle 
cell lymphoma, and FL.480 And although the argumentation of a “low budget impact” 
might hold true when considering one particular indication, the budgetary implications 
for these two treatments across all indications might differ significantly. Indeed, the results 
of Chapter 8 show that the costs for CAR T-cell therapy alone could be as high as 54.5 
million EUR for the treatment of patients with pALL and DLBCL in the Netherlands in 
2020. Similarly, a recently published investigation showed that lenalidomide alone generates 
a global annual revenue of approximately 6.2 million EUR, making it the most successful 
treatment in terms of total revenue.481
While BIAs can inform reimbursement decisions, they are also associated with consider-
able uncertainty.482 Due to limited data availability for most input parameters, standard 
methods used in economic evaluations such as one-way or probabilistic sensitivity analyses 
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cannot be conducted.483 A systematic review of BIAs on pharmaceutical drugs in the EU 
found that most of these analyses were conducted with poor methodological quality.484 In 
addition, 76% of the BIAs considered were not accompanied by a full economic evalua-
tion.484 Another review of BIAs for the US market found that the ratio of predicted versus 
actual budget impact ranged between 0.2 and 37.5 with a mean value of 5.5.485
Admittedly, for the particular case of tisagenlecleucel, outcomes of the economic evalu-
ation in Chapter 5 and results from the BIA would essentially lead to the same positive 
recommendation to reimburse tisagenlecleucel. However, this is not necessarily the case for 
Chapter 6, as the probability of R-LEN being cost-effective heavily depends on the chosen 
perspective and the several other assumptions.
Basing reimbursement decisions of novel and expensive treatment options on BIAs alone 
may be a way to quickly derive conclusions. Nevertheless, such an approach does not allow 
for optimal resource allocation or to generate evidence on the health gains of a particular 
intervention. In 2015, the ZIN warned that if no such information was gathered, “society 
may end up spending money on interventions that result in relatively few health gains for 
patients”.486 Using information from BIAs to derive reimbursement decisions undermines 
the goal to derive such decisions on the basis of a solid evidence-based framework. CUAs per 
contra are better suited to support such decisions.
The impact of immature RCT data on reimbursement decisions
Chapter 7 demonstrated that, in the case of immature RCT data, reimbursement decisions 
can become increasingly uncertain. Although the estimated ICER in the study presented in 
Chapter 7 was below a WTP-threshold of 30,000 GBP/QALY gained, the NICE appraisal 
committee initially issued a negative reimbursement decision. This was because the com-
mittee found that the estimates of the cost-utility analysis were not robust enough, due to 
the immaturity of the clinical trial data. After narrowing down the patient population and 
providing a higher financial discount on the price for the intervention, the degree of decision 
uncertainty was reduced to an extent that the appraisal committee could issue a positive 
recommendation. This demonstrates that the choice of the patient population is of crucial 
importance to determine whether a treatment should be reimbursed. This finding correlates 
with the issues of post hoc subgroup analysis discussed earlier in this chapter. Hence, involving 
reimbursement authorities early in the discussion of which subgroups are of eventual interest 
for reimbursing novel treatments might help in setting-up RCTs with relevant subgroups.
The financial impact of novel immunotherapies in haemato-oncology
The chimeric antigen receptor (CAR) technology is seen a biologically and economically 
powerful tool.487 Biologically powerful because CAR T cell therapy has been able to cure 
cancer in some patients for whom chemotherapy had failed.487 Economically powerful be-
cause the CAR T cell therapy tisagenlecleucel was considered the most expensive oncological 
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therapy available at the time of its marketing approval by the US Food and Drug Administra-
tion (FDA) in 2017.451,488
Based on HTA evidence, all countries of the former EU-5 have adopted outcomes-based 
reimbursement scheme to safeguard patients’ access to the therapy.407 As mentioned earlier, 
in the Netherlands, “standard reimbursement” was negotiated on the basis of a BIA.
Nonetheless, the European Haematology Association (EHA) was concerned about the 
sustainability of the pricing of novel oncological treatments in haematology. Especially, since 
CAR T-cell therapies can be used to treat many more haematological malignancies than the 
ones for which they currently hold market approval (i.e. ALL and DLBCL). The potential 
financial impact of this therapy on European health systems was unknown, and Chapter 8 
aimed to shed light on this issue.
Based on ongoing clinical studies, it was estimated that the use for CAR T-cell thera-
pies might be expanded to include other haematological indications such as mantle cell 
lymphoma (MCL), FL, acute myeloid leukemia (AML), multiple myeloma (MM), and 
lymphocytic leukemia (CLL). Chapter 8 found that the future cost of CAR T-cell therapies 
in the field of haematology will be substantial and increasing. This increase will not only be 
caused by an extension of indication but also because the underlying population forecasts 
predicted an increase in the eligible patient population. Population growth and an increase 
in (haematological) cancer incidences were drivers for this trend. In addition, CAR T-cell 
therapies were approved only for third or later treatment lines. The aim of several RCTs 
was to determine the use of this therapy in second-line treatment.489 If this proves to be 
effective, the eligible patient population might once more increase drastically. Consequently, 
the healthcare costs associated with CAR T-cell therapies will again increase.
These findings indicate that the trend of increasing costs of cancer treatments (introduced 
in the Chapter 1), is unlikely to be a temporary phenomenon. Indeed, novel cancer treat-
ments such a CAR T-cell therapies showed to demand prices that were unheard of a couple 
of years before their introduction. With an extension of indication and a growing cancer 
incidence, healthcare systems might soon not able to afford any novel treatments. Paired 
with unequal access to novel treatments that lead to tremendous losses of life years in itself,490 
this trend can have devastating effects on the health of populations.
Decision makers have several tools at their disposal to control prices of medical treatments 
such as value-based pricing through HTA. This dissertation identified and addressed some of 
the current challenges researchers and reimbursement decision makers face when conduct-
ing or interpreting economic evaluations as part of formal HTA. Ultimately, it is in the hand 
of the decision makers whether or not economic evaluations should be used to decide on the 
reimbursement of novel and expensive treatments in haemato-oncology.
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CONCLUDINg REMARkS & RECOMMENDATIONS
The aim of this dissertation was threefold. First, challenges in the evidence synthesis for HTA 
were explored and addressed. Second, the cost-utility of novel and expensive treatments in 
the field of haemato-oncology was assessed. Third, several implications of CUAs on the 
healthcare decision-making were discussed.
More specifically, in the first part of this dissertation the current challenge of finding 
previously published economic evaluations was addressed by proposing a practical guidance 
aiding in systematically searching biomedical databases for such studies. In addition, several 
challenges were identified in synthesising evidence on effects of clinical studies, and evidence 
on costs from financial claims databases. The second part presented missing evidence on 
the cost-utility of two novel treatments in haemato-oncology and discussed the inclusion 
of future non-medical costs in a societal perspective of CUAs and the choice of health state 
utilities for these analyses. Finally, the third part placed the findings of the two CUAs of 
the second part into the context of healthcare decision making and provided an outlook on 
future healthcare expenditure in the field of haemato-oncology.
The findings of this dissertation lead to several implications and recommendations that 
are listed and explained below. It needs to be noted that the identified challenges in this 
dissertation do not represent an exhaustive list of all possible challenges in HTA. Nor are the 
here examined domains the sole domains of HTA. The following implications and recom-
mendations should therefore be read in this context. In addition, their order does not reflect 
preference.
One, future research should aim at enhancing and updating current guidelines to conduct 
systematic literature reviews of economic evaluations, taking into account improved and 
simplified user interfaces of biomedical databases. Simultaneously, novel approaches such 
as a machine learning algorithm should be studied for their suitability to automate (parts 
of ) such reviews. In case such tools are deemed appropriate their use should actively be 
recommended in up-to-date guidelines.
Two, future research needs to validate promising novel modelling techniques to extrapolate 
short-term empirical survival of clinical studies to a longer time horizon while considering 
external long-term data.
Three, results from cost-utility analyses that were based on efficacy data from phase II clini-
cal studies need to be validated with long-term efficacy data from pivotal trials. Furthermore, 
clinical studies to collect the needed data should become mandatory when reimbursement 
decisions are based in phase II studies to reduce long-term uncertainties of the reimburse-
ment decision.
Four, future research should determine strengths and weaknesses of synthesising evidence 
on resource use from financial claims databases compared to patient questionnaires. In addi-
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tion, such research should elucidate the possibilities to enhance financial claims databases in 
a way so that they are better suitable for scientific research.
Five, national pharmacoeconomic guidelines should be updated to specifically recom-
mend or discourage the inclusion of future non-medical costs in CUAs. It seems that the 
literature has a preference for including such costs since only then estimates from a societal 
perspective are complete. However, a lack in recommendations from said guidelines did not 
encourage their inclusion thus far. Clear recommendations such as in the US would help to 
generate comprehensive results from a societal perspective while ensuring a relative degree of 
comparability between studies that include such costs.
Six, future research should establish reliable methods to estimate potential future produc-
tivity gains for children and young adult cancer survivors. This is because CUAs typically 
consider future effects (e.g. long-term survival and HRQoL). Consequently, future costs 
such as those related to productivity, should be considered as well. While standard meth-
odological approaches to include productivity losses are well documented in the literature, 
similar techniques are lacking to estimate productivity gains of young cancer survivors. This 
is problematic because other than adult patients, paediatric and young adult patients do not 
usually incur productivity losses due to their age. Hence future cost estimates in this young 
group of patients are often incomplete.
Seven, further research is needed to determine reliable estimates of health state utility 
values for patients with haematological malignancies. A systematic literature review in this 
field could help to summarise available evidence and to identify gaps.
Eight, the use of budget impact analyses to guide reimbursement decision in healthcare, 
especially in the field of haemato-oncology should be reconsidered. Other than budget 
impact analyses, economic evaluations can address a broad range of uncertainty and should 
therefore be seen as the superior methodology to address the reimbursement decision prob-
lem.
In essence, this dissertation adds to the growing body of literature aiming at updating 
and enhancing (methods of ) economic evaluations through identifying and addressing chal-








Recent advances in the treatment of haematological cancers promise to further improve 
treatment outcomes for patients. Simultaneously, prices of these treatments are high and 
continuously increasing since a couple of decades. While improved treatment outcomes 
are desirable, the continuous price increase of novel and high budget impact therapies has 
become a major topic for decision makers in healthcare. Determining drug prices of novel 
treatments based on their value perceived by pateints and healthcare decision makers is one 
approach to control the increasing treatment prices. Through a formal health technology 
assessment (HTA) this value can be determined. This is typically done by systematically 
evaluating the clinical, economic, organisational, social and ethical aspects of the novel treat-
ment. Although the concept of HTA is already in use since the 1980’s, various challenges 
persist to this day. This dissertation identifies and addresses some of these challenges and is 
structured in three parts. In the first part, current challenges in the evidence synthesis for 
HTA are explored and addressed. The second part aims at providing missing evidence on the 
cost-utility of novel and expensive treatments in the field of haemato-oncology. Simultane-
ously, it is explored to what extent the inclusion of future non-medical consumption costs 
impact the ICER of cost-utility analyses. Finally, implications of cost-utility analyses (CUAs) 
on healthcare decision-making are described and discussed in the third part.
Part I: Challenges in the evidence synthesis for Health Technology 
Assessment
For a formal HTA, previously published economic evidence on the treatment of interest 
needs to be reviewed systematically. However, searching and finding economic evaluation 
studies in general has become challenging since previous economic evaluation databases 
are no longer updated or discontinued. Chapter 2 addresses this challenge by proposing a 
guideline to identify such studies in a systematic way. The recommendations include search-
ing at least five “basic” databases using validated search filters with minimal restrictions. 
In addition, the retrieved references should be independently screened by two reviewers 
and a biomedical information specialist should be consulted for the entire process. These 
recommendations were recently adopted by WHO-INTEGRATE (INTEGRATe Evidence) 
framework version 1.0 to gather economic evidence in health decision making.
Chapter 3 identifies challenges in synthesising evidence on costs. Using two distinct ap-
proaches, healthcare costs of paediatric patients with sickle cell disease were estimated. One 
approach used the current Dutch clinical practice guideline for the treatment of paediatric 
patients with sickle cell disease. For the other approach, healthcare costs were estimated using 
a hospital financial claims database. Estimating healthcare costs with the former approach 
was feasible and relatively uncomplicated. However, real-world resource use could not be 
included. Using financial claims data, did offer a detailed insight into real-word resource use 
but was related to some specific challenges. Some of these challenges included the suitability 
of the available variables for the desired analyses as well as limited access to the database for 
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research purposes. In total, 125 patients could be included for the analysis. Of those, 15% 
were responsible for 50% of the total healthcare costs. Inpatient hospital care was the main 
cost driver, followed by diagnostics, treatment, outpatient visits and emergency care. The 
yearly average healthcare expenditures for this patient group were 5,049 EUR per patient 
(SD: 1,634 EUR) but varied considerably between the different age groups analysed. From 
this chapter it could be concluded that hospital financial claims data can be used for the 
estimation of real-world healthcare costs. Nevertheless, future research needs to determine 
the usefulness of such an approach in other disease contexts.
One aim of the European Medicine Agency (EMA) is to ensure the timely access for 
patients to treatments targeting an unmet medical need. Ideally, phase III clinical data 
are used for such purposes. However, the completion of such studies is time consuming. 
Therefore, the EMA has increasingly issued marketing approval based on phase II clinical 
studies in recent years. Chapter 4 explores the usefulness of phase II clinical data to develop 
a decision model for health economic modelling purposes and to estimate long-term survival 
outcomes. It describes the development of a decision model for the second-line treatment 
of steroid-refractory acute graft-versus-host disease (SR-aGvHD) with mesenchymal stro-
mal cells (MSCs). The model was developed in conjunction with a group of international 
clinical experts and consisted of eight health states. In addition, published (anonymised) 
patient-level evidence from several phase II studies were used to estimate long-term efficacy 
outcomes. In total, data from 327 paediatric and adult patients with SR-aGvHD could 
be used to estimate long-term overall survival (OS). Patients in complete remission after 
MSCs had a median OS of 3.2 years while patients with no complete remission reached a 
median OS of 0.5 years. Nevertheless, the results of this analysis need to be interpreted as 
an indication for the studied patient population and data from phase III clinical trials need 
to validate these findings.
PART II: Cost-utility of novel treatments in haematology-oncology
In Chapter 5, the cost-effectiveness of the chimeric antigen receptor (CAR) T-cell 
therapy tisagenlecleucel is assessed for pediatric patients with relapsed/refractory (r/r) acute 
lymphoblastic leukemia (ALL) in the Netherlands. Comparator treatments were clofara-
bine monotherapy (Clo-M), clofarabine combination therapy (Clo-C), and blinatumomab 
(Blina). The analysis was conducted from societal perspective and in a separate scenario, 
future non-medical consumption costs were considered as well. The estimated ICERs ranged 
between 31,682 EUR per quality-adjusted life year (QALY) and 37,531 EUR per QALY 
when tisganelecleucel was compared to Blina and Clo-C, respectively. Including future non-
medical costs in a societal perspective lead to increase in the estimated ICER between 17% 
and 21% when compared to a societal perspective that did not include these costs. With a 
willingness-to-pay (WTP) threshold of 80,000 EUR per QALY gained, tisagenlecleucel was 
cost-effective compared to each of the comparators, and from all perspectives.
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In Chapter 6, the cost-effectiveness of rituximab plus lenalidomide (R-LEN) for previ-
ously treated patients with follicular lymphoma (FL) in the Netherlands is estimated. Similar 
to Chapter 5, this Chapter also includes a separate analysis considering future non-medical 
costs. With a WTP-threshold of 50,0000 EUR per QALY gained, R-LEN was cost-effective 
with an ICER of 40,493 EUR per QALY from a societal perspective when compared to 
R-mono. When future non-medical costs were considered as well, the ICER increased by 
approximately 22%.
Chapter 5 and 6 demonstrate that the studied treatments are expensive, but also cost-
effective from all perspectives and when compared to each comparator treatment. When 
future non-medical costs were considered in the analyses, the ICER became less favourable. 
Nevertheless, the conclusion as to whether the treatments could be considered cost-effective 
did not change.
PART III: Implications of cost-utility analyses of novel and expensive 
treatments in haemato-oncology on healthcare decision-making
Chapter 7 elicits the review process of a single technology appraisal (obinutuzumab in com-
bination with chemotherapy) to the National Institute for Health and Care Excellence (NICE). 
The ICER estimated through the underlying CUA was below the assumed WTP-threshold. 
Nevertheless, the appraisal committee issued a negative reimbursement recommendation 
for the treatment. This decision was based on the limited follow-up time of the clinical 
study used for the economic evaluation. After considering only a patient subgroup with high 
disease severity and granting a (confidential) price discount, the appraisal committee issued 
a positive reimbursement recommendation for the drug.
In recent years, novel and expensive anti-cancer therapies such as the CAR technology 
have sparked a debate about the costs of such therapies and the affordability of healthcare 
systems globally. In addition, there is growing concern about the sustainability of the pricing 
of novel oncological treatment in haematology. Chapter 8 assessed the health economic 
aspects of CAR T-cell therapies for haematological cancers for the former EU-5 and the 
Netherlands. Average cumulative expenditures across both existing and future indications 
for the years 2019 to 2029 were estimated to be 28.5 billion EUR, 32.8 billion EUR, and 
28.9 billion EUR, when considering costs of CAR T-cell therapy only, CAR T-cell therapy 
including pre- and post-treatment, and incremental CAR T-cell therapy cost, respectively. It 
was concluded that healthcare costs associated with this novel therapy are considerable and 
increasing in the near future.
This dissertation explores and addresses several challenges in the evidence synthesis for 
HTA, assesses the cost-utility of two novel and expensive haemato-oncological treatments, 
and discusses the implications of CUAs on the healthcare decision-making processes. While 
novel and expensive haemato-oncological treatments bear the potential to cure a group of 
patients, they also put the affordability of healthcare systems at risk. HTA, much more than 
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budget impact analyses can help to keep determining and control spiralling drug prices. 
However, it can also be concluded that methodological choices and unsolved challenges 
in HTA have a substantial impact on economic evaluations and reimbursement decisions. 
Ultimately, this dissertation adds to the growing body of literature aiming at updating and 
enhancing (methods of ) economic evaluations through identifying and addressing chal-








De nieuwste ontwikkelingen op het gebied van hematologische kankerbehandelingen 
zijn veelbelovend voor jonge en oudere patiënten. Tegelijkertijd zijn de prijzen van deze 
behandelingen hoog en stijgen ze al sinds enkele decennia. Hoewel verbeterde behandelre-
sultaten wenselijk zijn, is de voortdurende prijsstijging van nieuwe therapieën met een hoge 
budgetimpact een cruciaal onderwerp geworden voor beleidsmakers in de gezondheidszorg. 
Een manier om deze stijgende prijzen tegen te gaan is om medicijnprijzen op basis van 
de toegevoegde waarde voor patiënten en beleidsmakers te bepalen. Dit kan bijvoorbeeld 
door middel van een formele beoordeling van gezondheidstechnologie (Health Technology 
Assessment, HTA), waarbij kosten en baten (bijvoorbeeld klinische, economische, organisa-
torische, sociale en ethische aspecten) van de nieuwe behandeling systematisch onderzocht 
worden. Hoewel het concept van HTA al sinds de jaren 1980 in gebruik is, bestaan er 
nog steeds verschillende (methodologische) uitdagingen. Dit proefschrift identificeert en 
behandelt enkele van deze uitdagingen om het veld van HTA te verrijken. Hiervoor is het 
proefschrift gestructureerd in drie delen. In het eerste deel worden huidige uitdagingen in 
het combineren van bewijs voor HTA geadresseerd. Deel twee is gericht op het leveren van 
ontbrekend bewijs over de kosten-utiliteit van nieuwe en dure behandelingen op het gebied 
van hemato-oncologie. Tegelijkertijd wordt er bestudeerd in hoeverre het meenemen van 
toekomstige niet-medische consumptiekosten de uitkomsten van kostenutiliteitsanalyses 
(KUAs) beïnvloedt. Tenslotte worden de implicaties van KUAs op de besluitvorming in 
de gezondheidszorg werden beschreven en besproken in het derde deel van dit proefschrift.
DEEL I: UITDAgINgEN IN DE SyNTHESE vAN 
BEwIjS vOOR HEALTH TECHNOLOgy ASSESSMENT
Voor een formeel HTA moet eerder gepubliceerd economisch bewijs over de behandeling 
systematisch worden herzien. Het zoeken en vinden van economische evaluatiestudies in het 
algemeen is echter een uitdaging geworden, aangezien eerdere databases voor economische 
evaluatie niet langer worden bijgewerkt of zijn beëindigd. Hoofdstuk 2 gaat in op deze 
uitdaging en stelt een richtlijn voor om dergelijke studies op een systematische manier te 
identificeren. De aanbevelingen omvatten het gebruiken van ten minste vijf “basis” databan-
ken met gevalideerde zoekfilters. Bovendien wordt aanbevolen om de opgehaalde referenties 
door twee auteurs onafhankelijk te screenen en om een biomedische informatiespecialist te 
betrekken. Deze aanbevelingen zijn onlangs overgenomen door de WHO-INTEGRATE 
(INTEGRATe Evidence) framework versie 1.0 om economisch bewijs te verzamelen om 
besluitvorming voor de gezondheidszorg te informeren.
Hoofdstuk 3 identificeert uitdagingen gerelateerd aan het synthetiseren van bewijs over 
kosten. Met behulp van twee verschillende methoden werden de zorgkosten van pediatri-
sche patiënten met sikkelcelziekte geschat. Enerzijds werd de huidige Nederlandse richtlijn 
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voor de behandeling van pediatrische patiënten met sikkelcelziekte gebruikt. Anderzijds 
werden de zorgkosten geschat met behulp van een database met de financiële claims van 
ziekenhuizen. Hoewel het schatten van de zorgkosten met de eerste benadering haalbaar 
en relatief eenvoudig was, was dit niet representatief voor het daadwerkelijke zorggebruik 
van patiënten. Het gebruik van een financiële databank voor dit doel bood weliswaar een 
meer gedetailleerd inzicht in het zorggebruik van patiënten, maar kende ook specifieke 
uitdagingen. Bijvoorbeeld de geschiktheid van de beschikbare variabelen voor de analyses 
en een beperkte toegang tot de database voor onderzoeksdoeleinden. Uiteindelijk werden 
125 patiënten geïncludeerd voor de analyse waarvan 15% van de patiënten verantwoordelijk 
was voor 50% van de totale zorgkosten. Intramurale ziekenhuiszorg was de belangrijkste 
kostenfactor, gevolgd van diagnostiek, behandeling, poliklinische bezoeken en spoedeisende 
zorg. De gemiddelde jaarlijkse uitgaven voor de gezondheidszorg van deze patiëntengroep 
bedroeg 5.049 EUR per patiënt (SD: 1.634 EUR), maar varieerden aanzienlijk tussen de 
verschillende geanalyseerde leeftijdsgroepen. Op basis van de inzichten uit dit hoofdstuk 
kan worden geconcludeerd dat het mogelijk is om financiële claims data van ziekenhuizen 
te gebruiken voor het schatten van daadwerkelijke zorgkosten. Toekomstig onderzoek moet 
uitwijzen of deze methode in vergelijking met andere bronnen, ook in een andere ziektecon-
text mogelijk is.
Een van de doelstellingen van het Europees Geneesmiddelenbureau (European Medicines 
Agency, EMA) is om ervoor te zorgen dat patiënten tijdig toegang krijgen tot behandelin-
gen die gericht zijn op een onvervulde medische behoefte. Idealiter wordt data uit fase III 
klinische studies voor dergelijke doeleinden gebruikt. Echter kosten dergelijke onderzoeken 
kost echter veel tijd. Om deze reden heeft de EMA in de afgelopen jaren markttoelatin-
gen in toenemende mate gebaseerd op data van fase II studies. In reactie hierop wordt 
in Hoofdstuk 4 de mogelijkheid onderzocht om data uit fase II studies te gebruiken om 
een beslismodel te ontwikkelen dat gebruikt kan worden om lange termijn overleving en 
gezondheids-economische uitkomsten te voorspellen. Dit hoofdstuk beschrijft de ontwikke-
ling van een beslismodel voor de tweedelijnsbehandeling van steroïd-refractaire acute graft-
versus-host-ziekte (SR-aGvHD) met mesenchymale stromale cellen (MSC’s). Het model is 
ontwikkeld in samenwerking met een groep internationale klinische experts en bestaat uit 
acht gezondheidstoestanden. Daarbij is openbaar beschikbare (geanonimiseerde) data op 
patiëntniveau uit verschillende fase II-onderzoeken gebruikt om de effectiviteit op de lange 
termijn te schatten. In totaal zijn de gegevens van 327 pediatrische en volwassen patiënten 
met SR-aGvHD gebruikt om de algehele overleving op de lange termijn (overall survival, 
OS) te schatten. Patiënten in complete remissie na MSC’s hadden een mediaan OS van 3,2 
jaar terwijl patiënten zonder volledige remissie een mediane OS van 0,5 jaar bereikten. Des-
alniettemin moeten de resultaten van deze analyse geïnterpreteerd worden als een indicatie 
en moeten gegevens uit fase III klinische onderzoeken deze bevindingen volledig valideren.
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DEEL II: kOSTEN-UTILITEIT vAN NIEUwE 
BEHANDELINgEN IN DE HEMATOLOgIE-
ONCOLOgIE
In Hoofdstuk 5 wordt de kosteneffectiviteit van de chimere antigeenreceptor (CAR) 
T-celtherapie tisagenlecleucel beoordeeld voor pediatrische patiënten met recidiverende 
of refractaire (r/r) acute lymfatische leukemie (ALL) in Nederland. Andere vergelijkende 
behandelingen waren clofarabine monotherapie (Clo-M), clofarabine combinatietherapie 
(Clo-C) en blinatumomab (Blina). De analyse is uitgevoerd vanuit het maatschappelijk 
perspectief. In een apart scenario worden ook toekomstige niet-medische consumptiekosten 
meegenomen. De geschatte ICER’s varieerden tussen 31.682 EUR per kwaliteit gecorrigeerd 
levensjaar (quality-adjusted life year, QALY) en 37.531 EUR per QALY wanneer tisganelec-
leucel werd vergeleken met respectievelijk Blina en Clo-C. Het meenemen van toekomstige 
niet-medische kosten in een maatschappelijk perspectief leidde tot een toename van de 
geschatte ICER tussen de 17% en 21% vergeleken met een maatschappelijk perspectief 
waarin deze kosten niet zijn meegenomen. Met een drempelwaarde van 80.000 EUR per 
gewonnen QALY, was tisagenlecleucel kosteneffectief in vergelijking met elk andere bestu-
deerde behandeling, en vanuit alle perspectieven.
In Hoofdstuk 6 is de kosteneffectiviteit van rituximab plus lenalidomide (R-LEN) voor 
eerder behandelde patiënten met folliculair lymfoom (FL) in Nederland geschat. Net als in 
hoofdstuk 5, bevat dit hoofdstuk ook een afzonderlijke analyse waarin toekomstige niet-
medische kosten zijn meegenomen. Met een WTP-drempel van 50.0000 EUR per gewon-
nen QALY, was R-LEN kosteneffectief met een ICER van 40,493 EUR per QALY vanuit 
een maatschappelijk perspectief in vergelijking met R-mono. Wanneer ook rekening werd 
gehouden met toekomstige niet-medische kosten, steeg de ICER met zo’n 22%.
Hoofdstuk 5 en 6 tonen aan dat de bestudeerde behandelingen duur maar ook kosten-
effectief zijn vanuit alle perspectieven en vergeleken met elke vergelijkende behandeling. 
Wanneer toekomstige niet-medische kosten mee worden genomen in de analyse, werd de 
ICER minder gunstig. Desalniettemin veranderde de conclusie of de behandelingen als 
kosteneffectief kan worden beschouwd niet.
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DEEL III: IMPLICATIES vAN 
kOSTENUTILITEITSANALySES vAN NIEUwE 
EN DURE BEHANDELINgEN IN DE HEMATO-
ONCOLOgIE vOOR DE BESLUITvORMINg IN DE 
gEzONDHEIDSzORg
Hoofdstuk 7 beschrijft het beoordelingsproces van een nieuwe therapie (obinutuzumab in 
combinatie met chemotherapie) door het National Institute for Health and Care Excellence 
(NICE). De geschatte ICER lag onder de aangenomen WTP-drempel. Desondanks bracht 
de beoordelingscommissie een negatief vergoedingsadvies voor de behandeling uit. Deze be-
slissing was gebaseerd op de beperkte follow-uptijd van de klinische studie die werd gebruikt 
voor de economische evaluatie. Na alleen een subgroep van patiënten met een hoge ernst van 
ziekte te hebben overwogen en een (vertrouwelijke) prijskorting te hebben verleend, heeft de 
beoordelingscommissie het advies gegeven om het geneesmiddel te vergoeden.
In de afgelopen jaren hebben nieuwe en dure therapieën voor kanker, zoals de CAR-
technologie, tot een debat geleid over de kosten van dergelijke therapieën en de betaalbaar-
heid van gezondheidszorgsystemen wereldwijd. Bovendien is er een groeiende bezorgdheid 
over de duurzaamheid van de prijsstelling van nieuwe oncologische behandelingen in 
de hematologie. In Hoofdstuk 8 zijn de gezondheidseconomische aspecten van CAR 
T-celtherapieën voor hematologische kankers voor de voormalige EU-5 en Nederland 
onderzocht. De gemiddelde cumulatieve uitgaven voor zowel bestaande als toekomstige 
indicaties voor de jaren 2019 tot 2029 werden geschat op 28,5 miljard EUR, 32,8 miljard 
EUR en 28,9 miljard EUR, rekening houdend met de kosten van alleen CAR T-celtherapie, 
CAR T-celtherapie inclusief pre - en post-behandeling, en incrementele CAR T-celtherapie 
kosten, respectievelijk. Er is geconcludeerd dat de kosten van de gezondheidszorg in verband 
met deze nieuwe therapie aanzienlijk zijn en in de nabije toekomst verder zullen toenemen.
In dit proefschrift zijn verschillende uitdagingen in de synthese van bewijs voor HTA 
onderzocht, de kosten-utiliteit van twee nieuwe en dure hemato-oncologische behan-
delingen beoordeeld, en de implicaties van KUA’s op de besluitvormingsprocessen in de 
gezondheidszorg besproken. Hoewel nieuwe en dure hemato-oncologische behandelingen 
het potentieel hebben om een groep patiënten te genezen, zetten ze ook de betaalbaarheid 
van zorgstelsels onder druk. HTA, veel meer dan budgetimpactanalyses, kan helpen om 
de stijgende medicijnprijzen te bepalen en te beheersen. Er kan echter ook worden gecon-
cludeerd dat methodologische keuzes en onopgeloste uitdagingen in HTA een substantiële 
impact hebben op de uitkomsten van economische evaluaties en op vergoedingsbeslissingen. 
Uiteindelijk draagt dit proefschrift bij aan de groeiende hoeveelheid literatuur die gericht 
is op het actualiseren en verbeteren van (methoden van) economische evaluaties door het 
identificeren en aanpakken van uitdagingen in HTA, om ze een nog robuuster en betrouw-
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